Citation Report
List of articles citing

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

DOI: 10.1056/nejmoa1200694
New England Journal of Medicine, 2012, 366, 2455-65.

#	Paper	IF	Citations
2232	Drug targets and predictive biomarkers in the management of metastatic melanoma. **2012**, 5, 139-48		3
2231	The cancer antigenome. **2013**, 32, 194-203		172
2230	Role of lymphocytic choriomeningitis virus (LCMV) in understanding viral immunology: past, present and future. **2012**, 4, 2650-69		79
2229	Actualities in Medicine. **2012**, 8, 511-515		
2228	CD73-generated adenosine: orchestrating the tumor-stroma interplay to promote cancer growth. **2012**, 2012, 485156		64
2227	Programmed death 1 protects from fatal circulatory failure during systemic virus infection of mice. **2012**, 209, 2485-99		127
2226	Immunotherapies: the blockade of inhibitory signals. **2012**, 8, 1420-30		23
2225	New therapies in the treatment of melanoma. **2012**, 21, 1643-59		8
2224	AACR Cancer Progress Report 2012. **2012**, 18, S1-100		20
2223	The liver, liver metastasis and liver cancer: a special case for immunotherapy with cytokines and immunostimulatory monoclonal antibodies. **2012**, 4, 1081-5		6
2222	Targeted therapy for squamous cell lung cancer. **2012**, 1, 293-300		30
2221	Antigen shedding into the circulation contributes to tumor immune escape. **2012**, 1, 1620-1622		5
2220	Progress in immunotherapy of cancer. *New England Journal of Medicine*, **2012**, 367, 1168; author reply 1168	59.2	4
2219	Targeted treatment for melanoma. **2012**, 12, 1113-5		1
2218	Notable advances 2012. **2012**, 18, 1732-1734		78
2217	Mechanisms of action underlying the immunotherapeutic activity of Allovectin in advanced melanoma. **2012**, 19, 811-7		15
2216	Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression. **2012**, 189, 4674-83		172

2215	Changing the tumor microenvironment: new strategies for immunotherapy. **2012**, 72, 5159-64	22
2214	Targeting PD-1/PD-L1 interactions for cancer immunotherapy. **2012**, 1, 1223-1225	248
2213	ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4+ T cells. **2012**, 72, 6130-41	134
2212	Cell-intrinsic abrogation of TGF-β signaling delays but does not prevent dysfunction of self/tumor-specific CD8 T cells in a murine model of autochthonous prostate cancer. **2012**, 189, 3936-46	19
2211	Immunotherapy in breast cancer - towards a new understanding of both tumor and host. **2012**, 7, 258-60	1
2210	Immune therapies for lung cancer. **2012**, 7, S394-6	
2209	Clinical Significance of Programmed Death-1 Ligand-1 Expression in Patients with Non-Small Cell Lung Cancer: A 5-year-follow-up Study. **2012**, 98, 751-755	134
2208	Monoclonal antibodies and other targeted therapies for pancreatic cancer. **2012**, 18, 653-64	16
2207	Vaccines for pancreatic cancer. **2012**, 18, 642-52	31
2206	A therapeutic renaissance: emergence of novel targeted agents for metastatic melanoma. **2012**, 2, 883-893	1
2205	Polyfunctional CD4+ T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy. **2012**, 120, 2229-39	58
2204	Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1. **2012**, 18, 6580-7	415
2203	Immunology beats cancer: a blueprint for successful translation. **2012**, 13, 1129-32	130
2202	Advances in the management of melanoma: targeted therapy, immunotherapy and future directions. **2012**, 12, 1437-48	21
2201	Network analysis reveals centrally connected genes and pathways involved in CD8+ T cell exhaustion versus memory. **2012**, 37, 1130-44	337
2200	Gone baby gone - but how?. **2012**, 120, 4664-6	
2199	Bioinformatics for cancer immunology and immunotherapy. **2012**, 61, 1885-903	32
2198	Therapeutic application of monoclonal antibodies in cancer: advances and challenges. **2012**, 104, 41-59	52

2197	PD-1 blockade: promoting endogenous anti-tumor immunity. **2012**, 12, 1279-82		11
2196	Thinking inside the box: how T cell inhibitory receptors signal. **2012**, 18, 1338-9		8
2195	Mutated BCR-ABL generates immunogenic T-cell epitopes in CML patients. **2012**, 18, 5761-72		45
2194	Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. **2012**, 490, 412-6		397
2193	Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline--Update 2012. **2012**, 48, 2375-90		199
2192	Patient-tailored modulation of the immune system may revolutionize future lung cancer treatment. **2012**, 12, 580		21
2191	Ipilimumab in melanoma. **2012**, 12, 1511-21		6
2190	Immunotherapy for castration-resistant prostate cancer. **2012**, 39, 465-81		6
2189	Modeling and predicting clinical efficacy for drugs targeting the tumor milieu. **2012**, 30, 648-57		85
2188	Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade. **2012**, 12, 1597-611		94
2187	[What's new in oncology?]. **2012**, 139 Suppl 5, S217-22		
2186	Cancer: PD1 makes waves in anticancer immunotherapy. **2012**, 11, 601		21
2185	Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *New England Journal of Medicine*, **2012**, 366, 2443-54	59.2	8684
2184	Improving lung cancer survival; time to move on. **2012**, 12, 77		23
2183	Dabrafenib and its potential for the treatment of metastatic melanoma. **2012**, 6, 391-405		70
2182	When transgenes shape immunity: cancer immune-gene therapy. **2012**, 14, 384-5		1
2181	From ASCO-immunotherapy: programming cancer cell death. **2012**, 9, 427		
2180	Vitamin D-binding protein-derived macrophage-activating factor, GcMAF, and prostate cancer. **2012**, 61, 2377-8		1

2179	Cautious optimism surrounds early clinical data for PD-1 blocker. **2012**, 30, 729-30		7
2178	Tumor immunotherapy directed at PD-1. *New England Journal of Medicine*, **2012**, 366, 2517-9	59.2	476
2177	Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer. **2013**, 11, 147		44
2176	Targeting the immune system for management of NSCLC: the revival?. **2013**, 2, 22-39		1
2175	Intrinsic immune alterations in renal cell carcinoma and emerging immunotherapeutic approaches. **2013**, 13, 911-25		14
2174	Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma. **2013**, 144, 1230-40		198
2173	The immune microenvironment of human tumors: general significance and clinical impact. **2013**, 6, 117-22		93
2172	Potential biofluid markers and treatment targets for renal cell carcinoma. **2013**, 10, 336-44		20
2171	Nivolumab plus ipilimumab in advanced melanoma. *New England Journal of Medicine*, **2013**, 369, 122-33	59.2	3118
2170	An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma. **2013**, 6, 375-86		17
2169	Fool's gold, lost treasures, and the randomized clinical trial. **2013**, 13, 193		36
2168	Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors. **2013**, 9, 977-90		19
2167	Impact of genetic targets on cancer therapy. Forward. **2013**, 779, v-vi		1
2166	Combination checkpoint blockade--taking melanoma immunotherapy to the next level. *New England Journal of Medicine*, **2013**, 369, 187-9	59.2	61
2165	Update in lung cancer and mesothelioma 2012. **2013**, 188, 157-66		23
2164	New targets in non-small cell lung cancer. **2013**, 15, 411-23		12
2163	Programmed death 1 pathway inhibition in metastatic renal cell cancer and prostate cancer. **2013**, 15, 98-104		35
2162	Metastatic melanoma to the brain: surgery and radiation is still the standard of care. **2013**, 14, 264-79		15

2161	Effector CD4 and CD8 T cells and their role in the tumor microenvironment. **2013**, 6, 123-33	190
2160	Blockade of the negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis. **2013**, 17, R85	171
2159	A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium. **2013**, 31, 1008-15	24
2158	KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma. **2013**, 26, 1307-19	84
2157	Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies. **2013**, 49, 2968-71	70
2156	Management of non-small-cell lung cancer: recent developments. **2013**, 382, 709-19	563
2155	Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients. **2013**, 62, 1381-92	54
2154	Immune-suppressive properties of the tumor microenvironment. **2013**, 62, 1137-48	148
2153	FcRB controls the potency of agonistic anti-TNFR mAbs. **2013**, 62, 941-8	33
2152	Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas. **2013**, 62, 629-37	40
2151	Inhibition of both BRAF and MEK in BRAF(V600E) mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties. **2013**, 62, 811-22	85
2150	Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial. **2013**, 71, 183-91	36
2149	Re-examination of maintenance therapy in non-small cell lung cancer with the advent of new anti-cancer agents. **2013**, 73, 517-32	5
2148	Consensus guidelines. **2013**, 132-141	
2147	Targeting the immune system in the treatment of non-small-cell lung cancer. **2013**, 14, 580-94	11
2146	Deciphering and reversing tumor immune suppression. **2013**, 39, 61-73	392
2145	New therapeutic options in systemic treatment of advanced cutaneous melanoma. **2013**, 22, 181-90	11
2144	Does a reasonable treatment approach beyond second-line exist?. **2013**, 11, 169-71	

2143	Silica-induced chronic inflammation promotes lung carcinogenesis in the context of an immunosuppressive microenvironment. **2013**, 15, 913-24	26
2142	Individualising treatment choices in a crowded treatment algorithm. **2013**, 11, 160-8	2
2141	Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. **2013**, 73, 3591-603	475
2140	Humoral immune responses to CTL epitope peptides from tumor-associated antigens are widely detectable in humans: a new biomarker for overall survival of patients with malignant diseases. **2013**, 41, 68-76	13
2139	Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. **2013**, 110, 20212-7	1041
2138	Immune modulation by genetic modification of dendritic cells with lentiviral vectors. **2013**, 176, 1-15	17
2137	Adjuvant therapy in renal cell carcinoma-past, present, and future. **2013**, 40, 482-91	78
2136	Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine. **2013**, 24, 644-54	70
2135	Turning tumors into vaccines: co-opting the innate immune system. **2013**, 39, 27-37	72
2134	Regulatory T cell infiltration predicts outcome following resection of colorectal cancer liver metastases. **2013**, 20, 946-55	106
2133	Engineering synthetic vaccines using cues from natural immunity. **2013**, 12, 978-90	403
2132	Immunotherapy for advanced melanoma: fulfilling the promise. **2013**, 39, 879-85	40
2131	Renal Cell Carcinoma. **2013**,	3
2130	Promising systemic immunotherapies in head and neck squamous cell carcinoma. **2013**, 49, 1089-96	85
2129	Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. **2013**, 31, 4199-206	384
2128	Diagnosis and treatment of KIT-mutant metastatic melanoma. **2013**, 31, 3176-81	25
2127	A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. **2013**, 14, 1212-8	611
2126	PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. **2013**, 19, 3462-73	601

2125	Dynamic interplay of oncogenes and T cells induces PD-L1 in the tumor microenvironment. **2013**, 3, 1330-2	19
2124	Challenging resistance mechanisms to therapies for metastatic melanoma. **2013**, 34, 656-66	80
2123	Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo. **2013**, 172, 500-6	157
2122	Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. **2013**, 31, 860-7	1023
2121	Harnessing the immune system for the treatment of non-small-cell lung cancer. **2013**, 31, 1021-8	116
2120	Immune-checkpoint blockade and active immunotherapy for glioma. **2013**, 5, 1379-412	31
2119	Restoring antitumor immunity via PD-1 blockade after autologous stem-cell transplantation for diffuse large B-cell lymphoma. **2013**, 31, 4268-70	11
2118	Emerging antiangiogenics for renal cancer. **2013**, 18, 495-511	15
2117	Autoimmune effector memory T cells: the bad and the good. **2013**, 57, 12-22	62
2116	Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma. **2013**, 190, 5620-8	81
2115	Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. **2013**, 5, 200ra116	1133
2114	Handbook of Cutaneous Melanoma. **2013**,	
2113	Human T cells engineered to express a programmed death 1/28 costimulatory retargeting molecule display enhanced antitumor activity. **2013**, 191, 4121-9	70
2112	Immunotherapeutic strategies for the treatment of renal cell carcinoma: where are we now?. **2013**, 13, 1399-408	9
2111	Management of patients with castration-resistant disease. **2013**, 27, 1243-60, ix	2
2110	CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. **2013**, 19, 5300-9	485
2109	Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients. **2013**, 62, 1711-22	90
2108	Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer. **2013**, 11, 215	70

2107	The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies. **2013**, 6, 74	176
2106	Rational combinations of immunotherapeutics that target discrete pathways. **2013**, 1, 16	55
2105	Immune evasion in acute myeloid leukemia: current concepts and future directions. **2013**, 1,	54
2104	Autoimmune diseases and hypersensitivities improve the prognosis in ER-negative breast cancer. **2013**, 2, 357	4
2103	Immunological insights from patients undergoing surgery on ipilimumab for metastatic melanoma. **2013**, 20, 3106-11	39
2102	Immunotherapy for the management of advanced melanoma: the next steps. **2013**, 14, 261-72	14
2101	Cancer immunotherapy: are we there yet?. **2013**, 2, 33	20
2100	Targeted therapies for locally advanced or metastatic squamous cell carcinoma of the lung. **2013**, 14, 568-79	5
2099	Peripheral CD45RO, PD-1, and TLR4 expression in metastatic colorectal cancer patients treated with bevacizumab, fluorouracil, and irinotecan (FOLFIRI-B). **2013**, 30, 743	14
2098	Immune therapy for kidney cancer: a second dawn?. **2013**, 40, 492-8	16
2097	Innate and adaptive immune cells in the tumor microenvironment. **2013**, 14, 1014-22	2160
2096	Advances in the development of cancer immunotherapies. **2013**, 34, 90-8	34
2095	Checkpoint modulation in melanoma: an update on ipilimumab and future directions. **2013**, 15, 500-8	17
2094	Immunotherapy at large: Balancing tumor immunity and inflammatory pathology. **2013**, 19, 1100-1	24
2093	Cancer immunotherapy: current status and future directions. **2013**, 22, 765-83	18
2092	Lung cancer: potential targets for immunotherapy. **2013**, 1, 551-63	55
2091	Progress and potential of immune checkpoint blockade for treating advanced renal cell carcinoma. **2013**, 5, 607-19	3
2090	Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond. **2013**, 49, 3229-41	35

2089	Revisiting immune-based therapies for aggressive follicular cell-derived thyroid cancers. **2013**, 23, 529-42	12
2088	The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. **2013**, 10, 588-98	145
2087	The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. **2013**, 39, 11-26	554
2086	Epigenetic Approaches: Emerging Role of Histone Deacetylase Inhibitors in Cancer Immunotherapy. **2013**, 353-372	1
2085	Modulation of Immune System Inhibitory Checkpoints in Colorectal Cancer. **2013**, 9, 391-397	9
2084	Optimal management of metastatic melanoma: current strategies and future directions. **2013**, 14, 179-94	65
2083	Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation. **2013**, 62, 285-97	90
2082	PD-1 targeting in cancer immunotherapy. **2013**, 119, E1-3	17
2081	Invariant natural killer T (iNKT) cell exhaustion in sarcoidosis. **2013**, 43, 2194-205	21
2080	Melanomas of unknown primary have a mutation profile consistent with cutaneous sun-exposed melanoma. **2013**, 26, 852-60	40
2079	An altered maturation and adhesion phenotype of dendritic cells in diseased individuals compared to asymptomatic carriers of human T cell leukemia virus type 1. **2013**, 29, 1273-85	10
2078	Thyroid dysfunction as an unintended side effect of anticancer drugs. **2013**, 23, 1345-66	76
2077	Foreword. Monoclonal antibody treatment of human disease. **2013**, 13, 1-2	
2076	Current and future directions for Phase II trials in high-grade glioma. **2013**, 13, 369-87	4
2075	GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability. **2013**, 1, 320-31	114
2074	Repositioning therapeutic cancer vaccines in the dawning era of potent immune interventions. **2013**, 12, 1219-34	7
2073	Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. **2013**, 3, 1355-63	831
2072	Advances in catheter-ablation treatment of AF. **2013**, 10, 63-4	6

2071	Could interferon still play a role in metastatic renal cell carcinoma? A randomized study of two schedules of sorafenib plus interferon-alpha 2a (RAPSODY). **2013**, 63, 254-61	24
2070	Interferon-α in combination with sorafenib: RAPSODY or requiem?. **2013**, 63, 262-4; discussion 264-5	0
2069	Reply from Author re: Axel Bex. Interferon-α in Combination with Sorafenib: RAPSODY or Requiem? Eur Urol 2013;63:262–4. **2013**, 63, 264-265	
2068	What can be learned from a chaotic cancer model?. **2013**, 322, 7-16	70
2067	Harnessing the power of the immune system to target cancer. **2013**, 64, 71-90	103
2066	Impact of genetic markers on treatment of non-small cell lung cancer. **2013**, 779, 145-64	6
2065	IL-27 in tumor immunity and immunotherapy. **2013**, 19, 108-16	65
2064	Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer. **2013**, 19, 28-33	147
2063	Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. **2013**, 73, 1733-41	564
2062	T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. **2013**, 25, 214-21	413
2061	Targeting oncogenic drivers and the immune system in melanoma. **2013**, 31, 499-506	82
2060	Durable adoptive immunotherapy for leukemia produced by manipulation of multiple regulatory pathways of CD8+ T-cell tolerance. **2013**, 73, 605-16	38
2059	Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. **2013**, 19, 462-8	407
2058	In vivo blockade of the PD-1 receptor suppresses HIV-1 viral loads and improves CD4+ T cell levels in humanized mice. **2013**, 190, 211-9	86
2057	The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. **2013**, 19, 598-609	330
2056	Novel immunotherapeutic strategies in development for renal cell carcinoma. **2013**, 63, 881-9	31
2055	Chemoimmunotherapy: reengineering tumor immunity. **2013**, 62, 203-16	162
2054	Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein. **2013**, 19, 205-14	128

2053	Interfering with coinhibitory molecules: BTLA/HVEM as new targets to enhance anti-tumor immunity. **2013**, 151, 71-5	42
2052	Immunotherapy of melanoma. **2013**, 11, 97-105	39
2051	[Pigmentary disorders induced by anticancer agents. Part II: targeted therapies]. **2013**, 140, 266-73	17
2050	Évaluation RECIST en cancérologie thoracique. **2013**, 5, 361-366	
2049	Melanoma-associated leukoderma - immunology in black and white?. **2013**, 26, 796-804	30
2048	[What's new in dermato-oncology?]. **2013**, 140 Suppl 3, S283-92	
2047	Current advances in immunotherapy for pancreatic cancer. **2013**, 37, 273-9	11
2046	Mission impossible: how HPV-associated head and neck cancers escape a primed immune response. **2013**, 49, 723-5	6
2045	Translational research in melanoma. **2013**, 22, 785-804	
2044	Immunotherapeutic strategies for relapse control in acute myeloid leukemia. **2013**, 27, 209-16	60
2043	CD33+/p-STAT1+ double-positive cell as a prognostic factor for stage IIIa gastric cancer. **2013**, 30, 442	21
2042	Advances in targeting cell surface signalling molecules for immune modulation. **2013**, 12, 130-46	192
2041	Review of the 92nd Annual Meeting of the British Association of Dermatologists, 3-5 July 2012, Birmingham, U.K. **2013**, 168, 32-8	
2040	The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. **2013**, 138, 105-15	491
2039	Genetic variations of PD1 and TIM3 are differentially and interactively associated with the development of cirrhosis and HCC in patients with chronic HBV infection. **2013**, 14, 240-6	43
2038	Melanoma prognostics and personalized therapeutics at a crossroad. **2013**, 133, 292-5	1
2037	Macrophage regulation of tumor responses to anticancer therapies. **2013**, 23, 277-86	724
2036	Other signalization targets. **2013**, 8, 69-77	5

2035	Personalized immune-interception of cancer and the battle of two adaptive systems--when is the time right?. **2013**, 6, 173-6	6
2034	T-cell memory differentiation: insights from transcriptional signatures and epigenetics. **2013**, 139, 277-84	111
2033	Kidney cancer in 2012: new frontiers in kidney cancer research. **2013**, 10, 70-2	3
2032	Agonist antibodies to TNFR molecules that costimulate T and NK cells. **2013**, 19, 1044-53	122
2031	Emerging targeted agents in metastatic breast cancer. **2013**, 10, 191-210	138
2030	Agonistic CD40 antibodies and cancer therapy. **2013**, 19, 1035-43	300
2029	The search for an HIV cure: tackling latent infection. **2013**, 13, 614-21	51
2028	Dissecting graft-versus-leukemia from graft-versus-host-disease using novel strategies. **2013**, 81, 183-93	61
2027	Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?. **2013**, 13, 365-76	191
2026	The future of epigenetic therapy in solid tumours--lessons from the past. **2013**, 10, 256-66	262
2025	Endocrine side effects induced by immune checkpoint inhibitors. **2013**, 98, 1361-75	299
2024	Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. **2013**, 25, 268-76	275
2023	Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy. **2013**, 13, 847-61	96
2022	Immunotherapy for Renal Cell Carcinoma. **2013**, 279-301	
2021	Cancer stem cell antigen-based vaccines: the preferred strategy for active specific immunotherapy of metastatic melanoma?. **2013**, 13, 643-56	21
2020	Coinhibitory molecules in cancer biology and therapy. **2013**, 24, 147-61	24
2019	PD-1 coinhibitory signals: the link between pathogenesis and protection. **2013**, 25, 219-27	44
2018	At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. **2013**, 94, 25-39	266

2017	The risks of targeting co-inhibitory pathways to modulate pathogen-directed T cell responses. **2013**, 34, 193-9		15
2016	Antibody-based therapy in colorectal cancer. **2013**, 5, 533-45		21
2015	NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors. **2013**, 91, 435-40		48
2014	Melanoma immunotherapy: historical precedents, recent successes and future prospects. **2013**, 5, 169-82		24
2013	Developing melanoma therapeutics: overview and update. **2013**, 5, 257-71		13
2012	Phase I/II RAF kinase inhibitors in cancer therapy. **2013**, 22, 739-49		9
2011	Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. *New England Journal of Medicine*, **2013**, 369, 134-44	59.2	2661
2010	Combining Vaccines with Therapies that Render Tumor Cells more Susceptible to Immune Mediated Killing. **2013**, 621-642		
2009	Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity. **2013**, 162, 313-25		76
2008	At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. **2013**, 94, 41-53		232
2007	Cancer immunotherapies, their safety and toxicity. **2013**, 12, 631-45		94
2006	Current clinical immunotherapy targets in advanced nonsmall cell lung cancer (NSCLC). **2013**, 94, 1201-6		8
2005	Novel antibodies targeting immune regulatory checkpoints for cancer therapy. **2013**, 76, 233-47		31
2004	What can be done for patients with NSCLC without druggable targets?. **2013**, 14, 191-2		1
2003	HIV and co-infections. **2013**, 254, 114-42		81
2002	Emerging and mechanism-based therapies for recurrent or metastatic Merkel cell carcinoma. **2013**, 14, 249-63		48
2001	Targeted therapy for non-small-cell lung cancer: past, present and future. **2013**, 13, 745-58		68
2000	Therapeutic vaccines for ovarian cancer. **2013**, 130, 667-73		12

1999	Blockade of PD-1/PD-L1 immune checkpoint during DC vaccination induces potent protective immunity against breast cancer in hu-SCID mice. **2013**, 336, 253-9	61
1998	The Tumor Immunoenvironment. **2013**,	3
1997	Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. **2013**, 49, 2233-42	319
1996	Dendritic cell immunotherapy. **2013**, 1284, 31-45	40
1995	Cellular immunotherapy for plasma cell myeloma. **2013**, 48, 1377-86	6
1994	Dendritic cells in cancer immunotherapy: vaccines and combination immunotherapies. **2013**, 12, 285-95	49
1993	The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy. **2013**, 25, 230-7	124
1992	Manipulating the PD-1 pathway to improve immunity. **2013**, 25, 381-8	75
1991	Tumour heterogeneity and immune-modulation. **2013**, 13, 497-503	27
1990	Combination molecularly targeted drug therapy in metastatic melanoma: progress to date. **2013**, 73, 767-77	10
1989	Monitoring the immune response in sepsis: a rational approach to administration of immunoadjuvant therapies. **2013**, 25, 477-83	139
1988	Optimal management of metastatic renal cell carcinoma: current status. **2013**, 73, 427-38	84
1987	Management options for metastatic melanoma in the era of novel therapies: a primer for the practicing dermatologist: part II: Management of stage IV disease. **2013**, 68, 13.e1-13; quiz 26-8	10
1986	Lungenkarzinom. **2013**, 8, 20-27	
1985	Low total lymphocyte count is associated with poor survival in patients with resected pancreatic adenocarcinoma receiving a GM-CSF secreting pancreatic tumor vaccine. **2013**, 20 Suppl 3, S725-30	27
1984	Better performance of CARs deprived of the PD-1 brake. **2013**, 19, 5546-8	11
1983	Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model. **2013**, 19, 6151-62	80
1982	[Lung cancer. Molecular pathology and personalized therapy]. **2013**, 54, 179-80, 182-7	1

1981	[Personalized therapy concepts for malignant melanoma]. **2013**, 54, 188-93	3
1980	New landscape in the treatment of melanoma: a 2012 update. **2013**, 15, 71-77	1
1979	Structure-based design of altered MHC class II-restricted peptide ligands with heterogeneous immunogenicity. **2013**, 191, 5097-106	18
1978	Clinical trials in cellular immunotherapy for brain/CNS tumors. **2013**, 13, 405-24	15
1977	Cutting edge: IL-12 and type I IFN differentially program CD8 T cells for programmed death 1 re-expression levels and tumor control. **2013**, 191, 1011-5	55
1976	Preclinical vaccines against mammary carcinoma. **2013**, 12, 1449-63	9
1975	T cell immunotherapy for melanoma from bedside to bench to barn and back: how conceptual advances in experimental mouse models can be translated into clinical benefit for patients. **2013**, 26, 441-56	11
1974	Oncolytic vaccines. **2013**, 12, 1155-72	35
1973	Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer. **2013**, 1, 85-91	132
1972	Ipilimumab in prostate cancer. **2013**, 13, 303-13	5
1971	OX40 is a potent immune-stimulating target in late-stage cancer patients. **2013**, 73, 7189-7198	341
1970	The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be. **2013**, 19, 5283-91	45
1969	Emerging BRAF inhibitors for melanoma. **2013**, 18, 431-43	5
1968	Recent advances in the treatment of metastatic renal cell carcinoma. **2013**, 20, 944-55	44
1967	Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. **2013**, 31, 4311-8	447
1966	Soluble CD80 restores T cell activation and overcomes tumor cell programmed death ligand 1-mediated immune suppression. **2013**, 191, 2829-36	50
1965	Personalized Management of Lung Cancer. **2013**,	
1964	Personalized Management of Head & Neck Cancer. **2013**,	

1963	AMP-224, a Fusion Protein that Targets PD-1. **2013**, 24, i7	11
1962	Anti-CTLA-4 and BRAF inhibition in patients with metastatic melanoma and brain metastases. **2013**, 8, 479-487	3
1961	Immunotherapeutic strategies including transplantation: eradication of disease. **2013**, 2013, 151-7	10
1960	Blockade of the PD-1 pathway enhances the efficacy of adoptive cell therapy against cancer. **2013**, 2, e22691	28
1959	AACR Cancer Progress Report 2013. **2013**, 19, S4-98	47
1958	An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. **2013**, 12, 597-615	49
1957	New Chemotherapeutic Strategies Against Malaria, Leishmaniasis and Trypanosomiases. **2013**, 20, 502-526	1
1956	Getting personal with neoantigen-based therapeutic cancer vaccines. **2013**, 1, 11-5	133
1955	Differentiated thyroid carcinomas and their B7H1 shield. **2013**, 9, 1417-9	8
1954	Striving for synergy: how to improve cancer immunotherapy through multiple agonist costimulation. **2013**, 5, 1271-3	1
1953	Immune aspects of the breast tumor microenvironment. **2013**, 2, 231-244	11
1952	[Perspectives on immunotherapy for hepatocellular carcinoma]. **2013**, 138, 740-4	2
1951	CD4 T-cell immunotherapy for chronic viral infections and cancer. **2013**, 5, 975-87	43
1950	Immunotherapy treatments for small-cell lung cancer: past, present and future. **2013**, 2, 517-525	1
1949	[Immune-checkpoints: the new anti-cancer immunotherapies]. **2013**, 100, 601-10	7
1948	New therapeutic targets and drugs for the treatment of chronic hepatitis B. **2013**, 33, 130-7	21
1947	Immunotherapy in lung cancer: "b7-bombers" and other new developments. **2013**, 34, 810-21	6
1946	Pathological mobilization and activities of dendritic cells in tumor-bearing hosts: challenges and opportunities for immunotherapy of cancer. **2013**, 4, 435	16

1945	Immunotherapy and immune evasion in prostate cancer. **2013**, 5, 569-90	17
1944	Biologics in dermatology. **2013**, 6, 557-78	7
1943	Th2 cell-intrinsic hypo-responsiveness determines susceptibility to helminth infection. **2013**, 9, e1003215	44
1942	Targeted agents in non-small cell lung cancer therapy: What is there on the horizon?. **2013**, 12, 7	10
1941	Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy. **2013**, 2013, 371854	52
1940	Impact of MAPK Pathway Activation in BRAF(V600) Melanoma on T Cell and Dendritic Cell Function. **2013**, 4, 346	31
1939	The role of the immune response in merkel cell carcinoma. **2013**, 5, 234-54	28
1938	TIM-3 does not act as a receptor for galectin-9. **2013**, 9, e1003253	68
1937	Combining regulatory T cell depletion and inhibitory receptor blockade improves reactivation of exhausted virus-specific CD8+ T cells and efficiently reduces chronic retroviral loads. **2013**, 9, e1003798	59
1936	Xiao-Ai-Ping, a TCM Injection, Enhances the Antigrowth Effects of Cisplatin on Lewis Lung Cancer Cells through Promoting the Infiltration and Function of CD8(+) T Lymphocytes. **2013**, 2013, 879512	15
1935	Identification of Pre- and Post-Treatment Markers, Clinical, and Laboratory Parameters Associated with Outcome in Renal Cancer Patients Treated with MVA-5T4. **2013**, 3, 185	7
1934	Paradigm Shift in Metastatic Malignant Melanoma. **2013**, 23, 3-9	1
1933	Dendritic cell based vaccines for HIV infection: the way ahead. **2013**, 9, 2445-52	49
1932	Clonal expansion of renal cell carcinoma-infiltrating T lymphocytes. **2013**, 2, e26014	16
1931	Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. **2013**, 36, 382-9	393
1930	Immune checkpoint inhibitors as novel targets for renal cell carcinoma therapeutics. **2013**, 19, 348-52	16
1929	A new age for vaccine therapy in renal cell carcinoma. **2013**, 19, 365-70	15
1928	A pan-inhibitor of DASH family enzymes induces immune-mediated regression of murine sarcoma and is a potent adjuvant to dendritic cell vaccination and adoptive T-cell therapy. **2013**, 36, 400-11	7

1927 Vaccine and immunotherapeutic interventions. **2013**, 8, 236-42 17

1926 Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies. **2013**, 19, 50-8 17

1925 Immune activation and HIV persistence: considerations for novel therapeutic interventions. **2013**, 8, 211-6 57

1924 Locally advanced lung cancer: an optimal setting for vaccines and other immunotherapies. **2013**, 19, 247-62 14

1923 CD40 therapy and surgery: a potential immunologic partnership. **2013**, 36, 359-61 5

1922 Inhibiting autophagy: a novel approach for the treatment of renal cell carcinoma. **2013**, 19, 341-7 24

1921 Endogenous tumor-reactive CD8 T cells are differentiated effector cells expressing high levels of CD11a and PD-1 but are unable to control tumor growth. **2013**, 2, e23972 30

1920 Cancer vaccines: Looking to the future. **2013**, 2, e23403 45

1919 BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes. **2013**, 2, e26615 82

1918 Second-Line Therapy for Advanced NSCLC. **2013**, 18, 947-53 30

1917 Novel recombinant human b7-h4 antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses. **2013**, 73, 4820-9 79

1916 Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. **2013**, 19, 1021-34 381

1915 PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction. **2013**, 19, 1363-74 151

1914 Recent developments in the treatment of renal cell carcinoma. **2013**, 5, 338-53 57

1913 T-cell therapies for HIV. **2013**, 5, 407-14 40

1912 Myeloablation for lymphoma--question answered?. *New England Journal of Medicine*, **2013**, 369, 1750-1 59.2 5

1911 Chemotherapy and molecularly targeted therapies for recurrent head and neck cancer. **2013**, 100-115

1910 HLA-restricted CTL that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients. **2013**, 73, 1764-76 62

1909	What lies within: novel strategies in immunotherapy for non-small cell lung cancer. **2013**, 18, 1203-13	30
1908	Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy. **2013**, 210, 2435-66	197
1907	Tumor-specific T-cell help is associated with improved survival in melanoma. **2013**, 19, 4021-3	13
1906	Molecular insights for optimizing T cell receptor specificity against cancer. **2013**, 4, 154	27
1905	New treatment approaches in melanoma: current research and clinical prospects. **2013**, 5, 73-80	16
1904	Targeted therapies in non-small cell lung carcinoma: what have we achieved so far?. **2013**, 5, 249-70	34
1903	Radiation-induced equilibrium is a balance between tumor cell proliferation and T cell-mediated killing. **2013**, 190, 5874-81	122
1902	Endocrine side-effects of anti-cancer drugs: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses. **2013**, 169, R153-64	82
1901	Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm. **2013**, 5, 105-18	31
1900	Transnuclear TRP1-specific CD8 T cells with high or low affinity TCRs show equivalent antitumor activity. **2013**, 1, 99-111	37
1899	PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells. **2013**, 123, 2604-15	174
1898	Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. **2013**, 18, 123-33	376
1897	Batf3-dependent dendritic cells in the renal lymph node induce tolerance against circulating antigens. **2013**, 24, 543-9	29
1896	New combinations and immunotherapies for melanoma: latest evidence and clinical utility. **2013**, 5, 278-85	21
1895	Vemurafenib-induced cardiac tamponade: a rare but potentially life-threatening complication. **2013** , 31, e364-6	10
1894	Merkel polyomavirus-specific T cells fluctuate with merkel cell carcinoma burden and express therapeutically targetable PD-1 and Tim-3 exhaustion markers. **2013**, 19, 5351-60	143
1893	Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. **2013**, 19, 3936-43	331
1892	Harnessing immune responses in the tumor microenvironment: all signals needed. **2013**, 19, 6061-3	12

1891	Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer. **2013**, 1, 123-33	52
1890	Novel cancer therapies: treatments driven by tumour biology. **2013**, 89, 652-8	14
1889	PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis. **2013**, 210, 757-74	169
1888	Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial). **2013**, 24, 2875-80	38
1887	TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu. **2013**, 4, 363	64
1886	Statins Reduce Melanoma Development and Metastasis through MICA Overexpression. **2013**, 4, 62	33
1885	Immunotherapy in advanced cutaneous melanoma patients. **2013**, 5, 429-433	
1884	Influence of tumors on protective anti-tumor immunity and the effects of irradiation. **2013**, 3, 14	7
1883	Role of T cell receptor affinity in the efficacy and specificity of adoptive T cell therapies. **2013**, 4, 244	61
1882	Programmed Cell Death 1-Directed Immunotherapy for Enhancing T-Cell Function. **2013**, 78, 239-247	29
1881	Emerging treatments in management of prostate cancer: biomarker validation and endpoints for immunotherapy clinical trial design. **2014**, 3, 1-8	4
1880	Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management. **2013**, 2013, 857519	151
1879	Gene therapy for advanced melanoma: selective targeting and therapeutic nucleic acids. **2013**, 2013, 897348	14
1878	Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation. **2013**, 2, e22837	22
1877	Blockade of PD-1 immunosuppression boosts CAR T-cell therapy. **2013**, 2, e26286	86
1876	PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival. **2013**, 1, 54-63	277
1875	Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. **2013**, 31, e439-42	631
1874	Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1). **2013**, 110, 15001-6	134

1873	Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects. **2013**, 5, 169-81	121
1872	Surgical management of the patient with metastatic melanoma to the heart. **2013**, 28, 124-8	4
1871	PD-1 as a potential target in cancer therapy. **2013**, 2, 662-73	306
1870	Apolipoprotein A1 as a potential biomarker in the ascitic fluid for the differentiation of advanced ovarian cancers. **2013**, 18, 532-41	13
1869	Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer. **2013**, 73, 2381-8	115
1868	Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27-transgenic mice. **2013**, 191, 4174-83	74
1867	CTLA4Ig inhibits effector T cells through regulatory T cells and TGF-**2013**, 191, 3082-9	33
1866	Immunological responses to a multi-peptide vaccine targeting cancer-testis antigens and VEGFRs in advanced pancreatic cancer patients. **2013**, 2, e27010	36
1865	Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology. **2013**, 31, 131-61	35
1864	Adaptive immune resistance in HPV-associated head and neck squamous cell carcinoma. **2013**, 2, e24065	12
1863	Inverse association between programmed death ligand 1 and genes in the VEGF pathway in primary clear cell renal cell carcinoma. **2013**, 1, 378-85	31
1862	The role of personalized medicine in metastatic colorectal cancer: an evolving landscape. **2013**, 6, 381-95	28
1861	The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia. **2013**, 98, 953-63	148
1860	Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma. **2013**, 2, e24320	36
1859	Re-orienting the immune system: Durable tumor regression and successful re-induction therapy using anti-PD1 antibodies. **2013**, 2, e23661	21
1858	Trial watch: Monoclonal antibodies in cancer therapy. **2013**, 2, e22789	76
1857	Cutaneous T cell lymphoma cells are targets for immune checkpoint ligand PD-L1-specific, cytotoxic T cells. **2013**, 27, 2251-3	36
1856	Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer. **2013**, 109, 2665-74	145

1855	The delicate balance of melanoma immunotherapy. **2013**, 2, e5	21
1854	Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer. **2013**, 108, 1560-5	114
1853	Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. **2013**, 19, 5636-46	485
1852	Immune alterations in malignant melanoma and current immunotherapy concepts. **2013**, 13, 1413-27	19
1851	Adoptive T-cell transfer in melanoma. **2013**, 5, 79-90	19
1850	Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. **2013**, 19, 5626-35	293
1849	Strategies to improve the immunogenicity of anticancer vaccines based on dendritic cell/malignant cell fusions. **2013**, 2, e25994	13
1848	HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function. **2013**, 110, 9879-84	113
1847	Vaccine therapy for pancreatic cancer. **2013**, 2, e26662	40
1846	The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4 T cells. **2013**, 2, e23991	42
1845	Molecular profiling of tumor-specific T1 cells activated in vivo. **2013**, 2, e24383	11
1844	Targeting castration-resistant prostate cancer with monoclonal antibodies and constructs. **2013**, 5, 1347-55	4
1843	The immunological identity of tumor: Self implications. **2013**, 2, e23794	4
1842	SOX2-specific adaptive immunity and response to immunotherapy in non-small cell lung cancer. **2013**, 2, e25205	46
1841	Inhibiting the inhibitors: Checkpoints blockade in solid tumors. **2013**, 2, e26535	15
1840	Long-term Vaccination with Multiple Peptides Derived from Cancer-Testis Antigens Can Maintain a Specific T-cell Response and Achieve Disease Stability in Advanced Biliary Tract Cancer. **2013**, 19, 2224-31	42
1839	Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity. **2013**, 3, 3544	42
1838	Chemotherapy: still an essential player in non-small-cell lung cancer treatment?. **2013**, 2, 381-390	

1837	gene expression in Japanese lung cancer patients. **2013**, 1, 93-96	10
1836	Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes. **2013**, 122, 1399-410	64
1835	Inhibiting inhibitory pathways in human T cells. **2013**, 122, 857-8	2
1834	The role of B7 family molecules in hematologic malignancy. **2013**, 121, 734-44	132
1833	A shot in the arm for radiotherapy. **2013**, 121, 246-8	
1832	Exhausting T cells in CLL. **2013**, 121, 1485-6	21
1831	The microenvironment of AIDS-related diffuse large B-cell lymphoma provides insight into the pathophysiology and indicates possible therapeutic strategies. **2013**, 122, 424-33	42
1830	Advances in the treatment of late stage melanoma. **2013**, 346, f1265	5
1829	Melanoma mutagenesis and aberrant cell signaling. **2013**, 20, 261-81	20
1828	New targeted therapies in melanoma. **2013**, 20, 282-8	10
1827	Novel treatments for melanoma brain metastases. **2013**, 20, 298-306	12
1826	Next-generation cancer vaccine approaches: integrating lessons learned from current successes with promising biotechnologic advances. **2013**, 11, 766-72	9
1825	Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy. **2013**, 20, 289-97	80
1824	Development of targeted therapies for triple-negative breast cancer: can we harness tumor heterogeneity to improve patient outcomes?. **2013**, 2, 175-178	
1823	Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1). **2013**, 8, 803-5	105
1822	Current Advances in Therapy for Metastatic Melanoma. **2013**, 9, 8-23	
1821	Primary care for cancers at diagnosis and follow-up: a narrative review. **2013**, 1, 56-67	
1820	Molecular diagnostics of head and neck cancer. **2013**, 24-50	

1819	Mammary carcinoma cell derived cyclooxygenase 2 suppresses tumor immune surveillance by enhancing intratumoral immune checkpoint activity. **2013**, 15, R75	44
1818	Etiology and risk factors. **2013**, 10-22	
1817	Prognostic biomarkers in squamous cell carcinoma of the head and neck. **2013**, 116-131	
1816	Melanoma, version 2.2013: featured updates to the NCCN guidelines. **2013**, 11, 395-407	112
1815	Clinical significance of B7-H4 expression in matched non-small cell lung cancer brain metastases and primary tumors. **2013**, 6, 869-75	22
1814	Challenges and opportunities for cancer vaccines in the current NSCLC clinical scenario. **2013**, 13, 2551-61	2
1813	Targeting immunosuppression for cancer therapy. **2013**, 123, 2355-7	42
1812	What are the molecules involved in regulatory T-cells induction by dendritic cells in cancer?. **2013**, 2013, 806025	19
1811	Tivozanib in the treatment of renal cell carcinoma. **2013**, 7, 139-48	14
1810	Engineering Anti-Tumor T Cell Immunity. **2013**, 02,	
1809	Molecular targeted therapies in metastatic melanoma. **2013**, 6, 49-56	20
1808	Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalities. **2013**, 2, 73-90	23
1807	Influence of the oncolytic parvovirus H-1, CTLA-4 antibody tremelimumab and cytostatic drugs on the human immune system in a human in vitro model of colorectal cancer cells. **2013**, 6, 1119-27	14
1806	Immunotherapy for colorectal cancer. **2013**, 19, 8531-42	65
1805	T cell immunoglobulin domain and mucin domain-3 as an emerging target for immunotherapy in cancer management. **2013**, 2, 135-41	3
1804	Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia. **2013**, 8, e55818	92
1803	High SOX2 levels predict better outcome in non-small cell lung carcinomas. **2013**, 8, e61427	38
1802	A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection. **2013**, 8, e63818	181

1801	The role of the e3 ligase cbl-B in murine dendritic cells. **2013**, 8, e65178	10
1800	PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer. **2013**, 8, e65821	173
1799	Expression of IL-27 by tumor cells in invasive cutaneous and metastatic melanomas [corrected]. **2013**, 8, e75694	19
1798	Natural killer T cells in advanced melanoma patients treated with tremelimumab. **2013**, 8, e76829	14
1797	PD-1 blockade in chronically HIV-1-infected humanized mice suppresses viral loads. **2013**, 8, e77780	75
1796	Phenotypic and transcriptional fidelity of patient-derived colon cancer xenografts in immune-deficient mice. **2013**, 8, e79874	28
1795	Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go. **2013**, 4, 417	53
1794	Dendritic cell-targeted approaches to modulate immune dysfunction in the tumor microenvironment. **2013**, 4, 436	14
1793	Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. **2013**, 3, 54	25
1792	Chemokines as Cancer Vaccine Adjuvants. **2013**, 1, 444-62	25
1791	Current trends in glioblastoma multiforme treatment: radiation therapy and immune checkpoint inhibitors. **2013**, 1, 2-8	12
1790	Current and emerging treatment options for uveal melanoma. **2013**, 7, 1669-82	56
1789	Cancer testis antigen and immunotherapy. **2013**, 2, 11-9	34
1788	New chemotherapeutic strategies against malaria, leishmaniasis and trypanosomiases. **2013**, 20, 502-26	20
1787	Melanoma vaccines: trials and tribulations. **2013**, 57	8
1786	Developments in the treatment of locally advanced and metastatic squamous cell carcinoma of the skin: a rising unmet need. **2014**, e397-404	18
1785	Programmed death-1/programmed death-1 ligand axis as a therapeutic target in oncology: current insights. **2014**, 1	1
1784	New modalities of cancer treatment for NSCLC: focus on immunotherapy. **2014**, 6, 63-75	55

1783 Avoidance of Cancer Cell Destruction by the Immune System. **2014**, 434-443

1782 Interferon-□and celecoxib inhibit lung-tumor growth through modulating M2/M1 macrophage ratio in the tumor microenvironment. **2014**, 8, 1527-38 23

1781 [Tumor hypoxia: a key player in the regulation of stromal and anti-tumor responses]. **2014**, 30, 422-8 3

1780 Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma. **2014**, 7, 567-73 172

1779 Therapeutic cancer vaccines and combination immunotherapies involving vaccination. **2014**, 3, 135-50 8

1778 PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer. **2014**, 9, e89350 135

1777 Systemic CD8+ T cell-mediated tumoricidal effects by intratumoral treatment of oncolytic herpes simplex virus with the agonistic monoclonal antibody for murine glucocorticoid-induced tumor necrosis factor receptor. **2014**, 9, e104669 9

1776 Advances and Prospects in Cancer Immunotherapy. **2014**, 2014, 1-13 16

1775 Current and future roles of targeted therapy and immunotherapy in advanced melanoma. **2014**, 20, 346-56 44

1774 Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway. **2014**, 7, 357-65 49

1773 Pathways and therapeutic targets in melanoma. **2014**, 5, 1701-52 158

1772 Non-Small Cell Lung Cancer beyond Biomarkers: The Evolving Landscape of Clinical Trial Design. **2014**, 4, 386-401 12

1771 Immunotherapy for non-small cell lung cancer. **2014**, 77, 111-5 18

1770 PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence. **2014**, 7, 1349-59 32

1769 Immunotherapy for Bladder Cancer: Changing the Landscape. **2014**, 3,

1768 An updated overview of HPV-associated head and neck carcinomas. **2014**, 5, 3956-69 83

1767 Molecular pathways and therapeutic targets in lung cancer. **2014**, 5, 1392-433 135

1766 PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases. **2014**, 5, 166-72 116

1765	Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma. **2014**, 8, 775-87	25
1764	The CD28-B7 Family in Anti-Tumor Immunity: Emerging Concepts in Cancer Immunotherapy. **2014**, 14, 265-76	65
1763	Pancreatic Cancer Fostered Immunosuppression Privileges Tumor Growth and Progression. **2014**, 05,	3
1762	Harnessing immunosurveillance: current developments and future directions in cancer immunotherapy. **2014**, 3, 151-65	9
1761	EBV-driven LMP1 and IFN-□up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy. **2014**, 5, 12189-202	246
1760	Druggable Targets in Pancreatic Adenocarcinoma. **2014**, 5, 195-214	
1759	Manipulating Immune Regulatory Pathways to Enhance T Cell Stimulation. **2014**,	3
1758	Molecular Targeted Therapy in Lung Cancer. **2014**, 34, 37	1
1757	. **2014**,	1
1756	50 Years of progress in the systemic therapy of non-small cell lung cancer. **2014**, 177-89	75
1755	Precision cancer medicine: the future is now, only better. **2014**, 61-9	30
1754	Erfolge und Grenzen zielgerichteter Therapien beim Nierenzellkarzinom. **2014**, 1, 66-74	
1753	Adding fuel to the fire: immunogenic intensification. **2014**, 10, 3306-12	3
1752	Targeting programmed cell death ligand 1 in osteosarcoma: an auto-commentary on therapeutic potential. **2014**, 3, e954467	13
1751	The changing immune system in sepsis: is individualized immuno-modulatory therapy the answer?. **2014**, 5, 45-56	181
1750	PI3K pathway inhibitors: potential prospects as adjuncts to vaccine immunotherapy for glioblastoma. **2014**, 6, 737-53	14
1749	Subverting the adaptive immune resistance mechanism to improve clinical responses to immune checkpoint blockade therapy. **2014**, 3, e954868	8
1748	Molecular pathways: interleukin-15 signaling in health and in cancer. **2014**, 20, 2044-50	118

1747	PD-1 and PD-L1 antibodies for melanoma. **2014**, 10, 3111-6	41
1746	Recent progress in peptide vaccination in cancer with a focus on non-small-cell lung cancer. **2014**, 13, 87-116	3
1745	Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. **2014**, 3, e27297	86
1744	Economic evaluation of therapeutic cancer vaccines and immunotherapy: a systematic review. **2014** , 10, 3415-24	28
1743	Non-BRAF-targeted therapy, immunotherapy, and combination therapy for melanoma. **2014**, 14, 663-86	16
1742	Active specific immunotherapy: using tumor heterogeneity to successfully fight cancer. **2014**, 10, 3286-96	1
1741	Ocular Melanoma: Advances in Diagnostic and Therapeutic Strategies. **2014**,	
1740	Role of the MEK inhibitor trametinib in the treatment of metastatic melanoma. **2014**, 10, 1559-70	16
1739	Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy. **2014**, 10, 3354-68	53
1738	Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome. **2014**, 2, 40	41
1737	Engineered chimeric antigen receptor-expressing T cells for the treatment of pancreatic ductal adenocarcinoma. **2014**, 3, e28327	9
1736	Detailed characterization of tumor infiltrating lymphocytes in two distinct human solid malignancies show phenotypic similarities. **2014**, 2, 38	25
1735	Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer. **2014**, 14, 748	74
1734	Melanoma immunotherapy. **2014**, 15, 665-74	54
1733	Im Fokus das Nierenzellkarzinom. **2014**, 17, 23-26	
1732	Intratumoral anti-HuD immunotoxin therapy for small cell lung cancer and neuroblastoma. **2014**, 7, 91	18
1731	Lungenkarzinom. **2014**, 17, 14-21	
1730	Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy. **2014**, 3, e27817	157

1729	Harnessing the immune system to provide long-term survival in patients with melanoma and other solid tumors. **2014**, 3, e27560	34
1728	Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects. **2014**, 13, 219	28
1727	Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013. **2014**, 12, 277	10
1726	Functional expression cloning identifies COX-2 as a suppressor of antigen-specific cancer immunity. **2014**, 5, e1568	38
1725	Myeloid cells' evasion of melanoma immunity. **2014**, 134, 2675-2677	3
1724	Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression. **2014**, 4, e236	40
1723	Current advances in T-cell-based cancer immunotherapy. **2014**, 6, 1265-78	92
1722	Antibodies to watch in 2014. **2014**, 6, 5-14	80
1721	Successes and limitations of targeted therapies in renal cell carcinoma. **2014**, 41, 98-112	8
1720	Third- and further-line therapy in advanced non-small-cell lung cancer patients: an overview. **2014**, 10, 2081-96	13
1719	Fc□receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerization. **2014**, 193, 1828-35	45
1718	The pancreatic cancer microenvironment: an immunologic battleground. **2014**, 3, e950171	20
1717	Ovarian cancer from an immune perspective. **2014**, 182, 239-51	3
1716	CD271 on melanoma cell is an IFN-□nducible immunosuppressive factor that mediates downregulation of melanoma antigens. **2014**, 134, 1369-1377	41
1715	Immune checkpoints: A therapeutic target in triple negative breast cancer. **2014**, 3, e28325	31
1714	Overcoming tumor-mediated immunosuppression. **2014**, 6, 973-88	28
1713	Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. **2014**, 24, 743-50	440
1712	The future of cancer therapy: selecting patients likely to respond to PD1/L1 blockade. **2014**, 20, 4982-4	70

1711	Advanced pancreatic cancer: flourishing novel approaches in the era of biological therapy. **2014**, 19, 937-50	7
1710	Autoimmunity as a double agent in tumor killing and cancer promotion. **2014**, 5, 116	32
1709	Does the immune system naturally protect against cancer?. **2014**, 5, 197	141
1708	Promising targets and current clinical trials in metastatic squamous cell lung cancer. **2014**, 4, 320	5
1707	Exploiting synergy: immune-based combinations in the treatment of prostate cancer. **2014**, 4, 351	12
1706	B7-H4 expression and its role in interleukin-2/interferon treatment of clear cell renal cell carcinoma. **2014**, 7, 1474-1478	17
1705	HIV-1 latency: an update of molecular mechanisms and therapeutic strategies. **2014**, 6, 1715-58	46
1704	Is vaccine research still relevant for metastatic melanoma?. **2014**, 1, 91-94	4
1703	Induction of Wnt-inducible signaling protein-1 correlates with invasive breast cancer oncogenesis and reduced type 1 cell-mediated cytotoxic immunity: a retrospective study. **2014**, 10, e1003409	35
1702	The role of inflammation in kidney cancer. **2014**, 816, 197-234	62
1701	BRAF and beyond: Tailoring strategies for the individual melanoma patient. **2014**, 13, 1	13
1700	Human cytomegalovirus antigens in malignant gliomas as targets for adoptive cellular therapy. **2014**, 4, 338	9
1699	Restoring the balance: immunotherapeutic combinations for autoimmune disease. **2014**, 7, 503-13	65
1698	Melanoma stem cells and metastasis: mimicking hematopoietic cell trafficking?. **2014**, 94, 13-30	56
1697	Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC. **2014**, 4, 329	30
1696	Immune correlates of talactoferrin alfa in biopsied tumor of relapsed/refractory metastatic non-small cell lung cancer patients. **2014**, 36, 182-6	1
1695	Immunotherapeutic and oncolytic viral therapeutic strategies in pancreatic cancer. **2014**, 10, 1255-75	5
1694	Treating advanced melanoma: current insights and opportunities. **2014**, 6, 349-56	26

1693	Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection. **2014**, 10, e1003856	185
1692	New clinical research strategies in thoracic oncology: clinical trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of response. **2014**, 23, 367-78	60
1691	Whole-Cell Vaccines. **2014**, 1-14	
1690	Combining chemotherapy and checkpoint blockade in thoracic cancer: how to proceed?. **2014**, 3, 443-457	7
1689	Identification of a novel HLA-A 02:01-restricted cytotoxic T lymphocyte epitope derived from the EML4-ALK fusion gene. **2014**, 32, 33-9	5
1688	Recent advances of immunotherapy in lung cancer: anti-programmed cell death-1/programmed death ligand-1 antibodies. **2014**, 3, 175-190	1
1687	[Immunotherapies and melanoma]. **2014**, 101 Suppl 2, S13-24	1
1686	New treatments for metastatic melanoma. **2014**, 186, 754-60	9
1685	Targeting CD8+ T-cell tolerance for cancer immunotherapy. **2014**, 6, 833-52	37
1684	Treatment strategies for clinically detectable metastatic uveal melanoma. **2014**, 168-190	
1683	Perspektiven f□eine Immuntherapie beim hepatozellul□en Karzinom. **2014**, 35, 286-290	
1682	Tivozanib for the treatment of renal cell carcinoma: results and implications of the TIVO-1 trial. **2014**, 10, 1819-26	6
1681	Does vaccine-primed pancreatic cancer offer better candidates for immune-based therapies?. **2014**, 6, 1017-20	9
1680	The expanding horizon of immunotherapy in the treatment of malignant disorders: allogeneic hematopoietic stem cell transplantation and beyond. **2014**, 46, 384-96	12
1679	Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. **2014**, 40, 1056-64	146
1678	New Approaches in Immunotherapy for the Treatment of Lung Cancer. **2017**, 405, 1-31	6
1677	High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial. **2014**, 28, 2367-75	239
1676	Tumoral immune suppression by macrophages expressing fibroblast activation protein-□and heme oxygenase-1. **2014**, 2, 121-6	91

1675	Identification and characterization of bovine programmed death-ligand 2. **2014**, 58, 388-97	1
1674	Immunotherapy and lung cancer: current developments and novel targeted therapies. **2014**, 6, 1221-35	41
1673	CD160 expression defines a uniquely exhausted subset of T lymphocytes in HTLV-1 infection. **2014**, 453, 379-84	9
1672	Newly discovered olfactory receptors in epidermal keratinocytes are associated with proliferation, migration, and re-epithelialization of keratinocytes. **2014**, 134, 2677-2679	10
1671	Moving receptor redirected adoptive cell therapy toward fine tuning of antitumor responses. **2014**, 33, 402-16	10
1670	Immunotherapy in pediatric malignancies: current status and future perspectives. **2014**, 10, 1659-78	10
1669	Significant involvement of herpesvirus entry mediator in human esophageal squamous cell carcinoma. **2014**, 120, 808-17	23
1668	Adoptive cellular therapy of cancer: exploring innate and adaptive cellular crosstalk to improve anti-tumor efficacy. **2014**, 10, 1779-94	7
1667	Signals and pathways controlling regulatory T cells. **2014**, 258, 117-31	41
1666	Immunotherapy and radiation therapy: considerations for successfully combining radiation into the paradigm of immuno-oncology drug development. **2014**, 182, 252-7	12
1665	Re-adapting T cells for cancer therapy: from mouse models to clinical trials. **2014**, 257, 145-64	60
1664	Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. **2014**, 23, 2965-70	348
1663	Advances in Tumor Immunology and Immunotherapy. **2014**,	0
1662	Future agents and treatment directions in multiple myeloma. **2014**, 7, 127-41	25
1661	Nano-Oncologicals. **2014**,	4
1660	Assessment of MAGE-A expression in resected non-small cell lung cancer in relation to clinicopathologic features and mutational status of EGFR and KRAS. **2014**, 2, 943-8	17
1659	Antibody engineering and therapeutics, The Annual Meeting of the Antibody Society: December 8-12, 2013, Huntington Beach, CA. **2014**, 6, 577-618	5
1658	Recent evidence, advances, and current practices in surgical treatment of lung cancer. **2014**, 52, 322-9	11

1657	The use of endogenous T cells for adoptive transfer. **2014**, 257, 250-63	49
1656	Universes collide: combining immunotherapy with targeted therapy for cancer. **2014**, 4, 1377-86	62
1655	PD-1 blockade induces responses by inhibiting adaptive immune resistance. **2014**, 515, 568-71	4014
1654	Astronomy: Cosmic triangles and black-hole masses. **2014**, 515, 498-9	
1653	Cancer: Antitumour immunity gets a boost. **2014**, 515, 496-8	77
1652	Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. **2014**, 515, 563-7	3354
1651	The evolving genomic classification of lung cancer. **2014**, 232, 121-33	74
1650	High-dose IL2 in metastatic melanoma: better survival in patients immunized with antigens from autologous tumor cell lines. **2014**, 29, 53-7	13
1649	Current management and future perspectives of metastatic renal cell carcinoma. **2014**, 21, 847-55	24
1648	The immunogenicity of breast cancer--molecular subtypes matter. **2014**, 25, 1453-5	24
1647	Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. **2014**, 111, 11774-9	426
1646	Clinical impact of checkpoint inhibitors as novel cancer therapies. **2014**, 74, 1993-2013	77
1645	Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer. **2014**, 120, 624-32	39
1644	PD-1 blockade in renal cell carcinoma: to equilibrium and beyond. **2014**, 2, 1132-41	33
1643	Silibinin inhibits accumulation of myeloid-derived suppressor cells and tumor growth of murine breast cancer. **2014**, 3, 215-24	40
1642	Major therapeutic developments and current challenges in advanced melanoma. **2014**, 170, 36-44	18
1641	Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. **2014**, 5, 5241	573
1640	Investigating the positive relationship between tumor-infiltrating lymphocytes and trastuzumab therapy. **2014**, 6, 803-5	4

1639	Epitope mapping of epidermal growth factor receptor (EGFR) monoclonal antibody and induction of growth-inhibitory polyclonal antibodies by vaccination with EGFR mimotope. **2014**, 36, 309-15	9
1638	Emerging therapies for adult soft tissue sarcoma. **2014**, 14, 689-704	44
1637	Evolving role of tumor antigens for future melanoma therapies. **2014**, 10, 1457-68	11
1636	Harnessing the PD-1 pathway in renal cell carcinoma: current evidence and future directions. **2014**, 28, 513-26	7
1635	Dabrafenib for the treatment of melanoma. **2014**, 15, 1043-50	4
1634	[Immunotherapies and targeted therapies in medical oncology]. **2014**, 101, 31-9	2
1633	Evaluation of statistical designs in phase I expansion cohorts: the Dana-Farber/Harvard Cancer Center experience. **2014**, 106,	38
1632	Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. **2014**, 6, 254ra128	281
1631	Blimp-1 represses CD8 T cell expression of PD-1 using a feed-forward transcriptional circuit during acute viral infection. **2014**, 211, 515-27	101
1630	T-cell immune suppression in patients with hematologic malignancies: clinical implications. **2014**, 3, 289-297	4
1629	Role of immunotherapy in the treatment of advanced non-small-cell lung cancer. **2014**, 10, 79-90	21
1628	Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade. **2014**, 2, 42	148
1627	The hepatitis B virus-associated tumor microenvironment in hepatocellular carcinoma. **2014**, 1, 396-412	50
1626	Regression of metastatic Merkel cell carcinoma following transfer of polyomavirus-specific T cells and therapies capable of re-inducing HLA class-I. **2014**, 2, 27-36	69
1625	Dacarbazine with or without oblimersen (a Bcl-2 antisense oligonucleotide) in chemotherapy-naive patients with advanced melanoma and low-normal serum lactate dehydrogenase: 'The AGENDA trial'. **2014**, 24, 237-43	28
1624	A phase I study of high-dose interleukin-2 with sorafenib in patients with metastatic renal cell carcinoma and melanoma. **2014**, 37, 180-6	9
1623	Renal cell carcinoma: molecular biology and targeted therapy. **2014**, 26, 321-7	41
1622	B7-H1/PD-1 blockade therapy in non-small cell lung cancer: current status and future direction. **2014**, 20, 281-9	52

1621	Implementing combinatorial immunotherapeutic regimens against cancer: The concept of immunological conditioning. **2014**, 3, e27588	12
1620	The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation. **2014**, 26, 204-14	57
1619	B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. **2014**, 9, 1036-1040	177
1618	Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation. **2014**, 20, 256-61	96
1617	Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC. **2014**, 9, 144-53	69
1616	Tumor-stroma crosstalk: targeting stroma in breast cancer. **2014**, 26, 551-5	37
1615	Biomarkers in early-stage non-small-cell lung cancer: current concepts and future directions. **2014**, 9, 1609-17	46
1614	Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain. **2014**, 38, 1715-23	117
1613	Harnessing the immune system for cancer therapy. **2014**, 26, 600-7	19
1612	Distinctive features of CD4+ T cell dysfunction in chronic viral infections. **2014**, 9, 446-51	35
1611	Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer. **2014**, 20, 272-80	14
1610	Tumor-associated antigen specific CD8 T cells in hepatocellular carcinoma - a promising target for immunotherapy. **2014**, 3, e954919	16
1609	Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation. **2014** , 4, 674-87	182
1608	Priming the pancreatic cancer tumor microenvironment for checkpoint-inhibitor immunotherapy. **2014**, 3, e962401	31
1607	Update in systemic therapy of urologic malignancies. **2014**, 126, 44-54	6
1606	Genetic evolution of T-cell resistance in the course of melanoma progression. **2014**, 20, 6593-604	106
1605	A novel combinatorial cancer immunotherapy: poly-IC and blockade of the PD-1/PD-L1 pathway. **2014**, 3, e28440	12
1604	Current readings: Window-of-opportunity trials for thoracic malignancies. **2014**, 26, 323-30	4

1603	Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. **2014**, 6, 237ra67	432
1602	Moving from histological subtyping to molecular characterization: new treatment opportunities in advanced non-small-cell lung cancer. **2014**, 14, 1495-513	6
1601	Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1. **2014**, 5, 206	89
1600	Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using myeloid-derived suppressor cells as a readout of therapeutic efficacy. **2014**, 3, e945378	27
1599	Novel immune checkpoint blocker approved for the treatment of advanced melanoma. **2014**, 3, e967147	23
1598	Postoperative dendritic cell vaccine plus activated T-cell transfer improves the survival of patients with invasive hepatocellular carcinoma. **2014**, 10, 970-6	36
1597	Discovering cancer immunotherapy targets in vivo. **2014**, 3, e28500	1
1596	PD-L1 expression and tumor-infiltrating lymphocytes: Revisiting the antitumor immune response potential in breast cancer. **2014**, 3, e29288	50
1595	Armed therapeutic viruses - a disruptive therapy on the horizon of cancer immunotherapy. **2014**, 5, 74	34
1594	Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. **2014**, 2, 643-54	190
1593	Structure and cancer immunotherapy of the B7 family member B7x. **2014**, 9, 1089-98	49
1592	Immunoguiding, the Final Frontier in the Immunotherapy of Cancer. **2014**, 37-51	
1591	Combinatorial immunotherapy of polyinosinic-polycytidylic acid and blockade of programmed death-ligand 1 induce effective CD8 T-cell responses against established tumors. **2014**, 20, 1223-34	71
1590	Combination therapies for the treatment of advanced melanoma: a review of current evidence. **2014**, 2014, 307059	14
1589	Oncolytic immunotherapy: where are we clinically?. **2014**, 2014, 862925	13
1588	Adoptive immunotherapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptors. **2014**, 7, 1049-68	17
1587	Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander". **2014**, 6, 914-33	51
1586	gene promoter polymorphisms correlate with a poor prognosis in non-small cell lung cancer. **2014**, 2, 1035-1042	18

1585	Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy. **2014**, 10, 207-17	49
1584	Immunologic treatments for precancerous lesions and uterine cervical cancer. **2014**, 33, 29	32
1583	Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy. **2014**, 2, 7	85
1582	Cancer immunoprevention--the next frontier. **2014**, 7, 1072-80	20
1581	Coinhibitory receptors and CD8 T cell exhaustion in chronic infections. **2014**, 9, 439-45	52
1580	Current and proposed molecular diagnostics in a genitourinary service line laboratory at a tertiary clinical institution. **2014**, 20, 29-42	15
1579	Blockade of the B7-H1/PD-1 pathway as a basis for combination anticancer therapy. **2014**, 20, 290-5	24
1578	Cutaneous melanoma. **2014**, 383, 816-27	379
1577	Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC. **2014**, 40, 445-56	100
1576	New drug targets in metastatic melanoma. **2014**, 232, 134-41	47
1575	A personalized view on cancer immunotherapy. **2014**, 352, 113-25	45
1574	Change of Address. **2014**, 70, 956	
1573	Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. **2014**, 50, 1361-9	241
1572	Summary report from the 13(th) Annual Targeted Therapies of the Treatment of Lung Cancer Meeting. **2014**, 15, 16-20	1
1571	Targeted therapies for cutaneous melanoma. **2014**, 28, 491-505	10
1570	Castration-resistant prostate cancer: from new pathophysiology to new treatment. **2014**, 65, 289-99	94
1569	Sequential therapy with targeted agents in metastatic renal cell carcinoma: beyond second-line and overcoming drug resistance. **2014**, 32, 19-29	10
1568	Harnessing the immune system for the treatment of breast cancer. **2014**, 15, 1-15	24

1567	Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. **2014**, 123, 2062-5	215
1566	Genetic alterations and personalized medicine in melanoma: progress and future prospects. **2014**, 106, djt435	57
1565	The new normal: immunomodulatory agents against sepsis immune suppression. **2014**, 20, 224-33	163
1564	Adoptive immunotherapy for cancer or viruses. **2014**, 32, 189-225	201
1563	STAT3, STAT4, NFATc1, and CTCF regulate PD-1 through multiple novel regulatory regions in murine T cells. **2014**, 192, 4876-86	90
1562	New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape. **2014**, 27, 16-25	882
1561	Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer. **2014**, 63, 215-24	81
1560	The GIST of targeted therapy for malignant melanoma. **2014**, 21, 2059-67	16
1559	Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs. **2014**, 12, 36	122
1558	Immunotherapy for non-small-cell lung cancer: current approaches. **2014**, 3, 19-25	2
1557	Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis. **2014**, 18, R3	177
1556	New treatment strategies for HPV-positive head and neck cancer. **2014**, 271, 1861-7	45
1555	CD4 T-cell subsets and tumor immunity: the helpful and the not-so-helpful. **2014**, 2, 91-8	199
1554	Regulatory T cells in cancer immunotherapy. **2014**, 27, 1-7	479
1553	Human relevance of NRAS/BRAF mouse melanoma models. **2014**, 93, 82-6	16
1552	B7-H4 as a potential target for immunotherapy for gynecologic cancers: a closer look. **2014**, 134, 181-189	36
1551	Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities. **2014**, 89, 140-65	122
1550	Immunotherapy for solid tumors--a review for surgeons. **2014**, 187, 525-35	14

1549	Targeted therapies in gastroesophageal cancer. **2014**, 50, 1247-58	41
1548	Orchestrating immune check-point blockade for cancer immunotherapy in combinations. **2014**, 27, 89-97	90
1547	Mechanisms of tumor escape from immune system: role of mesenchymal stromal cells. **2014**, 159, 55-72	81
1546	Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. **2014**, 120, 1695-701	151
1545	Endocrine therapy, immunotherapy and targeted therapies. **2014**, 215-224	
1544	Cancer Immunotherapy Meets Oncology. **2014**,	
1543	A killer choice for cancer immunotherapy. **2014**, 58, 300-6	16
1542	PD-L1 is a novel direct target of HIF-1□and its blockade under hypoxia enhanced MDSC-mediated T cell activation. **2014**, 211, 781-90	1136
1541	A soluble form of CD80 enhances antitumor immunity by neutralizing programmed death ligand-1 and simultaneously providing costimulation. **2014**, 2, 610-5	29
1540	Programmed death-1 pathway in cancer and autoimmunity. **2014**, 153, 145-52	182
1539	Anti-vascular endothelial growth factor receptor (VEGFR) 2 autoantibody identification in glioblastoma patient using single B cell-based antibody gene cloning. **2014**, 159, 15-22	6
1538	Effects of obesity on immune responses to renal tumors. **2014**, 59, 211-9	2
1537	Immunomodulation and immune reconstitution in chronic lymphocytic leukemia. **2014**, 51, 228-34	35
1536	Programmed death ligand-1 expression in non-small cell lung cancer. **2014**, 94, 107-16	591
1535	"In vitro" 3D models of tumor-immune system interaction. **2014**, 79-80, 145-54	63
1534	Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy. **2014**, 6, 459-75	76
1533	Recent clinical advances in lung cancer management. **2014**, 32, 973-82	169
1532	Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody. **2014**, 74, 2974-85	110

1531	Newer developments in the immunotherapy of malignant melanoma. **2014**, 20, 3-10	2
1530	Tumor-infiltrating lymphocytes and their significance in melanoma prognosis. **2014**, 1102, 287-324	61
1529	Palliative treatment of metastatic colorectal cancer: what is the optimal approach?. **2014**, 16, 363	8
1528	Adoptive T-cell therapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptors. **2014**, 99, 123-31	12
1527	Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma. **2014** , 28, 993-1000	81
1526	CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. **2014**, 20, 44-55	185
1525	Immune modulation in cancer with antibodies. **2014**, 65, 185-202	366
1524	Checkpoint blocking antibodies in cancer immunotherapy. **2014**, 588, 368-76	184
1523	Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines. **2014**, 33, 4623-31	96
1522	The immunoinhibitory B7-H1 molecule as a potential target in cancer: killing many birds with one stone. **2014**, 7, 1-17	72
1521	Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells. **2014**, 21, 262-71	62
1520	Beyond sipuleucel-T: immune approaches to treating prostate cancer. **2014**, 15, 115-26	11
1519	Mitigating the toxic effects of anticancer immunotherapy. **2014**, 11, 91-9	150
1518	The immune system and response to HER2-targeted treatment in breast cancer. **2014**, 15, e58-68	171
1517	Tolerance and exhaustion: defining mechanisms of T cell dysfunction. **2014**, 35, 51-60	380
1516	Immunotherapy for prostate cancer: recent developments and future challenges. **2014**, 33, 641-55	49
1515	In vivo discovery of immunotherapy targets in the tumour microenvironment. **2014**, 506, 52-7	159
1514	Molecularly targeted cancer therapy: some lessons from the past decade. **2014**, 35, 41-50	206

1513	DC-based immunotherapy for hematological malignancies. **2014**, 99, 117-22	4
1512	Soluble production of a biologically active single-chain antibody against murine PD-L1 in Escherichia coli. **2014**, 94, 60-6	9
1511	Biomarkers of renal cell carcinoma. **2014**, 32, 243-51	34
1510	Impaired and imbalanced cellular immunological status assessed in advanced cancer patients and restoration of the T cell immune status by adoptive T-cell immunotherapy. **2014**, 18, 90-7	24
1509	Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. **2014**, 11, 24-37	311
1508	Precision medicine for metastatic renal cell carcinoma. **2014**, 32, 5-15	14
1507	Targeting multiple pathways in breast cancer. **2014**, 3, 87-101	0
1506	Induced regulatory T cells in inhibitory microenvironments created by cancer. **2014**, 14, 1411-25	61
1505	The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer. **2014**, 18, 1407-20	28
1504	Immunotherapy for malignant pleural mesothelioma. Current status and future prospects. **2014**, 50, 870-5	21
1503	Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies. **2014**, 3, e22	48
1502	Immunotherapy and radiation. **2014**, 41, 702-13	7
1501	Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase. **2014**, 20, 221-32	94
1500	Novel Technologies for Vaccine Development. **2014**,	1
1499	Recent developments in the medical and surgical treatment of melanoma. **2014**, 64, 171-85	46
1498	Thérapies ciblées : quel traitement pour quel patient ?. **2014**, 6, 459-469	
1497	Adjuvant therapy for renal cell carcinoma. **2014**, 12, 408-12	5
1496	Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art. **2014**, 33, 1109-24	60

1495	Phenotyping of peripheral blood mononuclear cells of patients with advanced heavily pre-treated adenocarcinoma of the stomach and gastro-esophageal junction. **2014**, 63, 1273-84	1
1494	Current management of advanced melanoma: a transformed landscape. **2014**, 84, 612-7	11
1493	Programmed death 1 and B and T lymphocyte attenuator immunoreceptors and their association with malignant T-lymphoproliferative disorders: brief review. **2014**, 32, 113-9	13
1492	Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis. **2014**, 2, 15-8	82
1491	New Targets and New Drug Development in Colorectal Cancer. **2014**, 10, 288-295	1
1490	Induction of Bcl-xL-specific cytotoxic T lymphocytes in mice. **2014**, 80, 111-20	1
1489	Renal cell carcinoma. **2014**, 349, g4797	311
1488	Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. **2014**, 32, 3771-8	83
1487	Insights into the mechanism of organ-specific cancer metastasis. **2014**, 4, 1262-4	6
1486	Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. **2014**, 2, 616-31	322
1485	Specificity delivers: therapeutic role of tumor antigen-specific antibodies in pancreatic cancer. **2014**, 41, 559-75	3
1484	CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy. **2014**, 22, 1949-59	212
1483	Current perspectives on immunotherapy. **2014**, 41 Suppl 5, S14-29	23
1482	Impact of sepsis on CD4 T cell immunity. **2014**, 96, 767-77	98
1481	Metabolic orchestration between cancer cells and tumor microenvironment as a co-evolutionary source of chemoresistance in ovarian cancer: a therapeutic implication. **2014**, 92, 43-54	41
1480	Cancer immunotherapy: hype or ripe? [corrected]. **2014**, 44, 318-20	2
1479	Novel agents in development for advanced non-small cell lung cancer. **2014**, 6, 240-53	26
1478	PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics. **2014**, 25, 2433-2442	98

1477	The optimal partnership of radiation and immunotherapy: from preclinical studies to clinical translation. **2014**, 182, 170-81	70
1476	Hallmarks of gastrointestinal neuroendocrine tumours: implications for treatment. **2014**, 21, R445-60	38
1475	New strategies in acute myelogenous leukemia: leukemogenesis and personalized medicine. **2014**, 20, 6233-41	16
1474	Orchestration of pulmonary T cell immunity during Mycobacterium tuberculosis infection: immunity interruptus. **2014**, 26, 559-77	41
1473	Immune checkpoint inhibitors in NSCLC. **2014**, 15, 658-69	56
1472	The translation of cancer genomics: time for a revolution in clinical cancer care. **2014**, 6, 22	10
1471	Design and development of therapies using chimeric antigen receptor-expressing T cells. **2014**, 257, 107-26	338
1470	Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. **2014**, 20, 1301-9	596
1469	Combining radiation and immunotherapy: a new systemic therapy for solid tumors?. **2014**, 2, 831-8	226
1468	Immunotherapy advances for glioblastoma. **2014**, 16, 1441-58	136
1467	The carcinoma-associated fibroblast expressing fibroblast activation protein and escape from immune surveillance. **2014**, 2, 187-93	156
1466	PD-1(+) CD8(+) T cells are exhausted in tumours and functional in draining lymph nodes of colorectal cancer patients. **2014**, 111, 1391-9	68
1465	Fibroblast growth factor receptors as therapeutic targets in clear-cell renal cell carcinoma. **2014**, 23, 305-15	18
1464	Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. **2014**, 384, 1109-17	1340
1463	Acquired and intrinsic resistance in cancer immunotherapy. **2014**, 8, 1132-9	133
1462	Vaccine therapies for patients with glioblastoma. **2014**, 119, 531-46	24
1461	Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer?. **2014**, 14, 1173-87	23
1460	Tracking cellular and immune therapies in cancer. **2014**, 124, 257-96	24

1459 Immune modulation for cancer therapy. **2014**, 111, 2214-9 110

1458 Translational biology of osteosarcoma. **2014**, 14, 722-35 644

1457 Radionuclide imaging of drug delivery for patient selection in targeted therapy. **2014**, 11, 175-85 7

1456 LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses. **2014**, 74, 3418-28 180

1455 Programmed cell death 1 (PD-1) regulates the effector function of CD8 T cells via PD-L1 expressed on target keratinocytes. **2014**, 53, 1-9 38

1454 T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion?. **2014**, 14, 768-74 191

1453 No longer an untreatable disease: how targeted and immunotherapies have changed the management of melanoma patients. **2014**, 8, 1140-58 39

1452 New strategies in lung cancer: translating immunotherapy into clinical practice. **2014**, 20, 1067-73 36

1451 Enhancing efficacy of anticancer vaccines by targeted delivery to tumor-draining lymph nodes. **2014**, 2, 436-47 147

1450 Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. **2014**, 15, 829-40 237

1449 Non-small-cell lung cancers: a heterogeneous set of diseases. **2014**, 14, 535-46 934

1448 Heat-shock proteins-based immunotherapy for advanced melanoma in the era of target therapies and immunomodulating agents. **2014**, 14, 955-67 20

1447 Too much of a good thing? Tim-3 and TCR signaling in T cell exhaustion. **2014**, 193, 1525-30 111

1446 Mise au point 2014 du cancer bronchique non petites cellules (en dehors du dépistage). **2014**, 95, 708-712

1445 Antibodies in Cancer Treatment: Early Clinical Development. **2014**, 787-822

1444 PD-1 regulates extrathymic regulatory T-cell differentiation. **2014**, 44, 2603-16 68

1443 Follicular helper T-cells: expanding roles in T-cell lymphoma and targets for treatment. **2014**, 166, 326-35 39

1442 Programmed cell death ligand 1 expression in osteosarcoma. **2014**, 2, 690-698 135

1441	Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer. **2014**, 86, 231-6	32
1440	Systemic treatment for BRAF-mutant melanoma: where do we go next?. **2014**, 15, e371-81	114
1439	Towards a cure for HIV--are we making progress?. **2014**, 384, 209-11	18
1438	Role of lymphatic vasculature in regional and distant metastases. **2014**, 95, 46-52	59
1437	Therapeutic antibodies in breast cancer. **2014**, 41, 576-88	3
1436	Differential impact of PD-1 and/or interleukin-10 blockade on HIV-1-specific CD4 T cell and antigen-presenting cell functions. **2014**, 88, 2508-18	43
1435	Inflammatory biomarkers and bladder cancer prognosis: a systematic review. **2014**, 66, 1078-91	66
1434	Melanocytic Lesions. **2014**,	1
1433	Highlights from the latest articles in lung cancer personalized medicine. **2014**, 11, 377-379	
1432	The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity. **2014**, 193, 3835-41	127
1431	Molecular insights into the development of T cell-based immunotherapy for prostate cancer. **2014**, 10, 1547-57	6
1430	Strategies to eliminate HBV infection. **2014**, 9, 565-585	41
1429	Decade in review-cancer immunotherapy: entering the mainstream of cancer treatment. **2014**, 11, 630-2	121
1428	Systemic inflammation, as measured by the neutrophil/lymphocyte ratio, may have differential prognostic impact before and during treatment with fluorouracil, irinotecan and bevacizumab in metastatic colorectal cancer patients. **2014**, 31, 166	38
1427	Neue Substanzen f□ die Therapie solider Tumoren. **2014**, 29, 300-304	
1426	Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials. **2014**, 12, 132	50
1425	A pilot study of autologous tumor lysate-loaded dendritic cell vaccination combined with sunitinib for metastatic renal cell carcinoma. **2014**, 2, 30	21
1424	Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma. **2014**, 32, 3659-66	59

1423	Shaping of an effective immune microenvironment to and by cancer cells. **2014**, 63, 991-7	25
1422	Fc Receptors. **2014**,	8
1421	Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. **2014**, 74, 5458-68	704
1420	Dendritic cell-targeted vaccines--hope or hype?. **2014**, 14, 705-11	149
1419	TLR4 activation enhances the PD-L1-mediated tolerogenic capacity of colonic CD90+ stromal cells. **2014**, 193, 2218-29	51
1418	Human hepatocellular carcinoma-infiltrating CD4+CD69+Foxp3? regulatory T cell suppresses T cell response via membrane-bound TGF-1. **2014**, 92, 539-50	27
1417	Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer. **2014**, 92, 697-707	47
1416	PD-1(+) immune cell infiltration inversely correlates with survival of operable breast cancer patients. **2014**, 63, 395-406	111
1415	Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. **2014**, 63, 449-58	207
1414	Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy. **2014**, 63, 545-57	76
1413	Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula. **2014**, 63, 959-67	60
1412	Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial. **2014**, 140, 1615-24	67
1411	T helper responses are maintained by basal-like breast cancer cells and confer to immune modulation via upregulation of PD-1 ligands. **2014**, 145, 605-14	19
1410	Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. **2014**, 146, 15-24	375
1409	The role of targeted therapies in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline. **2014**, 118, 557-99	32
1408	PD-L1 expression in triple-negative breast cancer. **2014**, 2, 361-70	698
1407	Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer. **2014**, 2, 14	88
1406	Prolonged repeated vaccine immuno-chemotherapy induces long-term clinical responses and survival for advanced metastatic melanoma. **2014**, 2, 9	10

1405	Prognostic value of diametrically polarized tumor-associated macrophages in renal cell carcinoma. **2014**, 21, 3142-50	80
1404	PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection. **2014**, 2, 320-31	109
1403	Expression of programmed death receptor ligand 1 in melanoma may indicate tumor progression and poor patient survival. **2014**, 70, 954-6	17
1402	Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity. **2014**, 63, 1769-81	202
1401	Monoclonal antibodies as therapeutics in human malignancies. **2014**, 10, 609-36	18
1400	Targeting the tumor microenvironment with interferon- bridges innate and adaptive immune responses. **2014**, 25, 37-48	186
1399	Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. **2014**, 232, 199-209	882
1398	Adoptive immunotherapy for cancer. **2014**, 257, 14-38	100
1397	Whole genome gene copy number profiling of gastric cancer identifies PAK1 and KRAS gene amplification as therapy targets. **2014**, 53, 883-94	41
1396	Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges. **2014**, 32, 2248-54	158
1395	Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. **2014**, 20, 5064-74	1661
1394	Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. **2014**, 25, 1935-1940	428
1393	Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations. **2014**, 20, 4251-61	55
1392	Therapeutic vaccines for cancer: an overview of clinical trials. **2014**, 11, 509-24	522
1391	2014 update on non-small cell lung cancer (excluding diagnosis). **2014**, 95, 721-5	8
1390	Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor. **2014**, 74, 3652-8	178
1389	Tumor antigen discovery through translation of the cancer genome. **2014**, 58, 292-9	8
1388	Unmet needs in squamous cell carcinoma of the lung: potential role for immunotherapy. **2014**, 31, 960	16

1387 Monoklonale Antik□per in der Onkologie. **2014**, 29, 112-118

1386 A phase □study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study). **2014**, 12, 108 55

1385 What have we learned from cancer immunotherapy in the last 3 ́years?. **2014**, 12, 141 25

1384 Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancer. **2014**, 12, 61 45

1383 hMENA splicing program impacts the clinical outcome of early stage lung cancer patients. How and why?. **2014**, 12, P12 78

1382 Engineering vaccines and niches for immune modulation. **2014**, 10, 1728-40 37

1381 Immunologic and clinical effects of targeting PD-1 in lung cancer. **2014**, 96, 214-23 62

1380 Translational research in oncology--10 years of progress and future prospects. **2014**, 11, 649-62 51

1379 Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. **2014**, 32, 1020-30 1684

1378 VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy. **2014**, 2, 510-7 144

1377 Cancer-related inflammation and treatment effectiveness. **2014**, 15, e493-503 945

1376 In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. **2014**, 20, 2773-82 337

1375 Postnatal acquisition of primary rhesus cytomegalovirus infection is associated with prolonged virus shedding and impaired CD4+ T lymphocyte function. **2014**, 210, 1090-9 13

1374 Tumor-Induced Immune Suppression. **2014**, 1

1373 Emerging drugs targeting PD-1 and PD-L1: reality or hope?. **2014**, 19, 557-69 10

1372 Personalized treatments of cancer patients: a reality in daily practice, a costly dream or a shared vision of the future from the oncology community?. **2014**, 40, 1192-8 40

1371 Blockade of the programmed death-1 pathway restores sarcoidosis CD4(+) T-cell proliferative capacity. **2014**, 190, 560-71 71

1370 Cyclin-dependent kinases as therapeutic targets in melanoma. **2014**, 27, 351-65 18

1369	The targeting of immunosuppressive mechanisms in hematological malignancies. **2014**, 28, 1784-92	64
1368	Self-reactive T cells: suppressing the suppressors. **2014**, 63, 313-9	7
1367	Immunotherapy in the treatment of non-small cell lung cancer. **2014**, 85, 101-9	95
1366	Commentary: Molecular testing in melanoma. **2014**, 70, 863-70	4
1365	[Immunotherapy in epithelial ovarian carcinoma: hope and reality]. **2014**, 43, 198-210	1
1364	Immune checkpoint blockade: the hope for immunotherapy as a treatment of lung cancer?. **2014**, 41, 126-32	40
1363	Merkel cell carcinoma - recent advances in the biology, diagnostics and treatment. **2014**, 53, 536-46	18
1362	Progress in research on screening and genetics in lung cancer. **2014**, 2, 19-21	1
1361	The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck. **2014**, 50, 627-32	161
1360	Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder. **2014**, 40, 121-7	113
1359	Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies. **2014**, 40, 513-22	116
1358	Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies. **2014**, 35, 290-8	77
1357	Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells. **2014**, 2, 741-55	93
1356	Tumeurs [illegible]ales thymiques : aspects diagnostiques et th[illegible]apeutiques. **2014**, 16, 225-232	
1355	VISTA is an immune checkpoint molecule for human T cells. **2014**, 74, 1924-32	272
1354	A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates. **2014**, 63, 407-18	71
1353	VISTA Regulates the Development of Protective Antitumor Immunity. **2014**, 74, 1933-44	267
1352	Immunotherapy for non-small-cell lung cancer. **2014**, 14, 1061-4	4

1351	Updates on immunotherapy in non-small cell lung cancer. **2014**, 14, 411-8	2
1350	Current Advances in Osteosarcoma. **2014**,	7
1349	Immunomodulatory adjuvant therapy in severe community-acquired pneumonia. **2014**, 8, 587-96	21
1348	The prognostic value of liver tumor T cell infiltrates. **2014**, 191, 189-95	18
1347	Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. **2014**, 25, 590-604	273
1346	Ipilimumab in non-small cell lung cancer and small-cell lung cancer: new knowledge on a new therapeutic strategy. **2014**, 14, 1007-17	7
1345	State of melanoma: an historic overview of a field in transition. **2014**, 28, 415-35	25
1344	An (only) partially established paradigm of drug development of targeted therapies. **2014**, 50, 2037-9	6
1343	Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma. **2014**, 89, 504-19	63
1342	Cell-death-associated molecular patterns as determinants of cancer immunogenicity. **2014**, 20, 1098-116	31
1341	[Lung cancer: progress in diagnosis and treatments. Topics: III. Treatment; 5. Immune therapy]. **2014**, 103, 1330-6	
1340	Changes in the PD-1 and PD-L1 expressions of splenic dendritic cells in multiple-organ dysfunction syndrome mice and their significance. **2014**, 13, 7666-72	8
1339	Ipilimumab-induced autoimmune hypophysitis: a differential for sellar mass lesions. **2014**, 2014, 140098	8
1338	Pancreatic cancer stroma: understanding biology leads to new therapeutic strategies. **2014**, 20, 2237-46	86
1337	Milestones in the staging, classification, and biology of Merkel cell carcinoma. **2014**, 12, 1255-62	23
1336	Systemic and targeted therapies for early-stage lung cancer. **2014**, 21, 21-31	17
1335	PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy. **2014**, 21, 231-7	104
1334	Antibody therapies for melanoma: new and emerging opportunities to activate immunity (Review). **2014**, 32, 875-86	32

1333	Somatic Genome Alterations in Human Lung Cancers. **2014**, 67-89	1
1332	CMV-specific CD8+ T-cell function is not impaired in chronic lymphocytic leukemia. **2014**, 123, 717-24	48
1331	Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion. **2014**, 123, 1412-21	59
1330	Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer. **2014**, 1, 14004	28
1329	Pazopanib for the treatment of advanced renal cell cancer. **2014**, 2, 605-616	3
1328	Role of programmed death ligands in effective T-cell interactions in extranodal natural killer/T-cell lymphoma. **2014**, 8, 1461-1469	36
1327	[Intratumoral immune microenvironment and survival: the immunoscore]. **2014**, 30, 439-44	15
1326	Molecular Target Treatment for Personalized Radiotherapy in Lung Cancer. **2014**, 390-405	
1325	Immunologic Approaches to Lung Cancer Therapy. **2014**, 454-463	
1324	[Immuno-Oncology therapeutic principles in lung and renal cell carcinoma]. **2014**, 37 Suppl 4, 10-3	
1323	Update on immune checkpoint inhibitors in lung cancer. **2014**, 21, 80-9	69
1322	Cancer immunology, success without sequencing. **2014**, 12, 443-5	
1321	Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. **2014**, 2,	7
1320	Clinical implications of the interleukin 27 serum level in breast cancer. **2014**, 62, 627-31	19
1319	How anti-PD1 treatments are changing the management of melanoma. **2014**, 1, 165-172	3
1318	Overexpression of B7-H1 correlates with malignant cell proliferation in pancreatic cancer. **2014**, 31, 1191-8	36
1317	Clinical trial spots for cancer patients by tumour type: The cancer trials portfolio at clinicaltrials.gov. **2015**, 51, 2718-23	3
1316	P1318 : Phase I dose escalation study of the safety, immunoregulatory activity, pharmacokinetics, and preliminary antitumor activity of nivolumab in advanced hepatocellular carcinoma in patients with or without chronic viral hepatitis. **2015**, 62, S849	2

1315 Novel combination approaches for myeloma. **2015**, 2015, 286-93 4

1314 Clinical significance of expanded Foxp3+ Helios? regulatory T cells in patients with non-small cell lung cancer. **2015**, 47, 2082-90 16

1313 Expression of immune checkpoint molecules in endometrial carcinoma. **2015**, 10, 1947-1952 26

1312 Gene therapy: progress and predictions. **2015**, 282, 20143003 88

1311 [Molecular Concepts of Immunomodulation for the Treatment of Metastatic Renal Cell Carcinomas: Where are We Now?]. **2015**, 46, 473-80

1310 Associations among pretreatment tumor necrosis and the expression of HIF-1□and PD-L1 in advanced oral squamous cell carcinoma and the prognostic impact thereof. **2015**, 51, 1004-1010 47

1309 2015 Guidance on cancer immunotherapy development in early-phase clinical studies. **2015**, 106, 1761-71 11

1308 Cancer immunotherapy using novel tumor-associated antigenic peptides identified by genome-wide cDNA microarray analyses. **2015**, 106, 505-11 28

1307 Adjuvant for vaccine immunotherapy of cancer--focusing on Toll-like receptor 2 and 3 agonists for safely enhancing antitumor immunity. **2015**, 106, 1659-68 48

1306 New clinical advances in immunotherapy for the treatment of solid tumours. **2015**, 145, 182-201 26

1305 Implementation of modern therapy approaches and research for non-small cell lung cancer in Japan. **2015**, 20, 199-208 3

1304 Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy. **2015**, 106, 945-50 61

1303 Clinical significance of tumor-infiltrating immune cells focusing on BTLA and Cbl-b in patients with gallbladder cancer. **2015**, 106, 1750-60 35

1302 Immunotherapy for metastatic renal cell carcinoma. **2015**, 2

1301 Stereotactic ablative radiotherapy for centrally located early stage non-small-cell lung cancer: what we have learned. **2015**, 10, 577-85 96

1300 Ectopic expression of B and T lymphocyte attenuator in gastric cancer: a potential independent prognostic factor in patients with gastric cancer. **2015**, 11, 658-64 10

1299 [Development of mogamulizumab and establishment of an optimal therapy based on genomic biomarkers: from the academic viewpoint]. **2015**, 135, 663-9

1298 Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer. **2015**, 5, 13110 246

1297	Principles of Targeted Immunotherapy. **2015**, 27-38	
1296	Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. **2015**, 126, 2193-201	312
1295	The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy. **2015**, 126, 1203-13	71
1294	ADAP and SKAP55 deficiency suppresses PD-1 expression in CD8+ cytotoxic T lymphocytes for enhanced anti-tumor immunotherapy. **2015**, 7, 754-69	30
1293	Immune Checkpoint Blockade in Hepatocellular Carcinoma. **2015**, 4, 201-7	36
1292	A high-throughput RNAi screen for detection of immune-checkpoint molecules that mediate tumor resistance to cytotoxic T lymphocytes. **2015**, 7, 450-63	28
1291	Case studies of monoclonal antibodies for cancer therapy: technology drives clinical development. **2015**, 156-165	
1290	Molecular biomarkers in gastric cancer. **2015**, 13, e19-29	26
1289	Molecular Profiling of Refractory Adrenocortical Cancers and Predictive Biomarkers to Therapy. **2015**, 7, 69-76	7
1288	A Perspective of Immunotherapy for Breast Cancer: Lessons Learned and Forward Directions for All Cancers. **2015**, 9, 35-43	4
1287	Human Cancer Immunotherapy with PD-1/PD-L1 Blockade. **2015**, 7, 15-8	42
1286	???????????. **2015**, 12, 30-32	
1285	Spontaneous regression of non-small-cell lung cancer in AIDS after immune reconstitution. **2015**, 10, e1-2	8
1284	Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer. **2015**, 10, 1458-67	43
1283	Emerging immunotherapies for bladder cancer. **2015**, 27, 191-200	21
1282	Whole Cell Therapeutic Vaccine Modified With Hyper-IL6 for Combinational Treatment of Nonresected Advanced Melanoma. **2015**, 94, e853	10
1281	P1317 : Efficacy of ursodeoxycholic acid as a volume reducing treatment for symptomatic polycystic liver disease: An international, multicenter, randomized controlled trial. **2015**, 62, S848-S849	
1280	Radiation with immunotherapy: an emerging combination for cancer treatment. **2015**, 4, 331-338	5

1279	Tracheal squamous cell carcinoma (SCC) metastatic to the skin in a patient on a checkpoint inhibitor. **2015**, 1, 308-9	
1278	PD-L1 expression in renal cell carcinoma clear cell type is related to unfavorable prognosis. **2015**, 10, 189	56
1277	The relevance of positron emission tomography response in non-small cell lung cancer. **2015**, 8, 119-129	0
1276	The role of combined radiation and immunotherapy in breast cancer treatment. **2015**, 4, 347-354	2
1275	Combining radiotherapy and immunotherapy for prostate cancer: two decades of research from preclinical to clinical trials. **2015**, 4, 365-375	1
1274	Programmed death 1 blockade, an Achilles heel for MMR-deficient tumors?. **2015**, 8, 124	20
1273	Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enough. **2015**, 34, 310-9	8
1272	Incidence of secondary malignancies among patients with Waldenstrm macroglobulinemia: An analysis of the SEER database. **2015**, 121, 2230-6	18
1271	Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer. **2015**, 13, 247	45
1270	Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study. **2015**, 17, 124	151
1269	Integrating tumor microenvironment with cancer molecular classifications. **2015**, 7, 115	2
1268	MicroRNA expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy in metastatic melanoma treated on the ECOG-ACRIN trial E2603. **2015**, 7, 58	15
1267	A prospective evaluation of the role of Vascular Endothelial Growth Factor (VEGF) and the immune system in stage III/IV melanoma. **2015**, 4, 186	7
1266	Immunotherapy in endometrial cancer - an evolving therapeutic paradigm. **2015**, 2, 11	30
1265	Ovarian cancer immunotherapy using PD-L1 siRNA targeted delivery from folic acid-functionalized polyethylenimine: strategies to enhance T cell killing. **2015**, 4, 1180-9	107
1264	Inhibitory receptors as targets for cancer immunotherapy. **2015**, 45, 1892-905	84
1263	Treatment for metastatic melanoma: a new and evolving era. **2015**, 69, 273-80	2
1262	Immune checkpoint inhibitor therapy associated hypophysitis. **2015**, 8, 21-8	31

1261	B7-H1/PD-1 blockade therapy in urological malignancies: current status and future prospects. **2015**, 101, 549-54	5
1260	Pembrolizumab in the management of metastatic melanoma. **2015**, 2, 315-325	4
1259	Epitope characterization of an anti-PD-L1 antibody using orthogonal approaches. **2015**, 28, 269-76	15
1258	Tumor-infiltrating CD8(+) T lymphocytes associated with clinical outcome in anal squamous cell carcinoma. **2015**, 112, 421-6	29
1257	VAC chemotherapy with valproic acid for refractory/relapsing small cell lung cancer: a phase II study. **2015**, 1,	2
1256	RAC1 P29S regulates PD-L1 expression in melanoma. **2015**, 28, 590-8	44
1255	Recent advances in antibody-based therapies for Hodgkin Lymphoma. **2015**, 171, 171-178	4
1254	Checkpoint immunotherapy for cancer: superior survival, unaccustomed toxicities. **2015**, 45, 696-701	18
1253	Immunotherapy for Advanced Lung Cancer. **2015**, 21, 383-91	6
1252	PERIOPERATIVE PROGRAMMED DEATH 1 EXPRESSION ON CD4+ T CELLS PREDICTS THE INCIDENCE OF POSTOPERATIVE INFECTIOUS COMPLICATIONS. **2015**, 44, 323-9	4
1251	Tumor-targeted and immune-targeted monoclonal antibodies: Going from passive to active immunotherapy. **2015**, 62, 1317-25	11
1250	Blocking of the PD-1/PD-L1 Interaction by a D-Peptide Antagonist for Cancer Immunotherapy. **2015**, 127, 11926-11930	8
1249	Blocking of the PD-1/PD-L1 Interaction by a D-Peptide Antagonist for Cancer Immunotherapy. **2015**, 54, 11760-4	175
1248	Leukemic progenitor cells are susceptible to targeting by stimulated cytotoxic T cells against immunogenic leukemia-associated antigens. **2015**, 137, 2083-92	14
1247	Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy. **2015**, 35, 963-76	140
1246	Feasibility study of personalized peptide vaccination for advanced non-small cell lung cancer patients who failed two or more treatment regimens. **2015**, 46, 55-62	10
1245	Recent developments and future challenges in immune checkpoint inhibitory cancer treatment. **2015**, 27, 482-8	24
1244	Identification of Programmed Death Ligand 1-derived Peptides Capable of Inducing Cancer-reactive Cytotoxic T Lymphocytes From HLA-A24+ Patients With Renal Cell Carcinoma. **2015**, 38, 285-91	27

1243	Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors. **2015**, 38, 422-30	58
1242	T-cell checkpoint inhibitors in metastatic renal cell carcinoma. **2015**, 25, 411-5	7
1241	Immunotherapies for bladder cancer: a new hope. **2015**, 25, 586-96	13
1240	Management of Small Cell Lung Cancer: Progress and Updates. **2015**, 21, 425-33	18
1239	Tumor-Infiltrating Lymphocyte Therapy: Addressing Prevailing Questions. **2015**, 21, 450-64	30
1238	Ipilimumab-Induced Adrenalitis: A Possible Pitfall in 18F-FDG-PET/CT. **2015**, 40, e518-9	51
1237	Immunonkologisches Therapieprinzip beim Lungen- und Nierenzellkarzinom. **2015**, 3, 91-92	
1236	Emerging role for novel immunotherapy agents in metastatic renal cell carcinoma: from bench to bedside. **2015**, e291-7	4
1235	Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice. **2015**, 6, 34221-7	163
1234	Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma. **2015**, 6, 41228-36	140
1233	Prognostic and predictive value of PDL1 expression in breast cancer. **2015**, 6, 5449-64	313
1232	Emerging therapies for pancreatic ductal carcinoma. **2015**, 6,	1
1231	Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. **2015**, 125, 3384-91	815
1230	Targeting PD-1/PD-L1 in lung cancer: current perspectives. **2015**, 6, 55-70	9
1229	Long-term survival in advanced melanoma patients using repeated therapies: successive immunomodulation improving the odds?. **2015**, 7, 93-103	7
1228	Possible therapeutic implication of PD-L1/PD-1 axis in endometrial cancer. **2015**, 5,	
1227	Immunosuppressive Microenvironment in Head and Neck Cancer. **2015**,	1
1226	Cancer immunotherapy: harnessing the immune system to battle cancer. **2015**, 125, 3335-7	597

1225	The anaplastic lymphoma kinase as an oncogene in solid tumors. **2015**, 7, 269-82	5
1224	Inmunoterapia gen□ica con c□ulas dendr□icas para el tratamiento del c□icer. **2015**, 38, 279-287	
1223	The role of regulatory T cells in cancer immunology. **2015**, 4, 159-71	77
1222	Biomarkers of Response to Immune Modulatory Therapies in Cancer. **2015**, 06,	
1221	Impact of intraoperative blood loss on long-term survival after lung cancer resection. **2015**, 21, 18-23	15
1220	Therapeutic cancer vaccines. **2015**, 125, 3401-12	367
1219	Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches. **2015**, 7, 2397-414	51
1218	Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profiling. **2015**, 6, 37117-34	57
1217	New and promising strategies in the management of bladder cancer. **2015**, 105-12	14
1216	Zielgerichtete Therapien gegen PD-1 bei malignen Erkrankungen des Lymphsystems: Biologischer Hintergrund, klinische Herausforderungen und Chancen. **2015**, 2, 8-14	
1215	Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications. **2015**, 7, 6009-42	46
1214	Dendritic Cell-Based Adjuvant Vaccination Targeting Wilms' Tumor 1 in Patients with Advanced Colorectal Cancer. **2015**, 3, 1004-18	23
1213	A Quantitative Systems Pharmacology Perspective on Cancer Immunology. **2015**, 3, 235-256	7
1212	Establishing the pig as a large animal model for vaccine development against human cancer. **2015**, 6, 286	12
1211	Immune Reactivation by Cell-Free Fetal DNA in Healthy Pregnancies Re-Purposed to Target Tumors: Novel Checkpoint Inhibition in Cancer Therapeutics. **2015**, 6, 424	12
1210	Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical Applications. **2015**, 6, 505	71
1209	Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy. **2015**, 6, 516	51
1208	Identifying Individual T Cell Receptors of Optimal Avidity for Tumor Antigens. **2015**, 6, 582	44

1207	The Role of Chemokines in Shaping the Balance Between CD4(+) T Cell Subsets and Its Therapeutic Implications in Autoimmune and Cancer Diseases. **2015**, 6, 609	36
1206	4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity. **2015**, 5, 117	153
1205	Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy. **2015**, 5, 152	24
1204	Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types. **2015**, 8, 929-37	21
1203	Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies. **2015**, 9, 3529-45	101
1202	Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors. **2015**, 7, 5889-901	15
1201	Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. **2015**, 6, 4704-16	92
1200	Reinvigorating Exhausted T Cells by Blockade of the PD-1 Pathway. **2015**, 6, 7-17	48
1199	Positive expression of programmed death ligand-1 correlates with superior outcomes and might be a therapeutic target in primary pulmonary lymphoepithelioma-like carcinoma. **2015**, 8, 1451-7	24
1198	Immune derangements in patients with myelofibrosis: the role of Treg, Th17, and sIL2R **2015**, 10, e0116723	23
1197	Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma. **2015**, 10, e0118564	155
1196	Blockade of PD-1/PD-L1 promotes adoptive T-cell immunotherapy in a tolerogenic environment. **2015**, 10, e0119483	31
1195	High PD-L1 Expression Correlates with Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma. **2015**, 10, e0142656	138
1194	Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers. **2015**, 10, e0130142	339
1193	PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups. **2015**, 10, e0136023	167
1192	High Throughput Kinomic Profiling of Human Clear Cell Renal Cell Carcinoma Identifies Kinase Activity Dependent Molecular Subtypes. **2015**, 10, e0139267	28
1191	Immune Adjuvant Activity of Pre-Resectional Radiofrequency Ablation Protects against Local and Systemic Recurrence in Aggressive Murine Colorectal Cancer. **2015**, 10, e0143370	28
1190	Molecular profiling in the treatment of colorectal cancer: focus on regorafenib. **2015**, 8, 2949-57	6

1189	Mechanistic insights into the oncolytic activity of vesicular stomatitis virus in cancer immunotherapy. **2015**, 4, 157-67	11
1188	Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect. **2015**, 2015, 158038	42
1187	PD-1 Blockade in Advanced Melanoma in Patients with Hepatitis C and/or HIV. **2015**, 2015, 737389	61
1186	Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy. **2015**, 2015, 851387	94
1185	Immunotherapy for Bone and Soft Tissue Sarcomas. **2015**, 2015, 820813	15
1184	Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors. **2015**, 2015, 191832	40
1183	Harnessing the Microbiome to Enhance Cancer Immunotherapy. **2015**, 2015, 368736	41
1182	Clinical Development of Immune Checkpoint Inhibitors. **2015**, 2015, 605478	46
1181	Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma. **2015**, 2015, 341430	34
1180	Adverse events of monoclonal antibodies used for cancer therapy. **2015**, 2015, 428169	45
1179	Human Tumor Antigens and Cancer Immunotherapy. **2015**, 2015, 948501	130
1178	From mice to humans: developments in cancer immunoediting. **2015**, 125, 3338-46	188
1177	Patient-Specific Therapeutic Vaccines for Metastatic Melanoma. **2015**, 30, 48-57	2
1176	Monoclonal Antibodies for the Treatment of Cancer. **2015**, 683-694.e3	
1175	Principles of Cancer Immunobiology and Immunotherapy of Solid Tumors. **2015**,	3
1174	PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy. **2015**, 6, 13506-19	87
1173	Programmed death-1/programmed death-L1 signaling pathway and its blockade in hepatitis C virus immunotherapy. **2015**, 7, 2449-58	26
1172	Cancer and the Cellular Immune Response. **2015**, 695-708.e2	

1171	Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathway. **2015**, 6, 36041-52		71
1170	LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model. **2015**, 6, 27359-77		151
1169	Cancer Therapeutics. **2015**, 635-650.e1		
1168	Current therapeutic leads for the treatment of melanoma: targeted immunotherapy in the post-genomic era. **2014**, 7, 33-43		3
1167	IL-27 induces the expression of IDO and PD-L1 in human cancer cells. **2015**, 6, 43267-80		86
1166	microRNA-4717 differentially interacts with its polymorphic target in the PD1 3' untranslated region: A mechanism for regulating PD-1 expression and function in HBV-associated liver diseases. **2015**, 6, 18933-44		56
1165	New Insights in Cutaneous Melanoma Immune-Therapy Tackling Immune-Suppression and Specific Anti-Tumoral Response. **2015**,		2
1164	Thapie ciblé des glioblastomes : bilan et perspectives. **2015**, 199, 1323-1329		
1163	Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer. **2015**, 10, 426-30		125
1162	PD-L1 blockade for cancer treatment: MEDI4736. **2015**, 42, 474-83		71
1161	PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. *New England Journal of Medicine*, **2015**, 372, 2509-20	59.2	5560
1160	Genetically engineered lymphocytes and adoptive cell therapy: cancer immunotherapy's smart bombs. **2015**, 22, 63		4
1159	Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells. **2015**, 212, 1125-37		242
1158	T cell exclusion, immune privilege, and the tumor microenvironment. **2015**, 348, 74-80		1156
1157	Beyond CTLA-4: novel immunotherapy strategies for metastatic melanoma. **2015**, 11, 997-1009		2
1156	Targeted Therapy for Metastatic Renal Cell Carcinoma: Introduction. **2015**, 1-14		
1155	Vaccine immunotherapy in lung cancer: Clinical experience and future directions. **2015**, 153, 1-9		20
1154	Immunological markers predict the prognosis of patients with squamous non-small cell lung cancer. **2015**, 62, 316-24		18

1153	Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. **2015**, 33, 2780-8	1480
1152	Building better monoclonal antibody-based therapeutics. **2015**, 15, 361-70	411
1151	POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer. **2015**, 21, 3347-3355	184
1150	Programmed death-1 checkpoint blockade in acute myeloid leukemia. **2015**, 15, 1191-203	50
1149	Immune-related strategies driving immunotherapy in breast cancer treatment: a real clinical opportunity. **2015**, 15, 689-702	9
1148	A gender factor in shaping T-cell immunity to melanoma. **2015**, 5, 8	11
1147	PD-1/PD-L1 inhibitors. **2015**, 23, 32-8	358
1146	Blinded by the light: why the treatment of metastatic melanoma has created a new paradigm for the management of cancer. **2015**, 7, 107-21	8
1145	The role of active vaccination in cancer immunotherapy: lessons from clinical trials. **2015**, 35, 15-22	27
1144	Non-small-cell lung cancer. **2015**, 1, 15009	352
1143	Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen. **2015**, 3, 345-55	402
1142	Expression profile and in vitro blockade of programmed death-1 in human papillomavirus-negative head and neck squamous cell carcinoma. **2015**, 37, 1088-95	54
1141	Immunology and Immunotherapy of Breast Cancer. **2015**, 457-470	
1140	Development of Personalized Combination Cancer Immunotherapy Based on the Patients Immune Status. **2015**, 255-266	2
1139	Costimulation in Lymphomas and Cancers. **2015**, 185-254	4
1138	T-Cell Costimulation and Its Applications in Diseases. **2015**, 255-292	3
1137	Toward Localized Biomarker Concentration Measurements. **2015**, 51, 1-4	19
1136	Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma. **2015**, 94, 1545-52	56

1135	Survival patterns following brain metastases for patients with melanoma in the MAP-kinase inhibitor era. **2015**, 123, 75-84	6
1134	Immune modulation in advanced radiotherapies: Targeting out-of-field effects. **2015**, 368, 246-51	34
1133	The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. **2015**, 37, 764-82	360
1132	Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer. **2015**, 88, 117-23	35
1131	Potential role for targeted therapy in muscle-invasive bladder cancer: lessons from the cancer genome atlas and beyond. **2015**, 42, 201-15, viii	13
1130	Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eμ-TCL1 CLL mouse model. **2015**, 126, 212-21	82
1129	Immunostimulators and Immunomodulators in Cancer Treatment. **2015**, 411-431	
1128	Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma. **2015**, 11, 133-40	9
1127	Immunotherapy for non-small-cell lung cancer: the past 10 years. **2015**, 11, 2681-2695	6
1126	Optical in vivo imaging of the alarmin S100A9 in tumor lesions allows for estimation of the individual malignant potential by evaluation of tumor-host cell interaction. **2015**, 56, 450-6	24
1125	Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. **2015**, 33, 983-91	650
1124	Cancer immunotherapy: imaging assessment of novel treatment response patterns and immune-related adverse events. **2015**, 35, 424-37	128
1123	Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti-PD-L1 Antibodies. **2015**, 75, 2928-36	150
1122	Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. **2015**, 21, 712-20	180
1121	Immune checkpoint modulation for non-small cell lung cancer. **2015**, 21, 2256-62	72
1120	PD-1 Restrains Radiotherapy-Induced Abscopal Effect. **2015**, 3, 610-9	251
1119	Durable Responses With PD-1 Inhibition in Lung and Kidney Cancer and the Ongoing Search for Predictive Biomarkers. **2015**, 33, 1993-4	16
1118	Programmed death-1 controls T cell survival by regulating oxidative metabolism. **2015**, 194, 5789-800	76

1117	PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. **2015**, 89, 181-8	195
1116	Increased CCL17 serum levels are associated with improved survival in advanced melanoma. **2015**, 64, 1075-82	12
1115	PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. **2015**, 26, 1488-93	179
1114	Beyond adjuvants: immunomodulation strategies to enhance T cell immunity. **2015**, 33 Suppl 2, B21-8	19
1113	Anti-PD-L1 prolongs survival and triggers T cell but not humoral anti-tumor immune responses in a human MUC1-expressing preclinical ovarian cancer model. **2015**, 64, 1095-108	15
1112	Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. **2015**, 3, 1148-1157	281
1111	Stereotactic radiosurgery and immunotherapy for metastatic spinal melanoma. **2015**, 38, E6	15
1110	Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer. **2015**, 21, 4014-21	308
1109	Cancer and the Immune System: Basic Concepts and Targets for Intervention. **2015**, 42, 523-38	168
1108	New perspectives on targeted therapy in ovarian cancer. **2015**, 7, 189-203	81
1107	CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic. **2014**, 4, 385	135
1106	New strategies in melanoma: entering the era of combinatorial therapy. **2015**, 21, 2424-35	27
1105	Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation. **2015**, 3, 855-63	53
1104	DNA vaccines, electroporation and their applications in cancer treatment. **2015**, 11, 1889-900	45
1103	IL-1R-dependent priming of antitumor CD4 T cells and sustained antitumor immunity after peri-tumoral treatment with MSU and mycobacteria. **2015**, 4, e1042199	5
1102	[Recent advances in bladder urothelial carcinogenesis]. **2015**, 102, 1020-35	3
1101	Targeting the immune system in head and neck cancer. **2015**, 27, 157-8	0
1100	Checkpoint blockade in lymphoma. **2015**, 2015, 69-73	11

1099 Myasthenia Gravis Induced by Ipilimumab in Patients With Metastatic Melanoma. **2015**, 33, e122-4 82

1098 Pseudoprogression and Immune-Related Response in Solid Tumors. **2015**, 33, 3541-3 555

1097 Photodynamic Therapy of Non-Small Cell Lung Cancer. Narrative Review and Future Directions. **2016**, 13, 265-75 78

1096 Statistical Challenges in the Design of Late-Stage Cancer Immunotherapy Studies. **2015**, 3, 1292-8 21

1095 Developments in T Cell Based Cancer Immunotherapies. **2015**,

1094 Immunotherapies in Early and Advanced Renal Cell Cancer. **2015**, 42, 1-10 9

1093 Talimogene laherparepvec in the treatment of melanoma. **2015**, 15, 1517-30 8

1092 Insights on Peptide Vaccines in Cancer Immunotherapy. **2015**, 1-27 2

1091 Toward the Identification of Genetic Determinants of Responsiveness to Cancer Immunotherapy. **2015**, 99-127 4

1090 Advances in the Treatment of Metastatic Prostate Cancer. **2015**, 90, 1719-33 19

1089 Checkpoint inhibitors in bladder and renal cancers: results and perspectives. **2015**, 7, 1259-71 16

1088 Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. **2015**, 21, 4286-93 469

1087 Immunotherapy for Head and Neck Squamous Cell Carcinoma. **2015**, 29, 1033-43 22

1086 Cancer bronchopulmonaire dans la population des patients vivant avec le VIH. **2015**, 7, 531-538 1

1085 Targeting the Immune System for Cancer Therapy: Lessons for Perioperative Management?. **2015**, 5, 257-267

1084 Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab. **2015**, 8, 111 106

1083 Composition of inflammatory cells regulating the response to concurrent chemoradiation therapy for HPV (+) tonsil cancer. **2015**, 51, 1113-9 14

1082 Therapeutic options in advanced squamous cell lung carcinoma. **2015**, 4, 75-86

1081	Humanized Affinity-matured Monoclonal Antibody 8H9 Has Potent Antitumor Activity and Binds to FG Loop of Tumor Antigen B7-H3. **2015**, 290, 30018-29	64
1080	Immunothérapie dans le cancer bronchique : les inhibiteurs de Checkpoints. **2015**, 7, 353-360	
1079	Cyclin-Dependent Kinase 5 (CDK5) Controls Melanoma Cell Motility, Invasiveness, and Metastatic Spread-Identification of a Promising Novel therapeutic target. **2015**, 8, 295-307	22
1078	Novel insights into the pathophysiology and treatment of malignant pleural mesothelioma. **2015**, 4, 249-259	
1077	Expression of immune checkpoint molecules of T cell immunoglobulin and mucin protein 3/galectin-9 for NK cell suppression in human gastrointestinal stromal tumors. **2015**, 34, 2099-105	32
1076	The role of inflammation in progression of breast cancer: Friend or foe? (Review). **2015**, 47, 797-805	38
1075	A longitudinal study of CEACAM1 expression in melanoma disease progression. **2015**, 33, 1314-8	11
1074	T Cell Fate in the Tumor Microenvironment. **2015**, 53-74	
1073	[Rationale, visions and limits of Immuno-oncology: Checkpoint inhibition as a new pillar of tumor therapy]. **2015**, 38 Suppl 3, 2-5	1
1072	The Pekin duck programmed death-ligand 1: cDNA cloning, genomic structure, molecular characterization and mRNA expression analysis. **2015**, 42, 111-20	7
1071	Clinical impact of herpesvirus entry mediator expression in human hepatocellular carcinoma. **2015**, 51, 157-65	30
1070	Trametinib: a novel signal transduction inhibitor for the treatment of metastatic cutaneous melanoma. **2015**, 72, 101-10	13
1069	Developing biomarker-specific end points in lung cancer clinical trials. **2015**, 12, 135-46	36
1068	PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer. **2015**, 3, 326-32	232
1067	Checkpoint inhibitors in immunotherapy of ovarian cancer. **2015**, 36, 33-9	16
1066	[The role of the expansion cohort in phase I trials in oncology: guidelines of the phase I HUB]. **2015**, 102, 73-82	4
1065	Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies. **2015**, 42, 429-35	57
1064	Dabrafenib in combination with trametinib for the treatment of metastatic melanoma. **2015**, 8, 25-33	7

1063 Emerging drugs for squamous cell lung cancer. **2015**, 20, 149-60 14

1062 The role of CD95 and CD95 ligand in cancer. **2015**, 22, 549-59 149

1061 Mouse model for pre-clinical study of human cancer immunotherapy. **2015**, 108, 20.1.1-20.1.43 15

1060 Mechanisms of and strategies for overcoming resistance to anti-vascular endothelial growth factor therapy in non-small cell lung cancer. **2015**, 1855, 193-201 9

1059 PD-L1 expression in small cell neuroendocrine carcinomas. **2015**, 51, 421-6 157

1058 PACMEL: a phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxel. **2015**, 51, 359-66 18

1057 The immune system in the normal endometrium and implications for endometrial cancer development. **2015**, 109, 7-16 41

1056 Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. **2015**, 16, 177-86 160

1055 Immune checkpoint blockade and interferon-□n melanoma. **2015**, 42, 436-47 30

1054 [Breaking immune tolerance in cancer]. **2015**, 102, 34-52 2

1053 Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches. **2015**, 64, 842-8 124

1052 Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies. **2015**, 27, 138-48 99

1051 The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?. **2015**, 33, 23-35 246

1050 Radiation meets immunotherapy - a perfect match in the era of combination therapy?. **2015**, 91, 299-305 17

1049 Immune Checkpoint Blockade in Cancer Therapy. **2015**, 33, 1974-82 1690

1048 Immune checkpoint modulation: rational design of combination strategies. **2015**, 150, 23-32 62

1047 Lichenoid dermatitis in three patients with metastatic melanoma treated with anti-PD-1 therapy. **2015**, 3, 18-22 79

1046 PD-1 blockade therapy in renal cell carcinoma: current studies and future promises. **2015**, 41, 114-21 126

1045	Enhanced immunosuppression by therapy-exposed glioblastoma multiforme tumor cells. **2015**, 136, 2566-78	30
1044	Anti-programmed death receptor 1 immunotherapy in melanoma: rationale, evidence and clinical potential. **2015**, 7, 12-21	20
1043	Exploring the potential of immuno-oncology-based treatment for patients with non-small cell lung cancer. **2015**, 15, 69-83	10
1042	Cutaneous adverse effects of targeted therapies: Part II: Inhibitors of intracellular molecular signaling pathways. **2015**, 72, 221-36; quiz 237-8	121
1041	The potential role of immunotherapy to treat colorectal cancer. **2015**, 24, 329-44	23
1040	A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. **2015**, 21, 1019-27	494
1039	Systemic treatment of advanced hepatocellular carcinoma: from disillusions to new horizons. **2015**, 51, 327-39	45
1038	Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2. **2015**, 17, 487-95	71
1037	Building immunity to cancer with radiation therapy. **2015**, 368, 198-208	57
1036	Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. **2015**, 194, 950-9	269
1035	Anaplastic thyroid cancer: outcome and the mutation/expression profiles of potential targets. **2015** , 21, 695-701	26
1034	Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. **2015**, 112, E966-72	295
1033	ImmTACs for targeted cancer therapy: Why, what, how, and which. **2015**, 67, 67-74	59
1032	Checkpoint inhibitors for cancer immunotherapy. Multiple checkpoints on the long road towards cancer immunotherapy. **2015**, 93, 323-5	8
1031	Personalized Treatment Options in Dermatology. **2015**,	4
1030	[Immunotherapy in non-small cell lung cancer: inhibition of PD1/PDL1 pathway]. **2015**, 71, 44-56	6
1029	Tapping CD4 T cells for cancer immunotherapy: the choice of personalized genomics. **2015**, 194, 2049-56	92
1028	Both PD-1 ligands protect the kidney from ischemia reperfusion injury. **2015**, 194, 325-33	45

1027	Expression of coinhibitory receptors on T cells in the microenvironment of usual vulvar intraepithelial neoplasia is related to proinflammatory effector T cells and an increased recurrence-free survival. **2015**, 136, E95-106	21
1026	Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer. **2015**, 21, 3031-40	249
1025	PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. **2015**, 14, 847-56	1248
1024	Therapeutic efficacy of the F8-IL2 immunocytokine in a metastatic mouse model of lung adenocarcinoma. **2015**, 88, 9-15	14
1023	The clinical relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant non-small-cell lung cancer. **2015**, 23, 717-27	177
1022	Low immunogenicity in non-small cell lung cancer; do new developments and novel treatments have a role?. **2015**, 34, 129-44	9
1021	Targeted immune therapy of ovarian cancer. **2015**, 34, 53-74	23
1020	Nivolumab in NSCLC: latest evidence and clinical potential. **2015**, 7, 85-96	164
1019	Radiotherapy for cutaneous melanoma: current and future applications. **2015**, 11, 525-34	22
1018	Evaluation of Immune Restoration Potential of PD-1 Blockers. **2015**, 36, 567-72	1
1017	Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma. **2015**, 32, 86	75
1016	Immunotherapy for ovarian cancer. **2015**, 16, 317	20
1015	The immune response in cancer: from immunology to pathology to immunotherapy. **2015**, 467, 127-35	42
1014	Elevated Cancer-Specific Mortality Among HIV-Infected Patients in the United States. **2015**, 33, 2376-83	196
1013	Nivolumab and Olaparib. **2015**, 50, 356-66	2
1012	Genomic Classification of Cutaneous Melanoma. **2015**, 161, 1681-96	1807
1011	Evolving Concepts: Immunity in Oncology from Targets to Treatments. **2015**, 2015, 847383	20
1010	Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy. **2015**, 36, 1191-9	105

1009	Personalized medicine for gliomas. **2015**, 6, S89-95	23
1008	The Evolution of T-cell Therapies for Solid Malignancies. **2015**, 21, 3384-92	65
1007	A review of interventional clinical trials in renal cell carcinoma: a status report from the ClinicalTrials.gov WebSite. **2015**, 13, 142-9	7
1006	High ratio of programmed cell death protein 1 (PD-1)(+)/CD8(+) tumor-infiltrating lymphocytes identifies a poor prognostic subset of extrahepatic bile duct cancer undergoing surgery plus adjuvant chemoradiotherapy. **2015**, 117, 165-70	36
1005	Immunotherapy of Metastatic Colorectal Cancer: Prevailing Challenges and New Perspectives. **2015** , 11, 125-140	21
1004	Immunosuppressive activity of cancer-associated fibroblasts in head and neck squamous cell carcinoma. **2015**, 64, 1407-17	61
1003	Immune Checkpoint Inhibition in Renal Cell Carcinoma. **2015**, 259-279	
1002	[New immunotherapeutic approaches in oncology and hematology]. **2015**, 22, 132-40	1
1001	Targeted Therapies in Melanoma: Translational Research at Its Finest. **2015**, 135, 1929-1933	10
1000	Inflammation and Lung Cancer: Molecular Pathology. **2015**, 69-93	
999	Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2-/-IL2Rγnull Immunodeficient Mice. **2015**, 75, 3466-78	98
998	Pembrolizumab for the treatment of melanoma. **2015**, 8, 515-27	2
997	Chronic hepatitis B: Are we close to a cure?. **2015**, 47, 836-41	13
996	Immune Regulation by Self-Recognition: Novel Possibilities for Anticancer Immunotherapy. **2015**, 107,	32
995	[DNA mismatch repair and BRAF status in colorectal cancer: Interest for the therapeutic management?]. **2015**, 102, S72-81	1
994	Immune therapy of non-small cell lung cancer. The future. **2015**, 99, 217-22	12
993	Adoptive T-cell therapy: a need for standard immune monitoring. **2015**, 7, 513-33	16
992	New immunotherapies targeting the PD-1 pathway. **2015**, 36, 587-95	120

991	Inflammation and Lung Cancer. **2015**,	0
990	Charting Immune Signaling Proteomes En Route to New Therapeutic Strategies. **2015**, 3, 714-20	2
989	Biomarker testing in non-small cell lung cancer: a clinician's perspective. **2015**, 139, 448-50	5
988	Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some. **2015**, 6, 127	39
987	Modulation of Immune Cell Functions by the E3 Ligase Cbl-b. **2015**, 5, 58	49
986	Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity. **2015**, 34, 5960-70	57
985	Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors. **2015**, 107,	36
984	Targeted Therapies for Melanoma. **2015**, 1529-1541	
983	Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodies. **2015**, 20, 1127-34	23
982	Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy. **2015**, 21, 5543-51	103
981	Expression of Programmed Death 1 Ligand in Different Compartments of Chronic Lymphocytic Leukemia. **2015**, 134, 255-62	31
980	Surgical trauma induces postoperative T-cell dysfunction in lung cancer patients through the programmed death-1 pathway. **2015**, 64, 1383-92	24
979	Innate and Adaptive Cellular Immune Responses to Mycobacterium tuberculosis Infection. **2015**, 5,	50
978	Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status. **2015**, 28, 1154-66	121
977	Chondroitin sulfate proteoglycan 4 as a target for chimeric antigen receptor-based T-cell immunotherapy of solid tumors. **2015**, 19, 1339-50	16
976	Oxaliplatin regulates expression of stress ligands in ovarian cancer cells and modulates their susceptibility to natural killer cell-mediated cytotoxicity. **2015**, 27, 621-32	21
975	Cancer Immunotherapy with Vaccines and Checkpoint Blockade. **2015**, 709-738.e8	
974	Melanoma. **2015**, 49, 1-20	

973	Engineered Materials for Cancer Immunotherapy. **2015**, 10, 511-531	76
972	Impact of a New Fusion Receptor on PD-1-Mediated Immunosuppression in Adoptive T Cell Therapy. **2015**, 107,	69
971	Nivolumab in the treatment of advanced melanoma. **2015**, 3, 945-956	
970	CD1d expression in renal cell carcinoma is associated with higher relapse rates, poorer cancer-specific and overall survival. **2015**, 68, 200-5	27
969	The immunocheckpoints in modern oncology: the next 15 years. **2015**, 15, 917-21	18
968	Gene Therapy of Solid Cancers. **2015**,	1
967	Biological Therapy of Cancer. **2015**, 561-593	
966	Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system. **2015**, 21, 482-91	109
965	Frequent expression of PD-L1 on circulating breast cancer cells. **2015**, 9, 1773-82	233
964	Identifying genes that mediate anthracyline toxicity in immune cells. **2015**, 6, 62	4
963	Gaining momentum: New options and opportunities for the treatment of advanced melanoma. **2015**, 41, 660-70	46
962	Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. **2015**, 16, 908-18	1151
961	Papillary renal cell carcinoma: A review of the current therapeutic landscape. **2015**, 96, 100-12	72
960	OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal. **2015**, 5, 34	161
959	Novel therapeutic strategies for multiple myeloma. **2015**, 43, 732-41	79
958	Persistence of asthma following allergen avoidance is associated with proTh2 myeloid dendritic cell activation. **2015**, 70, 967-73	12
957	Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy. **2015**, 7, 641-52	38
956	Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses. **2015**, 23, 1630-40	136

955	The pharmacology of second-generation chimeric antigen receptors. **2015**, 14, 499-509	293
954	Antagonists of PD-1 and PD-L1 in Cancer Treatment. **2015**, 42, 587-600	206
953	Small molecule drugs with immunomodulatory effects in cancer. **2015**, 11, 2463-8	20
952	Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment. **2015**, 6, 46	60
951	Targeting the innate immune system as immunotherapy for acute myeloid leukemia. **2015**, 5, 83	22
950	Best practice in the treatment of advanced squamous cell lung cancer. **2015**, 9, 224-35	14
949	Tumor infiltrating lymphocytes in ovarian cancer. **2015**, 16, 807-20	173
948	Intratumoral Delivery of IL-21 Overcomes Anti-Her2/Neu Resistance through Shifting Tumor-Associated Macrophages from M2 to M1 Phenotype. **2015**, 194, 4997-5006	77
947	TLR3 triggering regulates PD-L1 (CD274) expression in human neuroblastoma cells. **2015**, 361, 49-56	48
946	Mechanisms of action of therapeutic antibodies for cancer. **2015**, 67, 28-45	98
945	Anti-PD-1-targeted therapies focusing on lymphatic malignancies: biological rationale, clinical challenges and opportunities. **2015**, 133, 129-35	8
944	Immunotherapy for urothelial cancer: from BCG to checkpoint inhibitors and beyond. **2015**, 15, 509-23	18
943	Immuno-regulatory antibodies for the treatment of cancer. **2015**, 15, 787-801	36
942	A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma. **2015**, 51, 376-82	41
941	Galectin-8 predicts postoperative recurrence of patients with localized T1 clear cell renal cell carcinoma. **2015**, 33, 112.e1-8	5
940	Precision Therapy for Lung Cancer: Tyrosine Kinase Inhibitors and Beyond. **2015**, 27, 36-48	7
939	Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers. **2015**, 88, 24-33	153
938	Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. **2015**, 33, 2013-20	337

937	Cancer prevention and therapy through the modulation of the tumor microenvironment. **2015**, 35 Suppl, S199-S223		201
936	STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. **2015**, 7, 283ra52		396
935	The future of immune checkpoint therapy. **2015**, 348, 56-61		2733
934	Pembrolizumab for the treatment of non-small-cell lung cancer. *New England Journal of Medicine*, **2015**, 372, 2018-28	59.2	3943
933	Broadening the repertoire of melanoma-associated T-cell epitopes. **2015**, 64, 609-20		8
932	A multi-institutional study of clinicopathological features and molecular epidemiology of epidermal growth factor receptor mutations in lung cancer patients living with human immunodeficiency virus infection. **2015**, 141, 1669-78		8
931	Clinical outcomes in 66 patients with advanced gastric cancer treated in phase I trials: the NCCHE experience. **2015**, 33, 664-70		2
930	The role of checkpoints in the treatment of GBM. **2015**, 123, 413-23		12
929	Re-defining response and treatment effects for neuro-oncology immunotherapy clinical trials. **2015** , 123, 339-46		8
928	Immunotherapy in upper GI malignancies. **2015**, 16, 20		8
927	Immunotherapeutic Strategies for Colon Cancer: Monoclonal Antibody Therapy. **2015**, 11, 84-91		
926	Immunstimulation durch Checkpoint-inhibition. **2015**, 18, 31-34		
925	Cancer therapy with Newcastle disease virus: rationale for new immunotherapeutic combinations. **2015**, 5, 75-87		1
924	Targeting cancer-specific mutations by T cell receptor gene therapy. **2015**, 33, 112-9		69
923	Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy. **2015**, 16, 64		329
922	The next steps in next-gen sequencing of cancer genomes. **2015**, 125, 462-8		25
921	PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy. **2015**, 88, 254-9		55
920	The prognostic value of PD-L1 expression for non-small cell lung cancer patients: a meta-analysis. **2015**, 41, 450-6		188

919	The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date. **2015**, 75, 563-75	16
918	Immune checkpoint blockade in hematologic malignancies. **2015**, 125, 3393-400	176
917	Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6C(low) F4/80(+) Extratumoral Macrophages. **2015**, 149, 201-10	182
916	From humble beginnings to success in the clinic: Chimeric antigen receptor-modified T-cells and implications for immunotherapy. **2015**, 240, 1087-98	37
915	Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma. **2015**, 3, 399-411	289
914	Refining the treatment of NSCLC according to histological and molecular subtypes. **2015**, 12, 511-26	189
913	Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect. **2015**, 161, 1035-1045	170
912	Circulating CD14(+)HLA-DR(-/low) myeloid-derived suppressor cell is an indicator of poor prognosis in patients with ESCC. **2015**, 36, 7987-96	25
911	Classifying Cancers Based on T-cell Infiltration and PD-L1. **2015**, 75, 2139-45	864
910	Targeting Heat-Shock Protein 90 (HSP90) as a Complementary Strategy to Immune Checkpoint Blockade for Cancer Therapy. **2015**, 3, 583-9	40
909	ACUTE LEUKEMIAS XV. **2015**, 94, 1-102	12
908	Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN). **2015**, 26, 1677-84	52
907	An immunogenomic stratification of colorectal cancer: Implications for development of targeted immunotherapy. **2015**, 4, e976052	64
906	Human tumor infiltrating lymphocytes cooperatively regulate prostate tumor growth in a humanized mouse model. **2015**, 3, 12	29
905	Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. **2015**, 3, 11	214
904	Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. **2015**, 7, 279ra41	369
903	Overcoming T cell exhaustion in infection and cancer. **2015**, 36, 265-76	619
902	Targeted Therapies for Solid Tumors. **2015**,	1

901	Adoptive cellular therapy: a race to the finish line. **2015**, 7, 280ps7	252
900	TLR5 Ligand-Secreting T Cells Reshape the Tumor Microenvironment and Enhance Antitumor Activity. **2015**, 75, 1959-1971	26
899	Cutting edge: identification of autoreactive CD4+ and CD8+ T cell subsets resistant to PD-1 pathway blockade. **2015**, 194, 3551-3555	37
898	Emerging therapeutic targets of sepsis-associated acute kidney injury. **2015**, 35, 38-54	27
897	PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials. **2015**, 28, 245-53	291
896	A stressful microenvironment: opposing effects of the endoplasmic reticulum stress response in the suppression and enhancement of adaptive tumor immunity. **2015**, 34, 104-22	8
895	Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma. **2015**, 16, e25-35	78
894	On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. **2015**, 7, 280sr1	113
893	The interplay of effector and regulatory T cells in cancer. **2015**, 33, 101-11	88
892	Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. **2015**, 520, 373-7	1509
891	Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies. **2015**, 21, 1127-38	45
890	Inflammation and Immunity in Cancer. **2015**,	1
889	Update on immunotherapy in melanoma. **2015**, 24, 337-46	9
888	Metastasectomy for stage IV melanoma. **2015**, 24, 279-98	18
887	Lymph node dissection for stage III melanoma. **2015**, 24, 261-77	7
886	Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. **2015**, 16, 375-84	1881
885	Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer. **2015**, 21, 976-84	155
884	Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy. **2015**, 67, 4-17	152

883	Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein. **2015**, 21, 2359-66	95
882	Immune Therapy in GI Malignancies: A Review. **2015**, 33, 1745-53	29
881	Targeting precision medicine toxicity: recent developments. **2015**, 6, 4-14	4
880	Strategies to relieve immunosuppression in pancreatic cancer. **2015**, 7, 363-76	16
879	The therapeutic promise of disrupting the PD-1/PD-L1 immune checkpoint in cancer: unleashing the CD8 T cell mediated anti-tumor activity results in significant, unprecedented clinical efficacy in various solid tumors. **2015**, 3, 15	47
878	Clinical Scale Zinc Finger Nuclease-mediated Gene Editing of PD-1 in Tumor Infiltrating Lymphocytes for the Treatment of Metastatic Melanoma. **2015**, 23, 1380-1390	67
877	The expanding role of therapeutic antibodies. **2015**, 34, 202-64	15
876	Safety of pembrolizumab for the treatment of melanoma. **2015**, 14, 957-64	22
875	B7-H4 expression by nonhematopoietic cells in the tumor microenvironment promotes antitumor immunity. **2015**, 3, 184-95	28
874	Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody. **2015**, 3, 1052-62	226
873	Cellular therapy in tuberculosis. **2015**, 32, 32-8	21
872	Melanoma. **2015**, 1, 15003	283
871	Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. **2015**, 10, S1-63	102
870	PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors. **2015**, 38, 1-11	270
869	Immune checkpoint inhibitors in advanced nonsmall cell lung cancer. **2015**, 27, 108-17	23
868	Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. **2015**, 12, 319-34	404
867	Epigenomes as therapeutic targets. **2015**, 151, 72-86	83
866	Immunohistochemical markers in lymphoid malignancies: Protein correlates of molecular alterations. **2015**, 32, 381-91	3

865	Phase II study of nab-paclitaxel and bevacizumab as first-line therapy for patients with unresectable stage III and IV melanoma. **2015**, 38, 61-7	29
864	A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G. **2015**, 68, 267-79	144
863	siRNA silencing of PD-1 ligands on dendritic cell vaccines boosts the expansion of minor histocompatibility antigen-specific CD8(+) T cells in NOD/SCID/IL2Rg(null) mice. **2015**, 64, 645-54	32
862	Immunologic checkpoint blockade in lung cancer. **2015**, 42, 402-17	21
861	Clinical deployment of antibodies for treatment of melanoma. **2015**, 67, 18-27	10
860	Anti-PD-1 therapy in melanoma. **2015**, 42, 466-73	34
859	Treatment algorithms in stage IV melanoma. **2015**, 22, 61-7	9
858	Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions. **2015**, 38, 96-106	129
857	New targets in breast cancer. **2015**, 8, 86-91	
856	CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1. **2015**, 64, 677-88	59
855	Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. **2015**, 112, 1421-7	168
854	Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases. **2015**, 21, 3149-59	248
853	Toxicity patterns with immunomodulating antibodies and their combinations. **2015**, 42, 423-8	45
852	Immunologic checkpoints blockade in renal cell, prostate, and urothelial malignancies. **2015**, 42, 495-505	36
851	Immune checkpoint blockade: a common denominator approach to cancer therapy. **2015**, 27, 450-61	2410
850	Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. **2015**, 161, 205-14	1388
849	A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy. **2015**, 13, 265-72	146
848	Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC). **2015**, 20, 370-8	92

847 NF-B regulates PD-1 expression in macrophages. **2015**, 194, 4545-54 93

846 Principles of cancer treatment by immunotherapy. **2015**, 33, 117-121

845 Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report. **2015**, 64, 765-7 116

844 Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma. **2015**, 50, 770-80 9

843 Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma. **2015**, 4, e1001236 17

842 Novel strategies for inhibiting PD-1 pathway-mediated immune suppression while simultaneously delivering activating signals to tumor-reactive T cells. **2015**, 64, 1287-93 14

841 Endlich neue Therapieoptionen beim malignen Melanom. **2015**, 36, 150-156

840 Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. **2015**, 14, 1507-18 40

839 Monoclonal Antibodies. **2015**, 33, 777-86 17

838 Immunotherapeutic options on the horizon in breast cancer treatment. **2015**, 156, 90-101 15

837 PD-1 and PD-L1 blockade in gastrointestinal malignancies. **2015**, 41, 893-903 44

836 Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. **2015**, 26, 2375-91 828

835 Predictive biomarkers in precision medicine and drug development against lung cancer. **2015**, 34, 295-309 29

834 Risk Factors for Melanoma Among Survivors of Non-Hodgkin Lymphoma. **2015**, 33, 3096-104 22

833 [Non-small cell lung cancer: news from immunotherapy]. **2015**, 140, 329-33 1

832 PD-L1 expression in melanocytic lesions does not correlate with the BRAF V600E mutation. **2015**, 3, 110-5 43

831 Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors. **2015**, 3, 1344-55 197

830 Introduction: Rationale for Precision Medicine Clinical Trials. **2015**, 1-8

829	Interferon-Induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression. **2015**, 4, e1008824	184
828	Re: MPDL3280A (Anti-PD-L1) Treatment Leads to Clinical Activity in Metastatic Bladder Cancer. **2015**, 194, 956	1
827	Immunothérapie anticancer : les molécules immunomodulatrices en développement clinique. **2015**, 17, 379-389	
826	The Rapid Emergence of Novel Therapeutics in Advanced Malignant Melanoma. **2015**, 5, 151-69	18
825	Decitabine Enhances Lymphocyte Migration and Function and Synergizes with CTLA-4 Blockade in a Murine Ovarian Cancer Model. **2015**, 3, 1030-41	99
824	Tumor Therapeutics Work as Stress Inducers to Enhance Tumor Sensitivity to Natural Killer (NK) Cell Cytolysis by Up-regulating NKp30 Ligand B7-H6. **2015**, 290, 29964-73	50
823	Immune checkpoints and immunotherapy for colorectal cancer. **2015**, 3, 289-97	61
822	Multifunctional receptor-targeting antibodies for cancer therapy. **2015**, 16, e543-e554	30
821	Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. **2015**, 16, e534-e542	425
820	Cancer immunotherapy: Strategies for personalization and combinatorial approaches. **2015**, 9, 2043-53	68
819	Optimizing systemic therapy for metastatic renal cell carcinoma beyond the first-line setting. **2015**, 33, 538-45	9
818	Targeting Programmed Cell Death 1 in Ovarian Cancer. **2015**, 33, 3987-9	16
817	Nivolumab for second-line treatment of metastatic squamous non-small-cell lung cancer. **2015**, 72, 1851-5	14
816	Immunothérapie anticancéreuse et cancers digestifs. **2015**, 9, 201-209	
815	T Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal Adenocarcinoma. **2015**, 28, 638-652	129
814	Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cells. **2015**, 14, 149	142
813	Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1. **2015**, 23, 2341-2348	267
812	Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy. **2015**, 21, 5427-33	196

811	Pharmacotherapy of head and neck cancer. **2015**, 16, 2409-22	6
810	Virotherapy with a Semliki Forest Virus-Based Vector Encoding IL12 Synergizes with PD-1/PD-L1 Blockade. **2015**, 3, 449-54	61
809	Synergy of molecular targeted approaches and immunotherapy in melanoma: preclinical basis and clinical perspectives. **2015**, 15, 1491-500	4
808	Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma. **2015**, 15, 981-93	37
807	Programmed death-1 & its ligands: promising targets for cancer immunotherapy. **2015**, 7, 777-92	16
806	Injectable cryogel-based whole-cell cancer vaccines. **2015**, 6, 7556	237
805	Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma-An exclamation sign with a question mark. **2015**, 4, e1058037	23
804	Comparing comparators: a look at control arms in kidney cancer studies over the years. **2015**, 112, 14-9	6
803	Emerging therapeutic approaches in renal cell carcinoma. **2015**, 15, 1305-14	12
802	Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics. **2015**, 6, 534-8	86
801	Epigenetic and Immune Regulation of Colorectal Cancer Stem Cells. **2015**, 11, 414-421	4
800	Targeting immune checkpoints: New opportunity for mesothelioma treatment?. **2015**, 41, 914-24	33
799	The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma. **2015**, 20, 1253-60	35
798	An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors. **2015**, 16, 54	35
797	Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas. **2015**, 51, 2698-707	121
796	Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients. **2015**, 5, e285	68
795	Neural immune modulation and immunotherapy assisted by focused ultrasound induced blood-brain barrier opening. **2015**, 11, 2682-7	14
794	Adoptive T-Cell Immunotherapy. **2015**, 391, 427-54	40

793	Chronic lymphocytic leukaemia induces an exhausted T cell phenotype in the TCL1 transgenic mouse model. **2015**, 170, 515-22	27
792	Are Epstein-Barr Virus-positive and -negative Gastric Carcinomas, With Lymphoid Stroma, Single Entity or Different Entities?. **2015**, 13, 1745-7	1
791	Nicht-kleinzelliges Lungenkarzinom: Neues aus der Immuntherapie. **2015**, 36, 341-346	
790	Translating Pembrolizumab to Clinical Practice: Speak Immunology and Learn Fast!. **2015**, 21, 4251-3	1
789	Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors. **2015**, 3, 1333-1343	25
788	Alphavirus-based vaccines in melanoma: rationale and potential improvements in immunotherapeutic combinations. **2015**, 7, 981-97	3
787	Br□es de l□AERIO. **2015**, 17, 405-408	1
786	Immunog□icit□de la chimioth□apie. **2015**, 17, 345-353	
785	Immune response to cancer therapy: mounting an effective antitumor response and mechanisms of resistance. **2015**, 1, 66-75	60
784	Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo. **2015**, 14, 119	35
783	HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade. **2015**, 3, 1375-85	246
782	PD-L1 Monoclonal Antibody Treats Ischemic Stroke by Controlling Central Nervous System Inflammation. **2015**, 46, 2926-34	24
781	Contemporary trends in high-dose interleukin-2 use for metastatic renal cell carcinoma in the United States. **2015**, 33, 496.e11-6	31
780	Metastatic clear cell renal cell carcinoma: A review of current therapies and novel immunotherapies. **2015**, 96, 527-33	44
779	Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells. **2015**, 4, e1016700	156
778	IL-36□Transforms the Tumor Microenvironment and Promotes Type 1 Lymphocyte-Mediated Antitumor Immune Responses. **2015**, 28, 296-306	62
777	Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy?. **2015**, 4, e1058597	48
776	Heterogeneity of T Cell Responses to Pandemic pH1N1 Monovalent Vaccine in HIV-Infected Pregnant Women. **2015**, 31, 1170-7	1

775	Current and future molecular profiling of cancer by next-generation sequencing. **2015**, 45, 895-9	11
774	Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma. **2015**, 166, 412-24	50
773	Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS. **2015**, 42, 640-55	133
772	The future of immunotherapy in the treatment of lung cancer. **2015**, 4, 57-73	2
771	Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis. **2015**, 11, 2471-84	59
770	Pembrolizumab. **2015**, 3, 36	131
769	Adoptive cell therapy for sarcoma. **2015**, 7, 21-35	9
768	Checkpoint modulation--A new way to direct the immune system against renal cell carcinoma. **2015**, 11, 1201-8	10
767	Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. **2015**, 162, 974-86	872
766	Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. **2015**, 162, 1229-41	1457
765	PDL1 expression is an independent prognostic factor in localized GIST. **2015**, 4, e1002729	51
764	PD-L1 and CD8+PD1+ lymphocytes exist as targets in the pediatric tumor microenvironment for immunomodulatory therapy. **2015**, 4, e1029701	40
763	Management of Dermatologic Complications of Lung Cancer Therapies. **2015**, 16, 50	12
762	Role of the Tumor Microenvironment in Breast Cancer. **2015**, 82, 142-52	185
761	Immune checkpoint inhibitors in melanoma. **2015**, 2, 267-284	4
760	Emerging cytokine networks in colorectal cancer. **2015**, 15, 615-29	230
759	Fas Ligand Deficiency Impairs Tumor Immunity by Promoting an Accumulation of Monocytic Myeloid-Derived Suppressor Cells. **2015**, 75, 4292-301	19
758	FcRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis. **2015**, 28, 285-95	179

757	Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma. **2015**, 51, 2580-6	69
756	Anti-PD1 and anti-PD-L1 in the treatment of metastatic melanoma. **2015**, 2, 41-50	6
755	Emerging immune checkpoints for cancer therapy. **2015**, 54, 1706-13	29
754	HIF-2α/ATPR1 axis: A new saboteur of NK-mediated lysis. **2015**, 4, e985951	10
753	Emerging strategies for cancer immunoprevention. **2015**, 34, 6029-39	31
752	Immune checkpoint blockade in microsatellite instable colorectal cancers: Back to the clinic. **2015**, 4, e1008858	7
751	Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. **2015**, 33, 4015-22	691
750	Leveraging Cancer Therapeutics for the HIV Cure Agenda: Current Status and Future Directions. **2015**, 75, 1447-59	6
749	Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies. **2015**, 10, 395-404	13
748	Epstein-Barr Virus-Associated Gastric Carcinoma: Use of Host Cell Machineries and Somatic Gene Mutations. **2015**, 82, 212-23	35
747	Immune Memory and Exhaustion: Clinically Relevant Lessons from the LCMV Model. **2015**, 850, 137-52	40
746	Cancer gene therapy with T cell receptors and chimeric antigen receptors. **2015**, 24, 113-8	26
745	Crossroads Between Innate and Adaptive Immunity V. **2015**,	2
744	Clinical Evaluation of ErbB-Targeted CAR T-Cells, Following Intracavity Delivery in Patients with ErbB-Expressing Solid Tumors. **2015**, 1317, 365-82	26
743	Breast cancer and immunology: biomarker and therapeutic developments. **2015**, 15, 1215-22	9
742	PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation. **2015**, 3, 1303-7	106
741	Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1/PD-1 signalling pathway in hepatocellular carcinoma. **2015**, 34, 141	115
740	Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non--Small-Cell Lung Cancer. **2015**, 16, 385-90	94

739	Turning Radiotherapy into an Effective Systemic Anti-cancer Treatment in Combination with Immunotherapy. **2015**, 27, 696-9	10
738	Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade. **2015**, 7, 315ra188	177
737	Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1. **2015**, 7, 1169-86	35
736	Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma. **2015**, 7, 365-77	90
735	Overview of current immunotherapeutic strategies for glioma. **2015**, 7, 1073-104	32
734	Developing an Immunotherapy Strategy for the Effective Treatment of Oral, Head and Neck Squamous Cell Carcinoma. **2015**, 73, S107-15	3
733	Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. **2015**, 7, 1213-27	71
732	Emerging strategies for biomaterial-assisted cancer immunotherapy. **2022**, 39, 227-240	
731	Therapeutic Perspectives in the Systemic Treatment of Kaposi's Sarcoma.. **2022**, 14,	1
730	Targeting pancreatic cancer by TAK-981: a SUMOylation inhibitor that activates the immune system and blocks cancer cell cycle progression in a preclinical model.. **2022**,	2
729	Immunotherapy for glioblastoma: the promise of combination strategies.. **2022**, 41, 35	12
728	Evaluation of MMR Status and PD-L1 Expression Using Specimens Obtained by EUS-FNB in Patients with Pancreatic Ductal Adenocarcinoma (PDAC).. **2022**, 12,	
727	Medikamenti induzierte Lungenerkrankungen. **2022**, 125-143	
726	Development of 3D breast cancer models with human T cells expressing engineered MAIT cell receptors.	
725	Histone deacetylases: A novel class of therapeutic targets for pancreatic cancer.. **2022**, 1877, 188676	2
724	A Randomized Phase II Trial of mFOLFOX6 + Bevacizumab Alone or with AdCEA Vaccine + Avelumab Immunotherapy for Untreated Metastatic Colorectal Cancer.. **2022**, 27, 198-209	0
723	PD-L1 Overexpression Correlates with JAK2-V617F Mutational Burden and Is Associated with 9p Uniparental Disomy in Myeloproliferative Neoplasms.. **2022**,	1
722	Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study.. **2022**, 10,	1

721	Programmed cell death 1 ligand 1 signals in cancer cells.. **2022**,	12
720	Novel Mouse Models for Cancer Immunology. **2022**, 6,	0
719	Pan-cancer analysis identifies RNA helicase DDX1 as a prognostic marker. **2022**, 2, 33	0
718	Identification of solute carrier family genes related to the prognosis and tumor-infiltrating immune cells of pancreatic ductal adenocarcinoma.. **2022**, 10, 57	
717	Self-blockade of PD-L1 with bacteria-derived outer-membrane vesicle for enhanced cancer immunotherapy. **2021**, e2106307	5
716	Latest Advances in the Use of Therapeutic Focused Ultrasound in the Treatment of Pancreatic Cancer.. **2022**, 14,	1
715	Overview of Immune Checkpoint Inhibitors in Gynecological Cancer Treatment.. **2022**, 14,	1
714	Presence of Tim3 and PD-1 CD8 T cells identifies microsatellite stable colorectal carcinomas with immune exhaustion and distinct clinicopathological features.. **2022**,	0
713	PD-L1 and HER2 expression in gastric adenocarcinoma and their prognostic significance.. **2022**,	1
712	Multiscale imaging of therapeutic anti-PD-L1 antibody localization using molecularly defined imaging agents.. **2022**, 20, 64	0
711	TGF- and Cancer Immunotherapy.. **2022**, 45, 155-161	2
710	Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity.. **2022**, 132,	4
709	Immunostimulation of tumor microenvironment by targeting tumor-associated macrophage with hypoxia-responsive nanocomplex for enhanced anti-tumor therapy.. **2022**, 343, 78-78	0
708	Targeting hedgehog signaling in pancreatic ductal adenocarcinoma.. **2022**, 108107	4
707	Myeloid-derived suppressor cell infiltration is associated with a poor prognosis in patients with hepatocellular carcinoma.. **2022**, 23, 93	1
706	Ferroptosis-associated molecular classification characterized by distinct tumor microenvironment profiles in colorectal cancer.. **2022**, 18, 1773-1794	1
705	Identification of SCN7A as the key gene associated with tumor mutation burden in gastric cancer.. **2022**, 22, 45	0
704	Disrupting CANCER angiogenesis and immune checkpoint networks for improved tumor immunity.. **2022**,	2

703	Novel systemic treatment approaches for metastatic pancreatic cancer.. **2022**,	0
702	Diagnostic Utility of the PD-L1 Immunostaining in Biopsy Specimens of Patients with Biliary Tract Neoplasms.. **2022**, 1	
701	Age as a risk factor in vasculitis.. **2022**, 1	2
700	The induction of peripheral trained immunity in the pancreas incites anti-tumor activity to control pancreatic cancer progression.. **2022**, 13, 759	3
699	Bibliometric analysis of the 100 top-cited articles on immunotherapy of urological cancer.. **2022**, 1-8	1
698	A DNA-Methylation-Driven Genes Based Prognostic Signature Reveals Immune Microenvironment in Pancreatic Cancer.. **2022**, 13, 803962	0
697	Tegaserod Maleate Inhibits Breast Cancer Progression and Enhances the Sensitivity of Immunotherapy.. **2022**, 2022, 5320421	0
696	Molecular methods for increasing the effectiveness of ovarian cancer treatment: a systematic review.. **2022**,	2
695	Tumour mutational burden: an overview for pathologists.. **2022**,	1
694	Current Therapy and Development of Therapeutic Agents for Lung Cancer. **2022**, 100015	1
693	ATRA promotes PD-L1 expression to control gastric cancer immune surveillance.. **2022**, 174822	
692	Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy.. **2022**, 41, 56	1
691	Intron-Retention Neoantigen Load Predicts Favorable Prognosis in Pancreatic Cancer.. **2022**, 6, e2100124	0
690	Fluorescence imaging of tumor immune contexture in immune checkpoint blockade therapy.. **2022**, 106, 108617	0
689	Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer.. **2022**, 3, 108-121	9
688	4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39+ CD8 T cells from primary and metastatic sites of epithelial ovarian cancers. **2020**, 8, e001650	8
687	Recent advances of nanotechnology-based tumor vessel-targeting strategies.. **2021**, 19, 435	5
686	The Use of Targeted Agents in the Treatment of Gynecologic Cancers.. **2022**, 23, 15	0

685	Chemoresistance in Colorectal Malignancies: Molecular Mechanisms and Strategies to Overcome.. **2022**, 123-141	
684	Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy.. **2022**, 22, e2	8
683	Effects of PD-1 Signaling on Immunometabolic Reprogramming.. **2022**, 4,	0
682	Metallodrugs in cancer nanomedicine.. **2022**,	10
681	Research Progress in Immunotherapy of Pancreatic Cancer. **2022**, 12, 1169-1177	
680	Investigation of Unprecedented Sites and Proposition of New Ligands for Programmed Cell Death Protein I through Molecular Dynamics with Probes and Virtual Screening.. **2022**,	0
679	D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1.. **2022**, 119,	5
678	Integratively Genomic Analysis Reveals the Prognostic and Immunological Characteristics of Pyroptosis and Ferroptosis in Pancreatic Cancer for Precision Immunotherapy.. **2022**, 10, 826879	1
677	RelB upregulates PD-L1 and exacerbates prostate cancer immune evasion.. **2022**, 41, 66	0
676	Evolution of Immunotherapy for Ovarian Cancer from a Bird's-Eye Perspective: A Text-Mining Analysis of Publication Trends and Topics.. **2022**, 12, 795129	0
675	Expression of CD28 in Hepatocellular Carcinoma and Its Prognostic Value. **2022**, 21,	
674	The Landscape of Nanovectors for Modulation in Cancer Immunotherapy.. **2022**, 14,	0
673	Biological and technical factors in the assessment of blood-based tumor mutational burden (bTMB) in patients with NSCLC.. **2022**, 10,	0
672	Diagnostic Performance of PD-L1 versus PD-1 Expression in Circulating CD20 Cells in Diffuse Large B-Cell Lymphoma.. **2022**, 11,	0
671	Clinical challenges associated with utility of neoadjuvant treatment in patients with pancreatic ductal adenocarcinoma.. **2022**,	0
670	Reactive oxygen species in cancer progression and its role in therapeutics. 43-57	1
669	Insufficiency of compound immune checkpoint blockade to overcome engineered T cell exhaustion in pancreatic cancer.. **2022**, 10,	0
668	Current Limitations and Novel Perspectives in Pancreatic Cancer Treatment.. **2022**, 14,	4

667	PKP1 and MYC create a feedforward loop linking transcription and translation in squamous cell lung cancer.. **2022**, 1	
666	Modulation of Type I Interferon Responses to Influence Tumor-Immune Cross Talk in PDAC.. **2022**, 10, 816517	1
665	The Immune Landscape of Human Pancreatic Ductal Carcinoma: Key Players, Clinical Implications, and Challenges.. **2022**, 14,	3
664	Advanced Pancreatic Cancer Patient Benefit From Personalized Neoantigen Nanovaccine Based Immunotherapy: A Case Report.. **2022**, 13, 799026	
663	Cohesin mutation sensitizes cancer cells to anti-PD-1 therapy through endogenous retrovirus-mediated PD-L1 upregulation.	
662	Tumor necrosis factor alpha neutralization attenuates immune checkpoint inhibitor-induced activation of intermediate monocytes in synovial fluid mononuclear cells from patients with inflammatory arthritis.. **2022**, 24, 43	1
661	Immune checkpoint silencing using RNAi-incorporated nanoparticles enhances antitumor immunity and therapeutic efficacy compared with antibody-based approaches.. **2022**, 10,	3
660	Long-Term Outcomes of Immune Checkpoint Inhibition in Metastatic Melanoma.. **2022**, 1	2
659	Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4.. **2022**, 15,	5
658	Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation.. **2022**, 15, 24	8
657	Anti-PD-L1 Antibody Enhances T Cell Immune Responses and Reduces Resistance of Breast Cancer Cells to Radiotherapy.. **2022**, 2022, 5938688	0
656	An Oxidative Stress-Related Genes Signature for Predicting Survival in Bladder Cancer: Based on TCGA Database and Bioinformatics.. **2022**, 15, 2645-2667	0
655	The pancreatic cancer immune tumor microenvironment is negatively remodeled by gemcitabine while TGF- receptor plus dual checkpoint inhibition maintains antitumor immune cells.. **2022**,	0
654	Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors.. **2022**, 10,	2
653	Targeting the PSGL-1 Immune Checkpoint Promotes Immunity to PD-1 Resistant Melanoma.. **2022**,	1
652	Immune checkpoint inhibitors and adrenal insufficiency: a large-sample case series study.. **2022**, 10, 251	2
651	Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia.. **2022**, 11, 11	3
650	Pivotal antitumor role of the immune checkpoint molecule B7-H1 in pancreatic cancer.. **2022**, 11, 2043037	0

649	SEOM-GECOD clinical guideline for unknown primary cancer (2021).. **2022**, 24, 681	0
648	Frequency of Immune Checkpoint Inhibitor-Induced Vasculitides: An Observational Study Using Data From the Japanese Adverse Drug Event Report Database.. **2022**, 13, 803706	0
647	Radiotherapy could increase the efficacy of immunotherapy in non-small cell lung cancer.	
646	Systematic Characterization of the Clinical Relevance of KPNA4 in Pancreatic Ductal Adenocarcinoma.. **2022**, 12, 834728	
645	Control of Dendritic Cell Function Within the Tumour Microenvironment.. **2022**, 13, 733800	4
644	Emerging Strategies in TCR-Engineered T Cells.. **2022**, 13, 850358	0
643	Retinoic Acid Induces an IFN-Driven Inflammatory Tumour Microenvironment, Sensitizing to Immune Checkpoint Therapy.. **2022**, 12, 849793	0
642	Betulin Attenuates TGF-β1- and PGE-Mediated Inhibition of NK Cell Activity to Suppress Tumor Progression and Metastasis in Mice.. **2022**, 45, 339-353	0
641	A Commotion in the Skin: Developing Melanoma Immunotherapies.. **2022**,	0
640	Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events.. **2022**, 13, 804597	4
639	CAR-T cell therapy for lung cancer: Potential and perspective.. **2022**,	5
638	CMTM6 as a master regulator of PD-L1.. **2022**, 1	1
637	Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial.. **2022**, 23, e105-e115	5
636	Nanotechnology in Immunotherapy for Type 1 Diabetes: Promising Innovations and Future Advances.. **2022**, 14,	1
635	Integrative Analysis of Multi-Omics Data-Identified Key Genes With KLRC3 as the Core in a Gene Regulatory Network Related to Immune Phenotypes in Lung Adenocarcinoma.. **2022**, 13, 810193	0
634	Evolution of surgical treatment of metastatic spine tumors.. **2022**, 157, 277	
633	PD-1 N58-Glycosylation-Dependent Binding of Monoclonal Antibody Cemiplimab for Immune Checkpoint Therapy.. **2022**, 13, 826045	2
632	Immunosuppressive TREM2(+) macrophages are associated with undesirable prognosis and responses to anti-PD-1 immunotherapy in non-small cell lung cancer.. **2022**, 1	0

631	Serum exosomal miR-16-5p functions as a tumor inhibitor and a new biomarker for PD-L1 inhibitor-dependent immunotherapy in lung adenocarcinoma by regulating PD-L1 expression.. **2022** ,	0
630	SLC1A5 Prefers to Play as an Accomplice Rather Than an Opponent in Pancreatic Adenocarcinoma.. **2022**, 10, 800925	2
629	Microbiota-dependent activation of the myeloid calcineurin-NFAT pathway inhibits B7H3- and B7H4-dependent anti-tumor immunity in colorectal cancer.. **2022**,	2
628	Local Ablative Therapy Associated with Immunotherapy in Locally Advanced Pancreatic Cancer: A Solution to Overcome the Double Trouble?-A Comprehensive Review.. **2022**, 11,	1
627	Association of the Microbiota and Pancreatic Cancer: Opportunities and Limitations.. **2022**, 13, 844401	0
626	The clinical and prognostic significance of CMTM6/PD-L1 in oncology.. **2022**, 1	
625	Identification of molecular subtypes premised on the characteristics of immune infiltration of endometrial cancer.. **2022**, 10, 337	0
624	Distinct myeloid antigen-presenting cells dictate differential fates of tumor-specific CD8+ T cells in pancreatic cancer.. **2022**, 7,	0
623	Impact of HPV status on immune responses in head and neck squamous cell carcinoma.. **2022**, 127, 105774	0
622	The microbial metabolite trimethylamine N-oxide promotes antitumor immunity in triple-negative breast cancer.. **2022**,	8
621	Patient-Derived Tumor Organoids: New Progress and Opportunities to Facilitate Precision Cancer Immunotherapy.. **2022**, 12, 872531	0
620	Dietary Lactobacillus-derived exopolysaccharide enhances immune checkpoint blockade therapy.. **2022**,	5
619	CAR-T Cells for the Treatment of Lung Cancer.. **2022**, 12,	0
618	Deubiquitinase USP10 maintains Cyr61 expression via YAP1 to augment immune escape and metastasis of PAAD.. **2022**,	1
617	Characteristics of immunophenotypes and immunological in tumor microenvironment and analysis of immune implication of CXCR4 in gastric cancer.. **2022**, 12, 5720	1
616	The role of tumor-infiltrating lymphocytes in cholangiocarcinoma.. **2022**, 41, 127	4
615	Dynamic profiling of immune microenvironment during pancreatic cancer development suggests early intervention and combination strategy of immunotherapy.. **2022**, 78, 103958	0
614	Splenic and PB immune recovery in neoadjuvant treated gastrointestinal cancer patients.. **2022**, 106, 108628	0

613	CCL2-mediated monocytes regulate immune checkpoint blockade resistance in pancreatic cancer.. **2022**, 106, 108598	0
612	Molecular testing panel in colorectal cancer. **2022**, 28, 300632	
611	Ag nanoparticles enhance immune checkpoint blockade efficacy by promoting of immune surveillance in melanoma.. **2022**, 616, 189-200	3
610	Anti-CTLA-4 and anti-PD-1 immunotherapies repress tumor progression in preclinical breast and colon model with independent regulatory T cells response.. **2022**, 20, 101405	0
609	Analysis of characteristics and predictive factors of immune checkpoint inhibitor-related adverse events. **2021**,	4
608	Research trends of immune checkpoint blockade in melanoma: a visualization and bibliometric analysis (Preprint).	0
607	Immunotherapy-Related Publications in Colorectal Cancer: A Bibliometric Analysis.. **2021**, 10,	1
606	SSR4 as a prognostic biomarker and related with immune infiltration cells in colon adenocarcinoma.. **2021**, 1-9	0
605	The multi-specific V-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity.. **2021**,	1
604	Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance. **2021**, 12, 7041	5
603	Vertebral body and splenic irradiation are associated with lymphopenia in localized pancreatic cancer treated with stereotactic body radiation therapy.. **2021**, 16, 242	1
602	Engineering polymer nanoparticles using cell membrane coating technology and their application in cancer treatments: Opportunities and challenges. **2021**,	1
601	Cancer-immunotherapy biomarkers in the tumor microenvironment. **2021**, 133, 151-157	
600	HOXA-AS3 Promotes Proliferation and Migration of Hepatocellular Carcinoma Cells via the miR-455-5p/PD-L1 Axis.. **2021**, 2021, 9289719	1
599	Protein phosphatase 2A inactivation induces microsatellite instability, neoantigen production and immune response.. **2021**, 12, 7297	1
598	Reversing T-cell Exhaustion in Cancer: Lessons Learned from PD-1/PD-L1 Immune Checkpoint Blockade.. **2021**,	8
597	Programmed Cell Death Protein 1 Blockade Reduces Glycogen Synthase Kinase 3 Activity and Tau Hyperphosphorylation in Alzheimer's Disease Mouse Models.. **2021**, 9, 769229	1
596	Cisplatin and gemcitabine exert opposite effects on immunotherapy with PD-1 antibody in K-ras-driven cancer. **2021**,	0

595	Current challenges of hematologic complications due to immune checkpoint blockade: a comprehensive review.. **2022**, 101, 1-10	6
594	Biomarkers of Central Nervous System Involvement from Epithelial Ovarian Cancer.. **2021**, 10,	1
593	Emerging Role of EGFR Mutations in Creating an Immune Suppressive Tumour Microenvironment.. **2021**, 10,	0
592	Pan-Cancer Analyses of the Tumor Microenvironment Reveal That Ubiquitin-Conjugating Enzyme E2C Might Be a Potential Immunotherapy Target.. **2021**, 2021, 9250207	1
591	Key Candidate Prognostic Biomarkers Correlated with Immune Infiltration in Hepatocellular Carcinoma.. **2021**, 8, 1607-1622	0
590	PARP Inhibitor Upregulates PD-L1 Expression and Provides a New Combination Therapy in Pancreatic Cancer.. **2021**, 12, 762989	2
589	OX40 agonism enhances efficacy of PD-L1 checkpoint blockade by shifting the cytotoxic T cell differentiation spectrum.	
588	Microfluidic Platforms for High-Throughput Pancreatic Ductal Adenocarcinoma Organoid Culture and Drug Screening.. **2021**, 9, 761807	1
587	Evaluation of PD-L1 Expression Level in Patients With Non-Small Cell Lung Cancer by F-FDG PET/CT Radiomics and Clinicopathological Characteristics.. **2021**, 11, 789014	4
586	Different subpopulations of regulatory T cells in human autoimmune disease, transplantation, and tumor immunity.. **2022**, 3, e137	0
585	A nanovaccine for antigen self-presentation and immunosuppression reversal as a personalized cancer immunotherapy strategy.. **2022**,	14
584	Immune Checkpoint Inhibitors as Therapy to Down-Stage Hepatocellular Carcinoma Prior to Liver Transplantation.. **2022**, 14,	2
583	Risk Analysis of Positive PD-L1 Expression and Clinicopathological Features and Survival Prognosis in Patients with Colorectal Cancer: Systematic Review and Meta-Analysis.. **2022**, 2022, 8212486	0
582	Research Trends and Most Influential Clinical Studies on Anti-PD1/PDL1 Immunotherapy for Cancers: A Bibliometric Analysis.. **2022**, 13, 862084	0
581	Antiangiogenic Strategies in Epithelial Ovarian Cancer: Mechanism, Resistance, and Combination Therapy.. **2022**, 2022, 4880355	1
580	Acquired resistance to anti-PD1 therapy in patients with NSCLC reveals changes in T cell phenotypes and MET amplification.	
579	DENR controls JAK2 translation to induce PD-L1 expression for tumor immune evasion.. **2022**, 13, 2059	3
578	The role of cellular proteostasis in anti-tumor immunity.. **2022**, 101930	0

577	Epigenetic Alterations and Inflammation as Emerging Use for the Advancement of Treatment in Non-Small Cell Lung Cancer.. **2022**, 13, 878740	1
576	Soluble form of CTLA-4 is a good predictor for tumor recurrence after radiofrequency ablation in hepatocellular carcinoma patients.. **2022**,	
575	Macrophage Associated Immune Checkpoint CD47 Blocking Ameliorates Endometriosis.. **2022**,	0
574	Data_Sheet_1.pdf. **2019**,	
573	Image_1.TIF. **2020**,	
572	Image_1.PDF. **2018**,	
571	Data_Sheet_1.docx. **2020**,	
570	image_1.PDF. **2018**,	
569	image_2.PDF. **2018**,	
568	table_1.PDF. **2018**,	
567	table_2.PDF. **2018**,	
566	table_3.PDF. **2018**,	
565	Presentation_1.pdf. **2020**,	
564	image_1.PDF. **2018**,	
563	image_2.PDF. **2018**,	
562	image_3.PDF. **2018**,	
561	image_4.PDF. **2018**,	
560	table_1.xlsx. **2018**,	

559 table_2.xlsx. **2018**,

558 Table_1.xlsx. **2019**,

557 Table_2.xlsx. **2019**,

556 Table_3.xlsx. **2019**,

555 Table_4.xlsx. **2019**,

554 Table_5.xlsx. **2019**,

553 Table_6.xlsx. **2019**,

552 Table_7.xlsx. **2019**,

551 Data_Sheet_1.docx. **2020**,

550 Data_Sheet_1.pdf. **2019**,

549 Image_1.TIFF. **2018**,

548 Image_2.TIFF. **2018**,

547 Image_3.TIFF. **2018**,

546 Image_4.TIFF. **2018**,

545 Image_5.TIFF. **2018**,

544 Image_6.TIFF. **2018**,

543 Image_7.TIFF. **2018**,

542 Image_8.TIFF. **2018**,

541 Data_Sheet_1.pdf. **2019**,

540 Data_Sheet_1.docx. **2019**,

539 Data_Sheet_1.docx. **2020**,

538 Image_1.JPEG. **2020**,

537 Image_2.JPEG. **2020**,

536 Image_3.JPEG. **2020**,

535 Image_4.JPEG. **2020**,

534 Image_5.JPEG. **2020**,

533 Table_1.pdf. **2020**,

532 Data_Sheet_1.PDF. **2018**,

531 Data_Sheet_1.docx. **2019**,

530 Data_Sheet_1.doc. **2019**,

529 Image_1.tif. **2020**,

528 Image_2.tif. **2020**,

527 Image_3.tif. **2020**,

526 Image_4.tif. **2020**,

525 Table_1.docx. **2020**,

524 Table_2.docx. **2020**,

523 Table_3.docx. **2020**,

522 Table_4.xlsx. **2020**,

521 Image1.PDF. **2018**,

520 Image2.PDF. **2018**,

519 Image3.PDF. **2018**,

518 Image4.PDF. **2018**,

517 Presentation1.pdf. **2018**,

516 Table1.PDF. **2018**,

515 Table2.PDF. **2018**,

514 Table3.PDF. **2018**,

513 Image_1.JPEG. **2019**,

512 Image_2.JPEG. **2019**,

511 Image_1.TIF. **2020**,

510 Image_2.TIF. **2020**,

509 Image_3.TIF. **2020**,

508 Table_1.doc. **2020**,

507 Table_2.doc. **2020**,

506 Table_3.doc. **2020**,

505 Presentation_1.pdf. **2019**,

504 Table_1.XLSX. **2019**,

503 Image_1.TIF. **2019**,

502 Data_Sheet_1.pdf. **2019**,

501 Table_1.XLSX. **2019**,

500 Table_2.xlsx. **2019**,

499 DataSheet_1.docx. **2021**,

498 Table_1.xlsx. **2021**,

497 Data_Sheet_1.docx. **2020**,

496 Table_1.XLSX. **2020**,

495 Data_Sheet_1.docx. **2019**,

494 Image_1.pdf. **2019**,

493 Image_2.pdf. **2019**,

492 DataSheet_1.pdf. **2019**,

491 Image_1.TIF. **2020**,

490 Table_1.DOCX. **2020**,

489 Table_2.DOCX. **2020**,

488 Table_1.docx. **2019**,

487	DataSheet_1.pdf. **2020**,	
486	DataSheet_2.docx. **2020**,	
485	Image_1.jpeg. **2019**,	
484	Image_2.jpeg. **2019**,	
483	Image_3.jpeg. **2019**,	
482	Image_4.jpeg. **2019**,	
481	Image_5.jpeg. **2019**,	
480	Table_1.docx. **2019**,	
479	Table_1.XLSX. **2019**,	
478	Data_Sheet_1.pdf. **2020**,	
477	Transcriptional and post-transcriptional regulation of checkpoint genes on the tumour side of the immunological synapse.. **2022**,	0
476	A variety of 'exhausted' T cells in the tumor microenvironment.. **2022**,	0
475	Diurnal expression of PD-1 on tumor-associated macrophages underlies the dosing time-dependent anti-tumor effects of the PD-1/PD-L1 inhibitor BMS-1 in B16/BL6 melanoma-bearing mice.. **2022**,	1
474	Association between plasma somatic copy number variations and response to immunotherapy in patients with programmed death-ligand 1-negative non-small cell lung cancer.. **2022**, 50, 3000605221093222	0
473	Effects of tumor derived exosomes on T cells markers expression.. **2022**, 84, e250556	
472	Phase Ib study on the humanized anti-CCR4 antibody, KW-0761, in advanced solid tumors.. **2021**, 83, 827-840	1
471	Personalizing first-line treatment in advanced colorectal cancer: Present status and future perspectives.. **2021**, 7, 771-785	
470	Polymer chimera of stapled oncolytic peptide coupled with anti-PD-L1 peptide boosts immunotherapy of colorectal cancer.. **2022**, 12, 3456-3473	3

469	High Dose Local Photon Irradiation Is Crucial in Anti-CTLA-4 Antibody Therapy to Enhance the Abscopal Response in a Murine Pancreatic Carcinoma Model.. **2022**, 14,	0
468	Targeting PARP1 to Enhance Anticancer Checkpoint Immunotherapy Response: Rationale and Clinical Implications.. **2022**, 13, 816642	1
467	Global research trends on immunotherapy in cancer: a visualization analysis (Preprint).	
466	The Role of Extracellular Matrix Remodeling in Skin Tumor Progression and Therapeutic Resistance.. **2022**, 9, 864302	0
465	DNA Hypermethylation-Regulated CX3CL1 Reducing T Cell Infiltration Indicates Poor Prognosis in Wilms Tumour.. **2022**, 12, 882714	0
464	In vivo labeling reveals continuous trafficking of TCF-1+ T cells between tumor and lymphoid tissue.. **2022**, 219,	2
463	Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC).. **2022**, JCO2102511	3
462	Companion Diagnostics.. **2022**,	
461	Immune Cell Metabolic Fitness for Life. **2022**, 11, 32	
460	Immune Checkpoint Protein Expression Defines the Prognosis of Advanced Thyroid Carcinoma.. **2022**, 13, 859013	0
459	Engineered nanomedicines block the PD-1/PD-L1 axis for potentiated cancer immunotherapy.. **2022**,	1
458	Identification and Validation of Immune Molecular Subtypes and Immune Landscape Based on Colon Cancer Cohort. **2022**, 9,	1
457	HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy.. **2022**, 132,	6
456	Immune checkpoint inhibition in patients with inactive pre-existing neuepuromuscular autoimmune diseases. **2022**, 120275	0
455	Intelligent Biomimetic Nanoplatform for Systemic Treatment of Metastatic Triple-Negative Breast Cancer Enhanced EGFR-Targeted Therapy and Immunotherapy.. **2022**,	1
454	Lymph node colonization induces tumor-immune tolerance to promote distant metastasis.. **2022**,	3
453	Is there a real risk of bacterial infection in patients receiving targeted and biological therapies?. **2022**, 40, 266-272	
452	Skin manifestations associated with checkpoint inhibitors.	0

451	Attenuated Toxoplasma gondii enhances the antitumor efficacy of anti-PD1 antibody by altering the tumor microenvironment in a pancreatic cancer mouse model.. **2022**, 1	1
450	Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma.. **2022**, 11, 2066767	3
449	Small Molecule Agents Targeting PD-1 Checkpoint Pathway for Cancer Immunotherapy: Mechanisms of Action and Other Considerations for Their Advanced Development.. **2022**, 13, 752065	2
448	Autologous dendritic cells pulsed with allogeneic tumour cell lysate induce tumour-reactive T-cell responses in patients with pancreatic cancer: A phase I study.. **2022**, 169, 20-31	1
447	Anti-IL-8 antibody activates myeloid cells and potentiates the anti-tumor activity of anti-PD-1 antibody in the humanized pancreatic cancer murine model.. **2022**, 539, 215722	1
446	CD39 - A bright target for cancer immunotherapy.. **2022**, 151, 113066	0
445	Exploring the association of intratumoral immune cell infiltrates with histopathologic grade in canine mast cell tumors.. **2022**, 147, 83-91	0
444	Immunotherapy for Colorectal Cancer.. **2022**,	
443	Immune responses of patients without cancer recurrence after a cancer vaccine over a long term. **2022**, 16,	
442	Cyclophilin A represses reactive oxygen species generation and death of hypoxic non-small-cell lung cancer cells by degrading thioredoxin-interacting protein.. **2022**,	
441	Dissecting Tissue Compartment-Specific Protein Signatures in Primary and Metastatic Oropharyngeal Squamous Cell Carcinomas. **2022**, 13,	0
440	??????T??????????????????. **2022**,	
439	Post-radiation neutrophil-to-lymphocyte ratio is a prognostic marker in patients with localized pancreatic adenocarcinoma treated with anti-PD-1 antibody and stereotactic body radiation therapy.	1
438	Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1/PD-L1 treatment efficacy. **2022**,	2
437	Monitoring and Management of the Patient with Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis: Current Perspectives. Volume 15, 3105-3118	2
436	Traitement de 1re ligne des CBNPC m□astatiques sans addiction oncog□ique. **2022**, 14, 1S52-1S67	
435	Exploration of Different Hypoxia Patterns and Construction of a Hypoxia-Related Gene Prognostic Index in Colorectal Cancer. **2022**, 13,	
434	Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy. 13,	1

433	Long Noncoding RNAs in Lung Cancer: From Disease Markers to Treatment Roles. Volume 14, 1771-1782	0
432	The Next Frontier in Pancreatic Cancer: Targeting the Tumor Immune Milieu and Molecular Pathways. **2022**, 14, 2619	0
431	Understanding Tricky Cellular and Molecular Interactions in Pancreatic Tumor Microenvironment: New Food for Thought. **2022**, 13,	0
430	Estimating the replicability of highly cited clinical research (2004-2018).	
429	Particle Therapy and the Immune System. **2022**, 151-163	
428	The clinicopathological features of programmed death ligand-1 expression in colorectal carcinoma. 039361552211041	
427	Pan-cancer analysis identifies CD300 molecules as potential immune regulators and promising therapeutic targets in acute myeloid leukemia.	
426	The Pyroptosis-Related Gene Prognostic Index Associated with Tumor Immune Infiltration for Pancreatic Cancer. **2022**, 23, 6178	0
425	Epi-immunotherapy for cancers: rationales of epi-drugs in combination with immunotherapy and advances in clinical trials.	2
424	Exploration of serum biomarkers in dogs with malignant melanoma receiving anti-PD-L1 therapy and potential of COX-2 inhibition for combination therapy. **2022**, 12,	0
423	Bafetinib Suppresses the Transcription of PD-L1 Through c-Myc in Lung Cancer. 13,	
422	Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial.	5
421	CAR-T Cells and Recent Advances in Clinical Cellular Immunotherapy. **2022**, 543-553	
420	Targeted therapy for metastatic colorectal cancer: what do we currently have in clinical practice?.	
419	Understanding the tumor microenvironment in head and neck squamous cell carcinoma. **2022**, 11,	0
418	Immunotherapy for patients with pancreatic adenocarcinoma. **2022**, 16, 127-129	
417	Taming metabolic competition via glycolysis inhibition for safe and potent tumor immunotherapy. **2022**, 115153	1
416	Synchronous Jejunal Sarcomatoid Carcinoma and Incidentally Associated Localized Peritoneal Malignant Mesothelioma. **2022**,	

415	Radiopharmaceuticals as Novel Immune System Tracers. **2022**, 100936	
414	Recent Advances and Clinical Pharmacology Aspects of Chimeric Antigen Receptor (CAR) T-Cellular Therapy Development.	1
413	Depleting Ly6G Positive Myeloid Cells Reduces Pancreatic Cancer-Induced Skeletal Muscle Atrophy. **2022**, 11, 1893	0
412	Synergistic Therapeutic Effects of Low Dose Decitabine and NY-ESO-1 Specific TCR-T Cells for the Colorectal Cancer With Microsatellite Stability. 12,	0
411	A single-cell atlas of tumor-infiltrating immune cells in pancreatic ductal adenocarcinoma. **2022**, 100258	
410	PD-1 Cellular Nanovesicles Carrying Gemcitabine to Inhibit the Proliferation of Triple Negative Breast Cancer Cell. **2022**, 14, 1263	0
409	Dosing Regimens of Immune Checkpoint Inhibitors: Attempts at Lower Dose, Less Frequency, Shorter Course. 12,	0
408	Self-Sustained Regulation or Self-Perpetuating Dysregulation: ROS-dependent HIF-YAP-Notch Signaling as a Double-Edged Sword on Stem Cell Physiology and Tumorigenesis. 10,	0
407	Comprehensive analyses indicated the association between m6A related long non-coding RNAs and various pathways in glioma.	
406	BCG hydrogel promotes CTSS-mediated antigen processing and presentation, thereby suppressing metastasis and prolonging survival in melanoma. **2022**, 10, e004133	0
405	Cemiplimab and Cutaneous Squamous Cell Carcinoma: From Bench to Bedside. **2022**,	0
404	Tumor-infiltrating OX40+ lymphocytes is an independent positive prognostic factor for patients with pancreatic ductal adenocarcinoma.	
403	Molecular and Clinical Characterization of CD80 Expression via Large-Scale Analysis in Breast Cancer. 13,	
402	Safety and tumour-specific immunological responses of combined dendritic cell vaccination and anti-CD40 agonistic antibody treatment for patients with metastatic pancreatic cancer: protocol for a phase I, open-label, single-arm, dose-escalation study (REACtiVe-2 trial). **2022**, 12, e060431	0
401	Blockade of interleukin 10 potentiates antitumour immune function in human colorectal cancer liver metastases. gutjnl-2021-325808	1
400	EZH2 inhibition remodels the inflammatory senescence-associated secretory phenotype to potentiate pancreatic cancer immune surveillance.	
399	Ursodeoxycholic acid reduces antitumor immunosuppression by inducing CHIP-mediated TGF-□ degradation. **2022**, 13,	2
398	Recent trends in cancer immunotherapy: Pathways and inhibitors. **2022**, 39-50	

397	A combination of stromal PD-L1 and tumoral nuclear Ecatenin expression as an indicator of colorectal carcinoma progression and resistance to chemoradiotherapy in locally advanced rectal carcinoma.	0
396	Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer. 13,	1
395	PD-L1 in gestational trophoblastic disease: an antibody evaluation.	
394	Arginase 1 is a key driver of immune suppression in pancreatic cancer.	0
393	Precision Approaches to Pancreatic Cancer Therapy: What Now and What Next?.	
392	Programmed death-ligand 1 expression in the immune compartment of colon carcinoma.	0
391	Dynamic Analysis of a Model on Tumor-Immune System with Regulation of PD-1/PD-L1 and Stimulation Delay of Tumor Antigen. **2022**, 21,	0
390	Significance of the effects of chemotherapy on programmed death-ligand 1 expression in triple-negative breast cancer.	
389	Clinical outcomes of PD-1/PD-L1 inhibitors in patients with advanced hepatocellular carcinoma: a systematic review and meta-analysis.	0
388	A Novel Computational Framework for Predicting the Survival of Cancer Patients With PD-1/PD-L1 Checkpoint Blockade Therapy. 12,	0
387	Mapping the Tumor Microenvironment in TNBC and Deep Exploration for M1 Macrophages-Associated Prognostic Genes. 13,	
386	Tumor immunotherapy: Mechanisms and clinical applications. **2022**, 1,	
385	Sequence-specific 1H, 13C and 15N backbone NMR assignments for the N-terminal IgV-like domain (D1) and full extracellular region (D1D2) of PD-L1.	1
384	ITCH facilitates proteasomal degradation of TXNIP in hypoxia- induced lung cancer cells.	1
383	Single cell sequencing reveals trajectory of tumor-infiltrating lymphocyte states in pancreatic cancer.	0
382	Personalized tumor vaccine for pancreatic cancer.	0
381	Immunologic Strategies in Pancreatic Cancer: Making Cold Tumors Hot.	3
380	Contribution of TLR4 to colorectal tumor microenvironment, etiology and prognosis.	

379	Construction of a Necroptosis-Associated Long Non-Coding RNA Signature to Predict Prognosis and Immune Response in Hepatocellular Carcinoma. 9,	0
378	Targeting CD47 as a Novel Immunotherapy for Breast Cancer. 12,	1
377	The predictive potential of autoimmune-inflammatory syndrome induced by adjuvants (ASIA) criteria to assess the risk of adverse events and efficacy of immune checkpoint inhibitor therapy.	
376	STAT3 in tumor fibroblasts promotes an immunosuppressive microenvironment in pancreatic cancer. **2022**, 5, e202201460	2
375	Pulmonary adverse events following immune checkpoint inhibitors. Publish Ahead of Print,	0
374	Retrospective Study of Clinical Outcomes and Toxicity Profile in Patients Treated with Immune Checkpoint Inhibitors.	
373	Comprehensive Analyses of Immune Subtypes of Stomach Adenocarcinoma for mRNA Vaccination. 13,	0
372	Antibody-Based Approaches to Target Pancreatic Tumours. **2022**, 11, 47	2
371	DOCK4 as a Potential Biomarker Associated with Immune Infiltration in Stomach Adenocarcinoma: A Database Analysis. Volume 15, 6127-6143	
370	A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma. Volume 18, 683-698	0
369	Facts and hopes for immunotherapy in renal cell carcinoma.	2
368	Combination of Low-Dose Gemcitabine and PD-1 Inhibitors for Treatment in Patients With Advanced Malignancies. 13,	0
367	Neoantigens in precision cancer immunotherapy: from identification to clinical applications. Publish Ahead of Print,	0
366	Interaction of immune checkpoint PD-1 and chemokine receptor 4 (CXCR4) promotes a malignant phenotype in pancreatic cancer cells. **2022**, 17, e0270832	0
365	CCND1 Amplification Profiling Identifies a Subtype of Melanoma Associated With Poor Survival and an Immunosuppressive Tumor Microenvironment. 13,	
364	Immune Checkpoint Inhibitors and Mismatch Repair Status in Advanced Endometrial Cancer: Elective Affinities. **2022**, 11, 3912	1
363	Comparison of actionable events detected in cancer genomes by whole-genome sequencing, in silico whole-exome and mutation panels. **2022**, 7, 100540	1
362	Irradiation combined with PD-L1 and autophagy inhibition enhances the antitumor effect of lung cancer via cGAS-STING-mediated T´cell activation. **2022**, 25, 104690	1

361	Normalization of tumor vasculature: A potential strategy to increase the efficiency of immune checkpoint blockades in cancers. **2022**, 110, 108968	1
360	Analysis of the OX40/OX40L immunoregulatory axis combined with alternative immune checkpoint molecules in pancreatic ductal adenocarcinoma. 13,	
359	The Role of Tumor Microenvironment and Immune Response in Colorectal Cancer Development and Prognosis. 28,	0
358	Machine Learning for Computed Tomography Radiomics: Prediction of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma. Publish Ahead of Print,	
357	Therapeutic targeting of PD-1/PD-L1 blockade by novel small-molecule inhibitors recruits cytotoxic T cells into solid tumor microenvironment. **2022**, 10, e004695	0
356	Knowledge mapping and research hotspots of immunotherapy in renal cell carcinoma: A text-mining study from 2002 to 2021. 13,	0
355	A 9-LncRNA Signature for Predicting Prognosis and Immune Response in Diffuse Large B-Cell Lymphoma. 13,	0
354	Local and systemic immune profiles of human pancreatic ductal adenocarcinoma revealed by single-cell mass cytometry. **2022**, 10, e004638	0
353	Tumor Budding Is an Independent Prognostic Factor in Pancreatic Adenocarcinoma and It Positively Correlates with PD-L1 Expression on Tumor Cells. **2022**, 10, 1761	
352	Targeting PD-1/PD-L1 axis as new horizon for ovarian cancer therapy. **2022**, 120827	1
351	Clinical characteristics and outcomes of immune checkpoint inhibitor-induced diabetes mellitus. **2022**, 24, 101473	1
350	The Generation of Dual-Targeting Fusion Protein PD-L1/CD47 for the Inhibition of Triple-Negative Breast Cancer. **2022**, 10, 1843	
349	CD8 T-cell heterogeneity during T-cell exhaustion and PD-1-targeted immunotherapy.	0
348	The molecular landscape of pancreatic ductal adenocarcinoma. **2022**,	0
347	Prognostic significance of programmed death-1 and programmed death ligand-1 proteins in breast cancer. **2022**, 1-20	
346	Genomic signature of MTOR could be an immunogenicity marker in human colorectal cancer. **2022**, 22,	
345	Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors. OF1-OF11	0
344	An integrated model of acinar to ductal metaplasia-related N7-methyladenosine regulators predicts prognosis and immunotherapy in pancreatic carcinoma based on digital spatial profiling. 13,	0

343	Powering single-cell genomics to unravel circulating tumour cell subpopulations in non-small cell lung cancer patients.	
342	Immunotherapy landscape analyses of necroptosis characteristics for breast cancer patients. **2022**, 20,	0
341	Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements. 13,	2
340	Engineered metal and their complexes for nanomedicine-elicited cancer immunotherapy. **2022**, 15, 100276	0
339	Metastatic Undifferentiated Osteoclast-Like Giant Cell Pancreatic Carcinoma. **2022**,	
338	Internal checkpoint regulates T´cell neoantigen reactivity and susceptibility to PD1 blockade. **2022**,	1
337	Spatially restricted drivers and transitional cell populations cooperate with the microenvironment in untreated and chemo-resistant pancreatic cancer.	2
336	The Use of Immunotherapy for Treatment of Gynecologic Malignancies.	
335	A Paradoxical Role for Regulatory T Cells in the Tumor Microenvironment of Pancreatic Cancer. **2022**, 14, 3862	0
334	Clinical and Biological Activity of Chemo-immunotherapy in Advanced Endometrial Adenocarcinoma: A Phase II Trial of the Big Ten Cancer Research Consortium.	
333	Long-Term Survival of FOLFIRINOX +toripalimab in a Patient with Metastatic Pancreatic Ductal Adenocarcinoma: A Case Report. Volume 15, 883-890	0
332	Fasting renders immunotherapy effective against low-immunogenic breast cancer while reducing side effects. **2022**, 40, 111256	1
331	Ocular Inflammation Induced by Immune Checkpoint Inhibitors. **2022**, 11, 4993	1
330	The combined prognostic model of copper-dependent to predict the prognosis of pancreatic cancer. 13,	0
329	Comprehensive Analysis of the Prognostic Value and Immune Infiltration of Butyrophilin Subfamily 2/3 (BTN2/3) Members in Pan-Glioma. 12,	0
328	Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors. **2022**, 10, e005147	0
327	A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer. 13,	1
326	Immunotherapy in the Treatment of Platinum-Resistant Ovarian Cancer: Current Perspectives. Volume 15, 853-866	1

325	The Role of Pathology-Based Methods in Qualitative and Quantitative Approaches to Cancer Immunotherapy. **2022**, 14, 3833	
324	Systemic Therapy of Advanced Well-differentiated Small Bowel Neuroendocrine Tumors Progressive on Somatostatin Analogues. **2022**, 23, 1233-1246	
323	Lipid Nanoparticle Delivery of Fas Plasmid Restores Fas Expression to Suppress Melanoma Growth In Vivo. **2022**, 16, 12695-12710	1
322	Immunotherapeutic targets in non-small cell lung cancer.	1
321	Inhibition of PCSK9 enhances the antitumor effect of PD-1 inhibitor in colorectal cancer by promoting the infiltration of CD8+ T cells and the exclusion of Treg cells. 13,	3
320	The expression and significance of efferocytosis and immune checkpoint related molecules in pancancer samples and the correlation of their expression with anticancer drug sensitivity. 13,	
319	Pituitary hormone □MSH promotes tumor-induced myelopoiesis and immunosuppression.	1
318	TGF-□regulates the stem-like state of PD-1+ TCF-1+ virus-specific CD8 T cells during chronic infection. **2022**, 219,	1
317	Biodegradable nanoparticles induce cGAS/STING-dependent reprogramming of myeloid cells to promote tumor immunotherapy. 13,	1
316	Intratumoral xenogeneic tissue-specific cell immunotherapy inhibits tumor growth by increasing antitumor immunity in murine triple negative breast and pancreatic tumor models. **2022**, 545, 115478	0
315	STAT3 and PD-L1 are negatively correlated with ATM and have impact on the prognosis of triple-negative breast cancer patients with low ATM expression.	0
314	Engineered T cell extracellular vesicles displaying PD-1 boost anti-tumor immunity. **2022**, 46, 101606	2
313	GZMA as a Potential Therapeutic Target Involved in Immune Infiltration in Breast Cancer.	0
312	Immunotherapy in Early Stage Non-Small Cell Lung Cancer. **2022**, 11, 31-44	0
311	Epigenetic Mediated Regulation of Cancer-Testis/Germline Antigen and Its Implication in Cancer Immunotherapy: A Treasure Map for Future Anticipatory Medicine. **2022**, 149-166	0
310	Phase 2 Study of Ipilimumab, Nivolumab, and Tocilizumab Combined with Stereotactic Body Radiotherapy in Patients with Refractory Pancreatic Cancer (TRIPLE-R).	0
309	Phase 2 Study of Ipilimumab, Nivolumab, and Tocilizumab Combined with Stereotactic Body Radiotherapy in Patients with Refractory Pancreatic Cancer (TRIPLE-R).	0
308	Targeting tumor microenvironment for breast cancer treatment. **2022**, 249-277	1

307	Homodimerized cytoplasmic domain of PD-L1 regulates its complex glycosylation in living cells. **2022**, 5,	1
306	Lipid Nanoparticles for mRNA Delivery to Enhance Cancer Immunotherapy. **2022**, 27, 5607	1
305	Cardiovascular complications of immune checkpoint inhibitors for cancer.	2
304	Disrupting the Interplay between Programmed Cell Death Protein 1 and Programmed Death Ligand 1 with Spherical Nucleic Acids in Treating Cancer. **2022**, 8, 1299-1305	0
303	Identification of the molecular subtype and prognostic characteristics of pancreatic cancer based on CD8 + T cell-related genes.	0
302	Cell death affecting the progression of gastric cancer. **2022**, 8,	0
301	UV-Induced Somatic Mutations Driving Clonal Evolution in Healthy Skin, Nevus, and Cutaneous Melanoma. **2022**, 12, 1339	0
300	Reversing PD-1 Resistance in B16F10 Cells and Recovering Tumour Immunity Using a COX2 Inhibitor. **2022**, 14, 4134	2
299	Safety and Efficacy of Allogeneic Natural Killer Cells in Combination with Pembrolizumab in Patients with Chemotherapy-Refractory Biliary Tract Cancer: A Multicenter Open-Label Phase 1/2a Trial. **2022**, 14, 4229	0
298	Clinical Strategies Targeting the Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma. **2022**, 14, 4209	1
297	Dynamic host immunity and PD-L1/PD-1 blockade efficacy: developments after IFN- from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer	1
296	Combating pancreatic cancer with ovarian cancer cells.	0
295	Recent advances in immune checkpoint inhibitors for non-small lung cancer treatment. 12,	0
294	Biofabrication of 3D breast cancer models for dissecting the cytotoxic response of human T cells expressing engineered MAIT cell receptors. **2022**, 14, 044105	0
293	Predicting colorectal cancer tumor mutational burden from histopathological images and clinical information using multi-modal deep learning.	0
292	Tumor-Homing and Immune-Reprogramming Cellular Nanovesicles for Photoacoustic Imaging-Guided Phototriggered Precise Chemoimmunotherapy.	0
291	m6A methylation regulators as predictors for treatment of advanced urothelial carcinoma with anti-PDL1 agent. 13,	0
290	An engineered concealed IL-15-R elicits tumor-specific CD8+T cell responses through PD-1-cis delivery. **2022**, 219,	0

289	TISSUE ENGINEERED CANCER METASTASES AS CANCER VACCINE TO IMPROVE CANCER IMMUNOTHERAPY. **2022**,	0
288	Development of a radiolabeled site-specific single-domain antibody positron emission tomography probe for monitoring PD-L1 expression in cancer. **2022**,	0
287	Prognostic and Predictive Role of Tumor-Infiltrating Lymphocytes (TILs) in Ovarian Cancer. **2022**, 14, 4344	0
286	The Role of Immunotherapy in Pancreatic Cancer. **2022**, 29, 6864-6892	1
285	The therapeutic effect of an autologous and allogenic mixed glioma cell lysate vaccine in a rat model.	0
284	In vitro models as tools for screening treatment options of head and neck cancer. 9,	0
283	Immune cells and their inflammatory mediators modify cells and cause checkpoint inhibitor induced diabetes. **2022**, 7,	0
282	Associating resistance to immune checkpoint inhibitors with immunological escape in colorectal cancer. 12,	0
281	Topically Applied Resiquimod versus Imiquimod as a Potential Adjuvant in Melanoma Treatment. **2022**, 14, 2076	2
280	Balance between immunoregulatory B cells and plasma cells drives pancreatic tumor immunity. **2022**, 3, 100744	1
279	Combination immunotherapy for pancreatic cancer: challenges and future considerations. 1-14	1
278	Tipping the scales: Immunotherapeutic strategies that disrupt immunosuppression and promote immune activation. 13,	0
277	Microfluidic devices: The application in TME modeling and the potential in immunotherapy optimization. 13,	0
276	Pan-cancer analysis reveals interleukin-17 family members as biomarkers in the prediction for immune checkpoint inhibitor curative effect. 13,	0
275	The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers. 13,	5
274	Prognostic N6-methyladenosine (m6A)-related lncRNA patterns to aid therapy in pancreatic ductal adenocarcinoma. 13,	0
273	Incidence risk of peripheral edema in cancer patients treated with PD-1/PD-L1 inhibitors: A PRISMA guideline systematic review and meta-analysis. **2022**, 101, e30151	0
272	The predictive value of total-body PET/CT in non-small cell lung cancer for the PD-L1 high expression. 12,	0

271	Neoantigens and their clinical applications in human gastrointestinal cancers. **2022**, 20,	0
270	Nanoparticle-Based Therapeutic Strategies for Enhanced Pancreatic Ductal Adenocarcinoma Immunotherapy. **2022**, 14, 2033	0
269	Molecular Biomarkers of Response to Cancer Immunotherapy. **2022**, 42, 469-484	0
268	The microbiome-derived metabolite TMAO drives immune activation and boosts responses to immune checkpoint blockade in pancreatic cancer. **2022**, 7,	6
267	Establishment, immunological analysis, and drug prediction of a prognostic signature of ovarian cancer related to histone acetylation. 13,	0
266	Successful treatment of metastatic vulvar malignant melanoma with toripalimab: A rare case report and review of the literature. **2022**, 101, e30239	0
265	Biomarkers and immunotherapy: where are we?. **2022**, 34, 579-586	1
264	Analysis of combination therapy of immune checkpoint inhibitors in osteosarcoma. 10,	1
263	Enhancer Reprogramming in Melanoma Immune Checkpoint Therapy Resistance.	0
262	Molecular dynamics identifies semi-rigid domains in the PD-1 checkpoint receptor bound to its natural ligand PD-L1. 10,	0
261	Lipid metabolic features of T cells in the Tumor Microenvironment. **2022**, 21,	0
260	Immunotherapy improves disease prognosis by affecting the tumor microenvironment: A bibliometric study. 13,	0
259	Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical Targets. OF1-OF11	0
258	Complete remission of ovarian clear cell carcinoma achieved after pseudoprogression during PD-1 inhibitor therapy. **2022**, 14, 1205-1209	0
257	A newly discovered PD-L1 B-cell epitope peptide vaccine (PDL1-Vaxx) exhibits potent immune responses and effective anti-tumor immunity in multiple syngeneic mice models and (synergizes) in combination with a dual HER-2 B-cell vaccine (B-Vaxx). **2022**, 11,	2
256	Nanomaterial-Based Drug Delivery Systems: A New Weapon for Cancer Immunotherapy. Volume 17, 4677-4696	0
255	AMU: Using mRNA Embedding in Self-Attention Network to Predict Melanoma Immune Checkpoint Inhibitor Response.	0
254	The Prospects of Immunotherapy in Pancreatic Cancer. **2022**, 269-281	0

253	Management of Locally Advanced/Metastatic Disease: Medical Oncology. **2022**, 97-106	0
252	Primary tracheal obstruction caused by adenoid cystic carcinoma during pregnancy: A case report. **2022**, 14, 203636132211350	0
251	Real-world treatment patterns and outcomes among patients with advanced non-small-cell lung cancer with spindle cell and/or giant cell carcinoma. **2022**, 14, 175883592211338	0
250	Mechanisms and Evidence on Pancreatic Cancer Prevention. **2022**, 299-316	0
249	Stromal Interaction Molecule 1 (STIM1) is a potential prognostic biomarker and correlated with immune infiltrates in solid tumors. **2022**,	0
248	Advances in the Application of Nanomaterials to the Treatment of Melanoma. **2022**, 14, 2090	0
247	Intestinal Microbiota: The Driving Force behind Advances in Cancer Immunotherapy. **2022**, 14, 4796	1
246	Loss of Major Histocompatibility Complex Class I, CD8+ Tumor-infiltrating Lymphocytes, and PD-L1 Expression in Ovarian Clear Cell Carcinoma. Publish Ahead of Print,	0
245	Colorectal Cancer and Purinergic Signalling: An Overview. **2022**, 14, 4887	0
244	Cuprotosis Programmed-Cell-Death-Related lncRNA Signature Predicts Prognosis and Immune Landscape in PAAD Patients. **2022**, 11, 3436	0
243	Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and CXCR4. **2022**, 22,	1
242	Nivolumab monotherapy in metastatic colorectal cancer: current approaches to response evaluation. **2022**, 21, 135-141	0
241	Tumor infiltrating CD8/CD103/TIM-3-expressing lymphocytes in epithelial ovarian cancer co-express CXCL13 and associate with improved survival. 13,	0
240	Case Report: Anlotinib combined with PD-1 inhibitor and sequential GA regimen or FOLFIRINOX Chemotherapy in treatment of KRAS G12V mutated pancreatic ductal adenocarcinoma with liver metastasis: A case and literature review. 13,	1
239	The primordial differentiation of tumor-specific memory CD8+ T´cells as bona fide responders to PD-1/PD-L1 blockade in draining lymph nodes. **2022**, 185, 4049-4066.e25	3
238	Targeting depletion of myeloid-derived suppressor cells potentiates PD-L1 blockade efficacy in gastric and colon cancers. **2022**, 11,	2
237	Identification and Validation of a lipid metabolism-Immune-Based Prognostic Multiomics Signature for Oral Squamous Cell Carcinoma.	0
236	Genetic and Immunological Characterization of Advanced NSCLC with SWItch/Sucrose NonFermentable Families Genetic Alterations and Its Impact on Response to Immune Checkpoint Inhibitors.	0

235	Epigenetic Contributions to Human Cancer. 1-13	0
234	Targeted Therapy and Immunotherapy in Nonmelanoma Skin Cancer. **2022**,	0
233	Human allogenic γδ T cells kill patient-derived glioblastoma cells expressing high levels of DNAM-1 ligands. **2022**, 11,	0
232	Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy. **2022**, 23, 13241	0
231	Neoplasms of the Head and Neck. 1-28	0
230	WNT signaling in the tumor microenvironment promotes immunosuppression in murine pancreatic cancer. **2023**, 220,	2
229	PD-1 and CTLA-4 inhibitors in combination vs. alone for the treatment of advanced melanoma: A systematic review and meta-analysis. **2022**, 101, e30561	0
228	Editorial: Automation and artificial intelligence in radiation oncology. 12,	0
227	Altered MUC1 epitope-specific CTLs: A potential target for immunotherapy of pancreatic cancer.	0
226	Midostaurin Modulates Tumor Microenvironment and Enhances Efficacy of Anti-PD-1 against Colon Cancer. **2022**, 14, 4847	0
225	Rerouting the drug response: Overcoming metabolic adaptation in KRAS-mutant cancers. **2022**, 15,	0
224	Neoplasms of the Exocrine Pancreas. 1-20	0
223	Neoplasms in People Living with Human Immunodeficiency Virus. 1-18	0
222	Molecular subtypes based on cuproptosis-related genes and tumor microenvironment infiltration characterization in ovarian cancer. **2022**, 22,	0
221	Engineered anti-PDL1 with IFNα targets both immunoinhibitory and activating signals in the liver to break HBV immune tolerance. gutjnl-2022-327059	1
220	The prognostic significance of PD-L1 expression in patients with glioblastoma: A meta-analysis. 12,	0
219	Orchestration of mesenchymal plasticity and immune evasiveness via rewiring of the metabolic program in pancreatic ductal adenocarcinoma. 12,	0
218	OncoTherad® is an immunomodulator of biological response that downregulate RANK/RANKL signaling pathway and PD-1/PD-L1 immune checkpoint in non-muscle invasive bladder cancer.	0

217	Novel prognostic implications of complement activation in the tumour microenvironment for de novo metastatic BRAF V600E mutant colorectal cancer.	0
216	Identification of CKS1B as a prognostic indicator and a predictive marker for immunotherapy in pancreatic cancer. 13,	0
215	Interdependence of sequential cytotoxic T lymphocyte and natural killer cell cytotoxicity against melanoma cells.	0
214	A photodynamically sensitized dendritic cell vaccine that promotes the anti-tumor effects of anti-PD-L1 monoclonal antibody in a murine model of head and neck squamous cell carcinoma. **2022**, 20,	0
213	Dostarlimab an Inhibitor of PD-1/PD-L1: A New Paradigm for the Treatment of Cancer. **2022**, 58, 1572	0
212	Targeting myeloid suppressive cells revives cytotoxic anti-tumor responses in pancreatic cancer. **2022**, 25, 105317	0
211	The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors. **2022**, 310, 121138	0
210	Cancer stem cells in immunoregulation and bypassing anti-checkpoint therapy. **2022**, 156, 113906	0
209	Unraveling the peripheral and local role of inflammatory cytokines in glioblastoma survival. **2023**, 161, 156059	0
208	Epithelial ovarian cancer. **2023**, 250-281.e8	0
207	Comprehensive landscape and future perspectives of long noncoding RNAs (lncRNAs) in colorectal cancer (CRC): Based on a bibliometric analysis. **2023**, 8, 33-52	0
206	Harnessing the Tumor Microenvironment for Cancer Immunotherapy. **2022**, 1-25	0
205	Lanthanide-based MOFs: synthesis approaches and applications in cancer diagnosis and therapy.	2
204	Amplified cancer immunotherapy of PD-L1 blockade by sequential tumor microenvironment reshaping and DC maturation. **2023**, 453, 139795	0
203	Newest Approaches in Immunotherapy for Non-Hodgkin Lymphoma. 40-48	0
202	Perspective Chapter: Liposome Mediated Delivery of Immunotherapeutics for Cancer.	0
201	Perioperative treatment and biomarker analysis of LP002 , an anti-PD-L1 antibody, plus chemotherapy in resectable gastric and gastroesophageal junction cancer.	0
200	Consortium bibliometric analysis of hotspots and frontiers of immunotherapy in pancreatic cancer.	0

199	Low expression of INMT is associated with poor prognosis but favorable immunotherapy response in lung adenocarcinoma. 13,	0
198	Retrospective study of the incidence of sarcoidosis-like reaction in patients treated with immunotherapy. **2022**,	0
197	TRPV1 in dorsal root ganglion contributed to bone cancer pain. 3,	0
196	CXCR1/2 dual-inhibitor ladarixin reduces tumour burden and promotes immunotherapy response in pancreatic cancer.	0
195	Global research trends on immunotherapy in cancer: a visualization analysis.	0
194	Immune Checkpoint Molecules and Glucose Metabolism in HIV-Induced T Cell Exhaustion. **2022**, 10, 2809	0
193	Mechanical destruction using a minimally invasive ultrasound needle induces anti-tumor immune responses and synergizes with the anti-PD-L1 blockade. **2022**, 216009	0
192	Rational pemetrexed combined with CIK therapy plus anti-PD-1 mAbs administration sequence will effectively promote the efficacy of CIK therapy in non-small cell lung cancer.	1
191	Aberrant hyperexpression of the RNA binding protein FMRP in tumors mediates immune evasion. **2022**, 378,	2
190	Advances of Electroporation-Related Therapies and the Synergy with Immunotherapy in Cancer Treatment. **2022**, 10, 1942	0
189	Current studies and future promises of PD-1 signal inhibitors in cervical cancer therapy. **2023**, 157, 114057	0
188	Novel biomimetic mesoporous silica nanoparticle system possessing targetability and immune synergy facilitates effective solid tumor immuno-chemotherapy. **2023**, 144, 213229	0
187	Downsizing Chemotherapy for Liver Metastases from Colorectal Cancer. **2022**, 217-229	0
186	Immunotherapy and Endocrine Oncology. **2022**, 1-36	0
185	A Review of Neurotoxicities Associated with Immune Checkpoint Inhibitors. **2022**, 1-16	0
184	Chemotherapy-free treatment of recurrent advanced ovarian cancer: myth or reality?. ijgc-2022-003719	0
183	Gallium-68-labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics.	0
182	Canvassing Prospects of Glyco-Nanovaccines for Developing Cross-Presentation Mediated Anti-Tumor Immunotherapy. **2022**, 10, 2049	0

181	Redox Dyshomeostasis with Dual Stimuli-Activatable Dihydroartemisinin Nanoparticles to Potentiate Ferroptotic Therapy of Pancreatic Cancer. 2200888	1
180	A Review of the Role of Stereotactic Radiosurgery and Immunotherapy in the Management of Primary Central Nervous System Tumors. **2022**, 10, 2977	0
179	The Role of 8-oxoG Repair Systems in Tumorigenesis and Cancer Therapy. **2022**, 11, 3798	0
178	Efficacy and safety of immune checkpoint inhibitors in advanced pancreatic cancer: A real world study in Chinese cohort. **2022**, 18,	0
177	Cell atlas of the immune microenvironment in gastrointestinal cancers: Dendritic cells and beyond. 13,	0
176	Advances in the Lung Cancer Immunotherapy Approaches. **2022**, 10, 1963	0
175	Bone Metastasis of Breast Cancer: Molecular Mechanisms and Therapeutic Strategies. **2022**, 14, 5727	0
174	B7 Family Members in Pancreatic Ductal Adenocarcinoma: Attractive Targets for Cancer Immunotherapy. **2022**, 23, 15005	1
173	Identification and experimental validation of a tumor-infiltrating lymphocytes□elated long noncoding RNA signature for prognosis of clear cell renal cell carcinoma. 13,	0
172	Dynamic Changes in the Extracellular Matrix in Primary, Metastatic, and Recurrent Ovarian Cancers. **2022**, 11, 3769	0
171	Evaluation of the ability of fatty acid metabolism signature to predict response to neoadjuvant chemoradiotherapy and prognosis of patients with locally advanced rectal cancer. 13,	0
170	Activity of Immunotherapy Regimens on Primary Renal Tumours: A Systematic Review. **2022**, 1-16	1
169	Cutting-Edge CAR Engineering: Beyond T Cells. **2022**, 10, 3035	0
168	Advanced diagnostic and therapeutic strategies in nanotechnology for lung cancer. 12,	1
167	CD244 regulates both innate and adaptive immune axes in melanoma by inhibiting autophagy-mediated M1 macrophage maturation.	0
166	Identification of CEACAM5 as a stemness-related inhibitory immune checkpoint in pancreatic cancer. **2022**, 22,	0
165	Current Status of Novel Agents for the Treatment of B Cell Malignancies: What□ Coming Next?. **2022**, 14, 6026	0
164	Case report: Variable response to immunotherapy in ovarian cancer: Our experience within the current state of the art. 13,	0

163	Role of senescent tumor cells in building a cytokine shield in the tumor microenvironment: mathematical modeling. **2023**, 86,	0
162	Prognosis and pain dissection of novel signatures in kidney renal clear cell carcinoma based on fatty acid metabolism-related genes. 12,	0
161	Systematic Analysis of Molecular Subtypes Based on the Expression Profile of Immune-Related Genes in Pancreatic Cancer. **2022**, 2022, 1-28	1
160	Fibroblast Programmed Cell Death Ligand 1 Promotes Osteoclastogenesis in Odontogenic Keratocysts. **2022**,	0
159	Predictive Value of 18F-Fluorodeoxyglucose Positron-Emission Tomography Metabolic and Volumetric Parameters for Systemic Metastasis in Tonsillar Cancer. **2022**, 14, 6242	0
158	Role of T cells in cancer immunotherapy: Opportunities and challenges. **2022**,	1
157	Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R). **2022**,	0
156	Suppression of PD-L1 release from small extracellular vesicles promotes systemic anti-tumor immunity by targeting ORAI1 calcium channels. **2022**, 11, 12279	0
155	Where Do We Stand with Immunotherapy for Advanced Pancreatic Ductal Adenocarcinoma: A Synopsis of Clinical Outcomes. **2022**, 10, 3196	0
154	Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy.	0
153	Safety and short-term outcomes of laparoscopic surgery for advanced gastric cancer after neoadjuvant immunotherapy: A retrospective cohort study. 13,	0
152	Extracellular Galectin 4 Drives Immune Evasion and Promotes T-cell Apoptosis in Pancreatic Cancer. OF1-OF21	0
151	A New Risk Factor for Cardiovascular Events in Patients Receiving Immune Checkpoint Inhibitor Therapy?. **2022**, 4, 670-672	1
150	Efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors in treating non-Hodgkin lymphoma: A systematic review and meta-analysis of clinical trials. **2022**, 101, e32333	0
149	Efficacy of a small molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer.	4
148	Quantification of the growth suppression of HER2+ breast cancer colonies under the effect of trastuzumab and PD-1/PD-L1 inhibitor. 12,	1
147	Neutrophil interactions with T cells, platelets, endothelial cells, and of course tumor cells.	0
146	ALKBH5 promotes PD-L1-mediated immune escape through m6A modification of ZDHHC3 in glioma. **2022**, 8,	0

145	Current Targeted Therapy for Metastatic Colorectal Cancer. **2023**, 24, 1702	1
144	Mace-Like Plasmonic Au-Pd Heterostructures Boost Near-Infrared Photoimmunotherapy. 2204842	1
143	Application of individualized multimodal radiotherapy combined with immunotherapy in metastatic tumors. 13,	0
142	Novel Treatment Strategies for Malignant Anterior Segment Tumors. **2022**, 291-309	0
141	Approaching the Dimerization Mechanism of Small Molecule Inhibitors Targeting PD-L1 with Molecular Simulation. **2023**, 24, 1280	1
140	The stromal tumor-infiltrating lymphocytes, cancer stemness, epithelial-mesenchymal transition, and B7-H4 expression in ovarian serous carcinoma. **2023**, 16,	0
139	Tumorigenesis from non-alcoholic steatohepatitis to hepatocellular carcinoma. **2023**,	0
138	Increased co-expression of stromal HHLA2 and fibroblast activation protein in upper tract urothelial carcinoma.	0
137	Notch signaling regulates immunosuppressive tumor-associated macrophage function in pancreatic cancer.	0
136	Size-optimized nuclear-targeting phototherapy enhances the type I interferon response for "cold" tumor immunotherapy. **2023**,	0
135	Target-Specific Nanoparticle Polyplex Down-Regulates Mutant Kras to Prevent Pancreatic Carcinogenesis and Halt Tumor Progression. **2023**, 24, 752	0
134	Equine Melanocytic Tumors: A Narrative Review. **2023**, 13, 247	0
133	Mapping the interplay between NK cells and HIV: therapeutic implications.	0
132	A Three-in-One Nanoscale Coordination Polymer for Potent Chemo-Immunotherapy. 2201437	1
131	Immunotherapy in Localized Microsatellite Instability‐High/Mismatch Repair Deficient Solid Tumors: Are We Ready for a New Standard of Care?.	0
130	Repurposing Ponatinib as a PD-L1 Inhibitor Revealed by Drug Repurposing Screening and Validation by In Vitro and In Vivo Experiments.	0
129	Application of Immune Checkpoint Inhibitors in Gynecological Cancers: What Do Gynecologists Need to Know before Using Immune Checkpoint Inhibitors?. **2023**, 24, 974	0
128	Identification and Validation of the Prognostic Panel in Clear Cell Renal Cell Carcinoma Based on Resting Mast Cells for Prediction of Distant Metastasis and Immunotherapy Response. **2023**, 12, 180	0

127	Spatial genomics reveals a high number and specific location of B cells in the pancreatic ductal adenocarcinoma microenvironment of long-term survivors. 13,	0
126	Targeting regulatory T cells in gastric cancer: Pathogenesis, immunotherapy, and prognosis. **2023**, 158, 114180	0
125	Second-line treatment options for patients with metastatic pancreatic ductal adenocarcinoma: A systematic literature review. **2023**, 113, 102502	0
124	SPP1 is´a prognostic related biomarker and correlated with tumor-infiltrating immune cells in ovarian cancer. **2022**, 22,	0
123	Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer.	1
122	Aerosolized immunotherapeutic nanoparticle inhalation potentiates PD-L1 blockade for locally advanced lung cancer.	0
121	5-Methylcytosine (m5C) Modification Patterns and Tumor Immune Infiltration Characteristics in Clear Cell Renal Cell Carcinoma. **2023**, 30, 559-574	0
120	Prognostic Role of Neutrophil-to-Lymphocyte Ratio (NLR), Lymphocyte-to-Monocyte Ratio (LMR), Platelet-to-Lymphocyte Ratio (PLR) and Lymphocyte-to-C Reactive Protein Ratio (LCR) in Patients with Hepatocellular Carcinoma (HCC) undergoing Chemoembolizations (TACE) of the Liver: The Unexplored Corner Linking Tumor Microenvironment, Biomarkers and Interventional Radiology.	1
119	Molecular characterization of feline immune checkpoint molecules and establishment of PD-L1 immunohistochemistry for feline tumors. **2023**, 18, e0281143	1
118	An Ionic Liquid Ablation Agent for Local Ablation and Immune Activation in Pancreatic Cancer. 2206756	0
117	PD-L1 and PD-L2 expression in colorectal cancer. **2023**, 66, 31	0
116	Syngeneic N1-S1 Orthotopic Hepatocellular Carcinoma in Sprague Dawley Rat for the Development of Interventional Oncology-Based Immunotherapy: Survival Assay and Tumor Immune Microenvironment. **2023**, 15, 913	0
115	A Look at Emerging Therapeutic Targets for Gallbladder Cancer: A Multi-Omics Approach. **2023**, 161-175	0
114	Clinical significance of immune checkpoint proteins in HPV-infected cervical cancer. **2023**,	0
113	Tumor immunology. **2023**, 245-452	0
112	Modeling tumour heterogeneity of PD-L1 expression in tumour progression and adaptive therapy. **2023**, 86,	0
111	High PD-L2 Predicts Early Recurrence of ER-Positive Breast Cancer. **2023**,	0
110	Bibliometric Analysis of Hotspots and Frontiers of Immunotherapy in Pancreatic Cancer. **2023**, 11, 304	0

109	Leading Edge: Intratumor Delivery of Monoclonal Antibodies for the Treatment of Solid Tumors. **2023**, 24, 2676	0
108	Role of FABP5 in T Cell Lipid Metabolism and Function in the Tumor Microenvironment. **2023**, 15, 657	0
107	Somatic mutations can induce a noninflamed tumour microenvironment via their original gene functions, despite deriving neoantigens.	0
106	Arginase 1 is a key driver of immune suppression in pancreatic cancer. 12,	0
105	p16-dependent upregulation of PD-L1 impairs immunosurveillance of senescent cells.	0
104	A multicenter, phase Ib/II, open-label study of tivozanib with durvalumab in advanced hepatocellular carcinoma (DEDUCTIVE). **2022**, 18, 4465-4471	0
103	Optimizing Patient Pathways in Advanced Biliary Tract Cancers: Recent Advances and a French Perspective. **2023**, 18, 51-76	0
102	Mesenchymal Stromal Cell-Based Targeted Therapy Pancreatic Cancer: Progress and Challenges. **2023**, 24, 3559	0
101	Neoplasia.	0
100	Cancer of unknown primary (CUP) through the lens of precision oncology – a single institution perspective.	0
99	Platycodin D induces neutrophil apoptosis by downregulating PD-L1 expression to inhibit breast cancer pulmonary metastasis. **2023**, 115, 109733	0
98	Identification of a PD1/PD-L1 inhibitor by Structure-Based Pharmacophore Modelling, Virtual Screening, Molecular docking and Biological Evaluation.	0
97	Mxene composite fibers with advanced thermal management for inhibiting tumor recurrence and accelerating wound healing. **2023**, 459, 141529	0
96	Combating pancreatic cancer with ovarian cancer cells. **2023**, 15, 2189-2207	0
95	Overcoming anti-PD-1/PD-L1 immune checkpoint blockade resistance: the role of macrophage, neutrophils and mast cells in the tumor microenvironment.	0
94	Immune Checkpoint Inhibitors in pMMR/MSS Colorectal Cancer.	0
93	Pancreatic cancer: Advances and challenges. **2023**, 186, 1729-1754	0
92	Engineered skin bacteria induce antitumor T cell responses against melanoma. **2023**, 380, 203-210	1

91	Targeting Rat Sarcoma Viral Oncogene Homolog for Treatment of Gastrointestinal Cancers. **2023**, 3, 161-177	0
90	The impact of hypoxia on tumor-mediated bypassing anti-PD-(L)1 therapy. **2023**, 162, 114646	0
89	Global research trends in immunotherapy for head and neck neoplasms: A scientometric study. **2023**, 9, e15309	0
88	Targeting ZDHHC9 potentiates anti-programmed death-ligand 1 immunotherapy of pancreatic cancer by modifying the tumor microenvironment. **2023**, 161, 114567	0
87	Targeting PARP for the optimal immunotherapy efficiency in gynecologic malignancies. **2023**, 162, 114712	0
86	Qualitative analysis of PD-L1 expression in non-small-cell lung cancer based on chest CT radiomics. **2023**, 84, 104815	0
85	Profile of treatment-related adverse events of PD-1 blockade-based therapies in advanced esophageal cancer: A systematic review and meta-analysis. **2023**, 183, 103922	0
84	Development and Verification of a novel cuproptosis- and immune-associated based prognostic genetic signature for pancreatic ductal adenocarcinoma. **2023**, 47, 102089	0
83	Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance. **2023**, 41, 272-287.e9	2
82	Subtyping of advanced lung cancer based on PD-L1 expression, tumor histopathology and mutation burden (EGFR and KRAS): a study from North India.	0
81	PD-L1 immunohistochemistry assay optimization to provide more comprehensive pathological information in classic Hodgkin lymphoma. **2023**, 16, 7-16	0
80	Association between Loss of Immune Checkpoint Programmed Cell Death Protein 1 and Active ANCA-Associated Renal Vasculitis. **2023**, 24, 2975	1
79	Recent advancement in breast cancer treatment using CAR T cell therapy:- A review. **2023**, 7, 100090	0
78	Challenges and Therapeutic Opportunities in the dMMR/MSI-H Colorectal Cancer Landscape. **2023**, 15, 1022	0
77	A Rare Case Presentation of Vitiligo Associated With Atezolizumab. **2023**, 11, 232470962311546	0
76	Characterization of the immune cell landscape in CRC: Clinical implications of tumour-infiltrating leukocytes in early- and late-stage CRC. 13,	0
75	Radiotherapy, PARP Inhibition, and Immune-Checkpoint Blockade: A Triad to Overcome the Double-Edged Effects of Each Single Player. **2023**, 15, 1093	0
74	Echinacea purpurea-derived homogeneous polysaccharide exerts anti-tumor efficacy via facilitating M1 macrophage polarization. **2023**, 4, 100391	0

73	PD-1: A New Candidate Target for Analgesic Peptide Design. **2023**,	0
72	Is the new angel better than the old devil? Challenges and opportunities in CD47- SIRP□based cancer therapy. **2023**, 184, 103939	0
71	Galectin-9 and PD-L1 antibody blockade combination therapy inhibits tumour progression in pancreatic cancer. **2023**, 15, 135-147	0
70	Identification and validation of a novel overall survival prediction model for immune-related genes in bone metastases of prostate cancer.	0
69	PLA2G2A+ cancer-associated fibroblasts mediate pancreatic cancer immune escape via impeding antitumor immune response of CD8+ cytotoxic T cells. **2023**, 558, 216095	0
68	OX40 agonism enhances PD-L1 checkpoint blockade by shifting the cytotoxic T´cell differentiation spectrum. **2023**, 4, 100939	0
67	Integrated clinical analysis and data mining assessed the impact of NOX4 on the immune microenvironment and prognosis of pancreatic cancer. 13,	0
66	Clinicopathological Features and Status of Programmed Death Ligand-1 (PD-L1) Expression in Lung Cancer: A Single Centre Study From North India. **2023**,	0
65	LncRNA and its role in gastric cancer immunotherapy. 11,	0
64	The role of LncRNAs in tumor immunotherapy. **2023**, 23,	0
63	The hipotises of the immune system's role in carcinogenesis. **2021**, 16, 82-91	0
62	Upregulation of Apolipoprotein L6 Improves Tumor Immunotherapy by Inducing Immunogenic Cell Death. **2023**, 13, 415	0
61	PD-L1, a Master Regulator of Immunity 2.0. **2023**, 24, 4385	0
60	The CSF-1R inhibitor Pexidartinib impacts dendritic cell differentiation through inhibition of FLT3 signaling and may antagonize the effect of durvalumab in patients with advanced cancer □results from a phase 1 study.	0
59	An angiogenesis-related three-long non-coding ribonucleic acid signature predicts the immune landscape and prognosis in hepatocellular carcinoma. **2023**, 9, e13989	0
58	Leveraging Tumor Microenvironment Infiltration in Pancreatic Cancer to Identify Gene Signatures Related to Prognosis and Immunotherapy Response. **2023**, 15, 1442	0
57	The Usefulness of Nanotechnology in Improving the Prognosis of Lung Cancer. **2023**, 11, 705	0
56	Paxillin is a potential prognostic biomarker associated with immune cell infiltration in ovarian cancer. **2023**, 9, e14095	0

55	Knocking down GALNT6 promotes pyroptosis of pancreatic ductal adenocarcinoma cells through NF-Ƀ/NLRP3/GSDMD and GSDME signaling pathway. 13,	0
54	Tumor-specific memory CD8+ T cells are strictly resident in draining lymph nodes during tumorigenesis. **2023**, 20, 423-426	0
53	Acral Melanoma Is Infiltrated with cDC1s and Functional Exhausted CD8 T Cells Similar to the Cutaneous Melanoma of Sun-Exposed Skin. **2023**, 24, 4786	0
52	5-Fluorouracil Suppresses Colon Tumor through Activating the p53-Fas Pathway to Sensitize Myeloid-Derived Suppressor Cells to FasL+ Cytotoxic T Lymphocyte Cytotoxicity. **2023**, 15, 1563	0
51	Stuttering as a signal of encephalopathy associated with toripalimab in a pancreatic ductal adenocarcinoma patient: a case report. **2023**, 23,	0
50	Single-cell and bulk RNA sequencing identifies T cell marker genes score to predict the prognosis of pancreatic ductal adenocarcinoma. **2023**, 13,	0
49	Immune Gene Therapy of Cancer. **2023**, 1-45	0
48	Glycodelin acts as an immunomodulator in NSCLC and is a predictor of poor prognosis for patients receiving immunotherapy.	0
47	Anti-angiogenic therapy in ovarian cancer: Current understandings and prospects of precision medicine. 14,	0
46	Discovery of 2H-Indazole-3-carboxamide Derivatives as Novel Potent Prostanoid EP4 Receptor Antagonists for Colorectal Cancer Immunotherapy.	0
45	Identification of GZMA as a Potential Therapeutic Target Involved in Immune Infiltration in Breast Cancer by Integrated Bioinformatical Analysis. Volume 15, 213-226	0
44	IDO1/COX2 Expression Is Associated with Poor Prognosis in Colorectal Cancer Liver Oligometastases. **2023**, 13, 496	0
43	Efficacy and safety of PD-1/PD-L1 inhibitors in the treatment of recurrent and refractory ovarian cancer: A systematic review and a meta-analysis. 14,	0
42	The Potential Revolution of Cancer Treatment with CRISPR Technology. **2023**, 15, 1813	0
41	Comparative effects of curcumin versus nano-curcumin on histological, immunohistochemical expression, histomorphometric, and biochemical changes to pancreatic beta cells and lipid profile of streptozocin induced diabetes in male SpragueƉawley rats.	0
40	Immunotherapies for advanced hepatocellular carcinoma. 14,	0
39	Therapeutic potential of TRPM8 channels in cancer treatment. 14,	0
38	Identification of ZBTB4 as an immunological biomarker that can inhibit the proliferation and invasion of pancreatic cancer. **2023**, 23,	0

37	Pre-existing TGF-Ƀspecific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhibitors combined with radiotherapy. **2023**, 11, e006432	0
36	Neutrophil Extracellular Traps and Cancer: Trapping Our Attention with Their Involvement in Ovarian Cancer. **2023**, 24, 5995	0
35	The role of CXCL12 axis in pancreatic cancer: New biomarkers and potential targets. 13,	0
34	Efficacy and toxicity profile of first-line treatment for extensive-stage small cell lung cancer: A Bayesian network meta-analysis.	0
33	Pancreatic cancer: Emerging field of regulatory B-cell-targeted immunotherapies. 14,	0
32	The role of dendritic cells in radiation-induced immune responses. **2023**,	0
31	Tumour microenvironment as a predictive factor for immunotherapy in non-muscle-invasive bladder cancer.	0
30	In Situ Formed ROS-Responsive Hydrogel with STING Agonist and Gemcitabine to Intensify Immunotherapy against Pancreatic Ductal Adenocarcinoma.	0
29	Neoadjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma: Expecting Its Application in Temporal Bone Squamous Cell Carcinoma.	0
28	ScRNA-seq of Diverse Pheochromocytoma Patients Reveals Distinct Microenvironment Characteristics and Supports an Informative Molecular Classification System.	0
27	Multi-omic characterization reveals a distinct molecular landscape in young-onset pancreatic cancer.	0
26	Oncogenic epidermal growth factor receptor signal-induced histone deacetylation suppresses chemokine gene expression in human lung adenocarcinoma. **2023**, 13,	0
25	Peripheral PD-1 and Tim-3 percentages are associated with primary sites and pathological types of peritoneal neoplasms. **2023**, 23,	0
24	Pancreatic Ductal Adenocarcinoma and Immune Checkpoint Inhibitors: The Gray Curtain of Immunotherapy and Spikes of Lights. **2023**, 30, 3871-3885	0
23	Sicca symptoms and sialoadenitis as immune-related adverse events of nivolumab treatment in renal malignancy. **2023**, 13, 21-23	0
22	ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers. **2023**, 11, e006345	0
21	Ubiquitin-Specific Protease 43 Impacts Pancreatic Ductal Adenocarcinoma Prognosis by Altering Its Proliferation and Infiltration of Surrounding Immune Cells. **2023**, 2023, 1-13	0
20	Modulation of pancreatic tumor immunity by NKG2D T cells through MICB shedding.	0

19	??????????????????????????. **2023**, 44, 36-46	0
18	Immune checkpoint inhibitors and cellular immunotherapy for advanced gastric, gastroesophageal cancer: a long pathway.	0
17	Role of Surgical Pathologist for the Detection of Immuno-oncologic Predictive Factors in Non-small Cell Lung Cancers. **2023**, 30, 174-194	0
16	Research Progress of Immunotherapy for Gastric Cancer. **2023**, 22, 153303382211505	0
15	Sintilimab Plus Modified FOLFIRINOX in Metastatic or Recurrent Pancreatic Cancer: The Randomized Phase II CISPD3 Trial.	0
14	CircSCUBE3 Reduces the Anti-gastric Cancer Activity of Anti-PD-L1.	0
13	Clustering analysis and prognostic model based on PI3K/AKT-related genes in pancreatic cancer. 13,	0
12	Cancer of unknown primary (CUP) through the lens of precision oncology: a single institution perspective.	0
11	Immune Checkpoint Inhibitor, Nivolumab, Combined with Chemotherapy Improved the Survival of Unresectable Advanced and Metastatic Esophageal Squamous Cell Carcinoma: A Real-World Experience. **2023**, 24, 7312	0
10	Overcoming the Fibrotic Fortress in Pancreatic Ductal Adenocarcinoma: Challenges and Opportunities. **2023**, 15, 2354	0
9	Cerium End-Deposited Gold Nanorods-Based Photoimmunotherapy for Boosting Tumor Immunogenicity. **2023**, 15, 1309	0
8	Extremely Differentiated T Cell Subsets Contribute to Tissue Deterioration During Aging. **2023**, 41, 181-205	0
7	Preoperative treatments in borderline resectable and locally advanced pancreatic cancer: Current evidence and new perspectives. **2023**, 186, 104013	0
6	Metronomic Chemotherapy: Anti-Tumor Pathways and Combination with Immune Checkpoint Inhibitors. **2023**, 15, 2471	0
5	Strategic Design of Conquering Hypoxia in Tumor for Advanced Photodynamic Therapy.	0
4	Nivolumab combination therapy as first-line treatments for unresectable, advanced or metastatic esophageal squamous cell carcinoma. 1-8	0
3	Inside PD-1/PD-L1,2 with their inhibitors. **2023**, 256, 115465	0
2	Clinical Implications of FGFR Mutations for Cancer Immunotherapy and Tumor Microenvironment: A Pan-Cancer Study. **2023**, 13, 7734-7745	0

1	Epigenetic reprogramming of Runx3 reinforces CD8 + T-cell function and improves the clinical response to immunotherapy. **2023**, 22,	0